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Understanding ECM Remodeling and Signaling in Breast Tumor 
Progression and Therapy Response 
Allison P. Drain 
Abstract 
 Breast cancer is the second leading cause of cancer-related death among women in the 
United States. While the five-year survival rate of premetastatic tumors is high, nearly 90%, this 
plummets to 27% once metastasis is detected within a distant organ, underscoring a pressing 
unmet clinical need to prevent and treat metastatic breast cancer. Excessive extracellular matrix 
(ECM) deposition and remodeling occurs alongside breast tumor progression and has been 
directly implicated in facilitating breast tumor metastasis. However, many of the mechanisms by 
which tumor-associated ECM remodeling promotes metastasis are unclear. This thesis 
addresses this knowledge gap from multiple angles, clarifying prometastatic mechanisms of 
biochemical and biomechanical ECM signaling as well as in-depth characterization of the causes 
and nature of pathological ECM remodeling in breast cancer. This research utilizes techniques 
across a spectrum of length scales including in vitro cell culture manipulations, orthotopic and 
genetically engineered mouse models, and human patient samples to establish robust, clinically 
relevant findings. First, this thesis examines the role of collagen-discoidin domain receptor 1 
(DDR1) signaling and shows that DDR1 expression may play an important role dictating 
mammary epithelial differentiation and loss of DDR1 signaling may in part explain how highly 
aggressive, basal-like tumors form. The next chapter characterizes collagen remodeling in human 
breast tumors and shows triple negative tumors are particularly enriched for collagen crosslinks. 
Manipulations in mice suggest stromal cells primarily drive collagen crosslinking, and infiltrating 
macrophages activate stromal cells in the early stages of tumor development. Moreover, we 
identify stromal lysyl hydroxylase 2, the enzyme responsible for the formation of high valency 
collagen crosslinks found in rigid and fibrotic tissues, as a predictor of poor survival and a 
potentially useful biomarker to stratify patients for therapy. The following chapter examines how 
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ECM stiffness in triple negative breast cancer influences therapy response. We demonstrate that 
treatment resistant residual disease occupies a soft ECM niche and that a compliant matrix tunes 
the NF-κB – JNK signaling axis to promote cell survival upon administration of apoptosis-inducing 
therapeutics such as chemotherapy and radiation. Finally, we explore the relationship between 
ECM stiffness and prometastatic tumor immunity. Collectively, these findings advance our 
understanding of mechanisms that promote breast tumor metastasis and provide considerable 
insights to inform the development of effective therapeutic strategies to prevent and treat 
metastatic disease.  
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Chapter 1: Introduction 
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 Breast cancer is the most commonly diagnosed malignancy in women in the US, with 
268,600 new cases and 41,760 deaths reported annually1. The primary cause of breast cancer-
related mortality is metastasis, the colonization of distant organs such as bone, liver, lung, and 
brain by disseminated breast tumor cells. Indeed, after a tumor has metastasized the five year 
survival rate plummets from 90% to 27%1. This suggests that while clinicians achieve moderate 
success in treating localized tumors, there is a pressing unmet clinical need to treat metastatic 
disease and if possible, prevent it altogether. Metastasis proceeds through a well-defined series 
of steps beginning with tumor cell invasion into the parenchyma and intravasation into lymphatic 
or hematologic vasculature. While the vast majority of intravasated cells will die prior to 
extravasation, a small subset will successfully exit circulation and enter a potential site of distant 
metastasis. Yet only a subset of these cells will persist in the secondary site, and these 
disseminated cells may remain dormant for many years before growing into an established 
metastatic tumor. Insights into both the biological factors that support progression through the 
metastatic cascade and impede therapeutic efficacy will be critical in reducing breast cancer 
specific mortality.  
 Alongside breast tumor growth and progression of the metastatic cascade is a progressive 
accumulation and remodeling of extracellular matrix (ECM). Importantly, the ECM has been 
directly implicated in promoting tumor metastasis and impairing therapeutic efficacy. The ECM is 
a complex, polymeric extracellular network of glycoproteins and proteoglycans that acts as a 
scaffold to support tissue structure, supports tissue organization, and provides signaling cues to 
orchestrate cell- and tissue-level behaviors. The broad spectrum of ECM functions within tissue 
can be ascribed to the extensive diversity and organizational complexity of constituent ECM 
molecules. Moreover, most ECM proteins contain multiple domains that incorporate various 
biological activities within a single protein. Many domains serve as binding sites for other common 
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ECM domains and thus facilitates the polymeric assembly of an extensively interconnected 
insoluble protein matrix.  
  Cells receive both biochemical and mechanical signals from ECM. Biochemical signals 
can be direct through cell ligation of different ECM proteins or indirect through ECM binding and 
sequestration of growth factors like TGFβ, FGF, and many others, thus regulating their availability 
for cell signaling. Glycosaminoglycan content also regulates tissue osmolarity that can affect cell 
behavior2–4. Cells sense and respond to a variety of physical and mechanical properties. ECM 
viscoelasticity plays a significant role regulating cellular activities. Viscoelasticity is a property of 
materials that display both elastic and viscous characteristics upon deformation. While it is known 
that most native ECMs are viscoelastic, due to technical limitations, only the elastic component 
has been well characterized in most tissues. Only recently has attention been devoted to 
understanding the biological implications of viscous effects upon ECM deformations5,6. 
Consequently, the terms ECM “stiffness” or “rigidity” in the literature often refer exclusively to ECM 
elasticity, and will be used as such hereafter. In addition to stiffness, matrix topology, that is the 
shape of assembled ECM network, can regulate cell motility and polarity7–10. Porosity, the size 
and quantity of pores within a 3D matrix also influences motility, and cell confinement can elicit 
unique cell behaviors as well10–12. Both ECM composition and organization significantly influence 
physical and mechanical ECM properties.  
Cells use a variety of cell surface receptors to bind and interact with ECM proteins. The 
most prominent and well-characterized class of ECM receptors are the integrins13,14. Integrins are 
obligate heterodimers consisting of one α subunit and one β subunit. In human cells there are 18 
known α subunits and 8 β subunits that combine to form 24 unique integrin pairs. Integrins vary 
in specificity, with some binding only one ligand and others capable of binding multiple. The 
cytoplasmic tail of integrins binds cytoskeletal elements thus connecting the ECM to intracellular 
activities. Tension generated by actomyosin contractility through integrin-mediated adhesions is 
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a dominant mechanism by which cells sense ECM stiffness14–18. Cells also bind ECM proteins 
and proteoglycans through several other receptors including discoidin domain receptors (DDRs), 
some transmembrane heparan sulfate proteoglycans like syndecans and agrin, laminin receptor, 
various hyaluronan receptors, lipoprotein receptors, immunoglobulin-like collagen receptors, 
collagen-binding mannose receptors, and others.  
 ECM is highly tissue specific, and in the human breast consists of two distinct ECM 
structures: a basement membrane surrounding milk ducts and an outlying interstitial matrix 
between ducts. The basement membrane organizes into a mesh-like architecture composed 
largely of laminin and collagen IV. Cell adhesion to the basement membrane is necessary for 
ductal epithelial cell survival and polarization19. Once neoplastic cells breach the basement 
membrane and invade into the interstitial space, they are defined as malignant tumor cells. At this 
stage, the tumor cells interact directly with the collagen I rich interstitial matrix. Collagen I forms 
a fibrillar matrix that can drastically vary in its mechanical properties depending on its architecture 
and abundance20–22.  
Extensive ECM deposition and remodeling coincide with breast tumorigenesis. Breast 
tumor ECM is largely comprised of collagen I, which is progressively reorganized and stiffens as 
tumors evolve. This fibrotic tumor-associated ECM both compromises therapeutic efficacy and 
promotes metastatic dissemination23–25. The characteristically more aggressive breast tumor 
subtypes, basal-like and HER2 positive, have thicker collagen fibers and overall stiffer collagen 
ECM compared to luminal breast tumors26. A stiff ECM promotes cell invasion through enhanced 
integrin clustering and Rho GTPase that mediates the assembly of filopodia and invadosomes27–
29. Thick, linearized bundles of collagen fibers also facilitate the migration of tumor cells out of the 
tumor core toward sites of intravasation30,31. Moreover, a stiff ECM can promote cell survival and 
proliferation via multiple molecular mechanisms including elevated focal adhesion kinase (FAK) 
activity and enhanced sensitivity to growth factor signaling27,32–34. A major factor increasing 
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collagen stiffness is enhanced intramolecular crosslinking catalyzed by the lysyl oxidase (LOX) 
family of enzymes. My lab has previously shown that orthotopically injected tumors grow 
substantially larger after LOX conditioning of the mammary fat pad and that attenuating collagen 
crosslinking using the pharmacological inhibitor β-aminoproprionitrile (BAPN) reduces the number 
of circulating tumor cells and inhibits the formation of distant metastases35 (unpublished data). 
These findings stress the clinical relevance of ECM stiffness to malignancy and metastasis and 
underscore the need to clarify the molecular pathways by which the ECM promotes metastasis 
and identify therapeutically actionable targets to antagonize them. 
 Despite an abundance of evidence establishing a link between ECM mechanics and 
breast tumor metastasis, our understanding is far from complete. Several crucial outstanding 
questions remain: 
1. How does signaling with the collagen matrix alter tumor progression and metastasis? 
2. What triggers the development of a fibrotic tumor-associated ECM and how does the ECM 
evolve with tumor progression? 
3. How can ECM signaling pathways be targeted to enhance therapeutic efficacy and reduce 
metastasis? 
4. How do stromal cells respond to tumor-associated ECM and how might this contribute to 
metastatic progression? 
The principal motif of my thesis centers around expanding our understanding of precise 
mechanisms by which the ECM is modified throughout tumor progression and the molecular 
mediators of prometastatic cell-ECM signaling. I took a highly quantitative approach utilizing both 
in vitro and in vivo models as well as human patient data to gain insight into these phenomena. 
Specifically, this motif is born out in four sections: 
1. Investigating the role of DDR1 signaling in breast homeostasis and tumor phenotype 
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2. Understanding the origin and nature of collagen crosslinks in breast tumors and their 
contribution to poor patient outcome 
3. ECM regulation of therapy response in triple negative breast cancer 
4. Examining cooperation of collagen crosslinking and ECM stiffening with prometastatic 
immune cell phenotypes in the primary tumor and premetastatic niche 
Investigating the role of DDR1 signaling in breast homeostasis and tumor phenotype 
 The discoidin domain receptor 1 is over-expressed in breast carcinoma cells. Low DDR1 
expression is associated with worse relapse-free survival reflecting its controversial role in cancer 
progression.  We detected DDR1 on luminal cells, but not on myoepithelial cells of DDR1+/+ mice. 
We found DDR1 loss compromises cell adhesion, consistent with data that older DDR1-/- 
mammary glands had more basal/myoepithelial cells. Basal cells isolated from older mice exerted 
higher traction forces than the luminal cells, in agreement with increased mammary branches 
observed in older DDR1-/- mice and higher branching by their isolated organoids. When we 
crossed DDR1-/- mice with MMTV-PyMT mice, the PyMT/DDR1-/- mammary tumors grew faster, 
had increased epithelial tension and matricellular fibrosis, with a more basal phenotype and 
increased lung metastases. DDR1 deletion induced basal differentiation of CD90+CD24+ tumor 
initiating cells, and the increase correlated with tumor cell mitoses. K14+ basal cells including 
K8+K14+ cells were increased adjacent to necrotic fields. These data suggest that the absence of 
DDR1 provides a growth and adhesion advantage that favors the expansion of basal cells, 
potentiates fibrosis and enhances necrosis/hypoxia and basal differentiation of transformed cells 
to increase their aggression and metastatic potential. 
Understanding the origin and nature of collagen crosslinks in breast tumors and their 
contribution to poor patient outcome 
Collagen deposition and stromal stiffening accompany malignancy, compromise 
treatment, and promote tumor aggression. Clarifying the molecular nature of and the factors that 
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regulate extracellular matrix stiffening in tumors should identify biomarkers to stratify patients for 
therapy and therapeutic interventions to improve outcome. We profiled lysyl hydroxylase- and 
lysyl oxidase-mediated collagen crosslinks and quantified the greatest abundance of total and 
complex collagen crosslinks in more aggressive human breast cancer subtypes with the stiffest 
stroma. These tissues also harbored the highest number of tumor-associated macrophages 
(TAM), whose therapeutic ablation not only reduced metastasis, but also concomitantly 
decreased accumulation of collagen crosslinks and stromal stiffening. Epithelial-targeted 
expression of the crosslinking enzyme lysyl oxidase had no impact on collagen crosslinking in 
PyMT mammary tumors, whereas stromal cell targeting did. Consistently, stromal cells in 
microdissected human tumors expressed the highest level of collagen crosslinking enzymes. 
Immunohistochemical analysis of a cohort of breast cancer patient biopsies revealed that stromal 
expression of lysyl hydroxylase two, an enzyme that induces hydroxylysine aldehyde-derived 
collagen crosslinks and stromal stiffening correlated significantly disease specific mortality. The 
findings link tissue inflammation, stromal cell-mediated collagen crosslinking and stiffening to 
tumor aggression and identify lysyl hydroxylase two as a novel stromal biomarker.  
ECM regulation of therapy response in triple negative breast cancer 
 Triple negative breast cancers (TNBCs) are associated with poor survival, which can be 
predicted in part by lack of response to neoadjuvant chemotherapy. TNBCs are highly fibrotic, yet 
little is known regarding how the extracellular matrix (ECM) evolves following therapy and whether 
it may impact treatment response. Analysis revealed that while primary untreated TNBCs are 
surrounded by a highly rigid microenvironment, treatment resistant residual tumors following 
neoadjuvant chemotherapy inhabit a softer niche. This suggests that the biophysical properties 
of the tumor microenvironment regulate treatment resistance. Consistently, 3D organoid cultures 
and xenograft studies of premalignant and malignant TNBC showed organoids interacting with a 
soft ECM exhibited a striking resistance to chemotherapy, ionizing radiation and death receptor 
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ligand TRAIL. A stiff ECM enhanced pro-apoptotic JNK activity to sensitize cells to treatment, 
whereas a soft ECM promoted treatment resistance by elevating NF-κB activity and compromising 
JNK activity. Critically, treatment resistant residual human TNBCs residing within soft stroma had 
elevated NF-κB levels, and disengaging NF-κB activity sensitized tumors in a soft matrix to 
therapy. Accordingly, the biophysical properties of the ECM modify treatment response, and 
ancillary agents that modulate stiffness-dependent NF-κB or JNK activity could enhance 
chemotherapeutic efficacy in patients with TNBC. 
Examining cooperation of collagen crosslinking and ECM stiffening with prometastatic 
immune cell phenotypes in the primary tumor and premetastatic niche 
 ECM remodeling modulates many facets of the tumor microenvironment and potentiates 
metastatic progression. Immune cells comprise a prominent portion of the tumor 
microenvironment and exert potent effects at multiple levels of the metastatic cascade. Reshaping 
immune cell phenotypes to antagonize tumor growth and metastasis also holds immense promise 
as a therapeutic strategy. Thus, understanding factors that influence immune phenotypes and 
function is critically important. Here, we examined how ECM stiffness may alter immune cell 
populations and phenotypes in the primary tumor and the premetastatic niche. We characterized 
immune cell infiltrate into the primary tumors and lungs of LOX overexpressing mice and found 
an increased accumulation of neutrophils, which we attribute primarily to prolonged survival and 
in part to increased bone marrow production and chemotaxis. Neutrophils may adopt either anti- 
or pro-tumorigenic phenotypes, and while our analysis of phenotype is not conclusive, the overall 
cytokine milieu of LOX overexpressing tumors supports conjecture of an anti-tumor neutrophil 
phenotype. In contrast, mice bearing PDX tumors injected in softer collagen matrix show higher 
levels of inflammatory signaling and have more neutrophils in the premetastatic lung. Moreover, 
LOX overexpression shows a strain-specific metastasis phenotype in which stromal 
overexpression promotes metastasis on the FVB background and restrains metastasis on the 
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C57BL6. These data point to a complex interplay of ECM stiffness, LOX, and neutrophil regulation 
that should be explored further.  
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Chapter 2: Discoidin domain receptor 1 (DDR1) ablation promotes 
an aggressive, basal-like breast tumor phenotype  
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Introduction 
The discoidin domain receptors (DDRs) are a unique subfamily of receptor tyrosine 
kinases (RTKs) that bind various types of collagen. DDR1 is widely expressed in human and 
mouse epithelial cells including mammary epithelium, while DDR2 is prominent in mesenchymal 
cells and connective tissue37. Both fibrillar and nonfibrillar collagens serve as ligands for DDR1, 
but fibrillar collagen binding has been more well characterized and is much better understood38–
40. In contrast to most RTKs, DDRs do not dimerize upon ligand binding but rather exist as 
stable dimers on the cell surface, even in the absence of ligand41–43. Instead, collagen binding 
induces DDR1 clustering on the cell surface, and DDR1 dimers phosphorylate neighboring 
dimers in trans leading to receptor activation44.  This likely explains in party why DDR1 exhibits 
much slower phosphorylation kinetics relative to other RTKs. DDRs are known to play a key role 
in embryonic development and have been linked to many pathologies including fibrosis, 
inflammation, atherosclerosis, and cancer45. DDR activation is known to regulate ECM 
remodeling and MMPs expression, but many of the specific tyrosine phosphorylations that occur 
within the DDR1 cytoplasmic domain have not been mapped to phenotypes45.  
DDR1 is critical for mammary gland development46. In mice, DDR1 knockout results in 
delayed pubertal mammary ductal outgrowth. However, by 3 months of age, the mammary 
glands of DDR1-/- mice show increased mammary branching along with a high rate of mammary 
epithelial proliferation and increased levels of stromal collagen. In part, these divergent roles of 
DDR1 in mammary development may be explained by the previous reports showing that in in 
vitro, DDR1 promotes cell proliferation, differentiation and migration by degrading collagen47–51. 
However, the possible mechanism of mammary hyperproliferation and hyperbranching by DDR1 
ablation at later stages remains obscure. 
Because tumor progression often mirrors developmental events, understanding of the 
role of DDR1 in development may yield insights into the role of DDR1 in cancer. Nevertheless, 
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the results of mammary development in DDR1-/- mice make it difficult to hypothesize whether 
DDR1 will promote or suppress cancer. Indeed, conflicting evidence exists suggesting both a 
pro- and anti-tumor role for DDR1. DDR1 is overexpressed in breast, ovarian, and lung 
carcinoma cell lines37,52–57, and high expression of DDR1 correlates with poor prognosis of 
serous ovarian cancer, lung cancer and pancreatic ductal adenocarcinoma58–60. Activation of 
DDR1 by collagen promotes pro-tumorigenic phenotypes, including upregulation of the 
expression of MMP-1, 2 and 9, increased degradation of collagen, upregulation of expression of 
SOX2 and NANOG, promotion of cell invasion, metastasis and regulation of cancer stem cell 
traits47,48,60,61. DDR1 stabilizes E-cadherin and mediates suppression of actomyosin at cell-cell 
contacts to promote collective cell migration51,62,63. Interference with DDR1 signaling in 
metastatic breast cancer cell lines decreases their ability to colonize lung tissue60,63. Moreover, 
knockdown of DDR1 decreases viability of breast, pancreatic, and ovarian cancer cell lines64. 
These studies indicate that DDR1 might function as an oncogene. 
In contrast, a moderate reduction in DDR1 mRNA levels was shown in the majority of 
middle to high-grade human breast carcinomas compared to normal mammary tissues49. 
Another clinical study of lung cancer showed that low expression of DDR1 is associated with a 
worse prognosis than its high expression57. Also, a clinical study of breast cancer patients 
showed that DDR1 expression was not predictive for survival65. Furthermore, induction of DDR1 
may inhibit migration of a DDR1-deficient breast cancer cell line66. Disruption of DDR1 in cell–
cell contacts in cancer may favor metastasis by invading blood vessels63. These data indicate 
that deletion of DDR1 might promote aggressive cancer. As a result, the role of DDR1 in 
cancers is controversial. 
To understand the role of DDR1 in breast tumorigenesis, we established an animal model 
using DDR1-knockout mice crossed into the MMTV-PyMT mouse and tested the hypothesis that 
13 
 
DDR1 ablation leads to an aggressive form of breast cancer. We then analyzed breast cancer 
databases to establish how DDR1 levels are related to prognosis.  
Results 
DDR1 is expressed in luminal epithelial cells and regulates basal/myoepithelial cells 
Since effects of genes in development may give insights into their roles in cancer, we first 
verified the role of DDR1 in normal mammary gland development using the DDR1-/- mouse model. 
When we analyzed the mammary gland tissues from DDR1+/+ mice by immunostaining with anti-
DDR1 antibody and anti-α-smooth muscle actin (α-SMA) antibody, which is a marker of 
myoepithelial cells, we detected DDR1 in the luminal cell compartment, but not on myoepithelial 
cells (Fig. 2.1A), as was found in the kidney, where DDR1 expression also does not co-localize 
with staining for α-SMA following kidney injury67.  
In whole-mount carmine red-stained mammary gland tissues in DDR+/+ and DDR1-/- mice, 
we observed two distinct phenotypes, one during active pubertal growth and another in adult 
mammary gland. Mammary development, as assayed by primary duct lengths and frequency of 
mammary duct branches, was delayed in 5-week-old DDR1-/- mice but was accelerated in 8-week-
old DDR1-/- mice (Fig. 2.1B and 2.1C). Our results showing distinct stage-specific effects of DDR1 
are consistent with a previous analysis showing that development of mammary glands was 
delayed in 3-week-old DDR1-/- mice, but that the number of mammary ducts was increased in 12-
week-old DDR1-/- mice due to hyper-proliferation of the epithelium46. 
To determine the mechanisms that might be involved in the altered branching phenotype, 
we generated a cell line with a DDR1 knockdown. Consistent with the literature, the DDR1 
knockdown mammary epithelial cells were slower in attaching to collagen than the wild type 
control68,69 (Fig. A1.1A). In keeping with this phenotype, the DDR1 knockdown cells were less 
contractile when seeded within collagen gels (Fig. A1.1B). These data along with the known role 
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of DDR1 in supporting collective cell migration, suggest that DDR1 knockout directly impairs the 
ability of the luminal population to properly organize and execute branching morphogenesis63. 
Indeed, by flow cytometry analysis, we observed that the basal/myoepithelial CD24lowCD49fhigh 
cell population was similar in DDR1-/- and DDR1+/+ mice in puberty at 5 weeks of age, but was 
significantly increased in adult 8-week-old DDR1-/- mouse mammary glands compared to DDR1+/+ 
mice (Fig. 2.1D and 2.1E).  
Collagen contraction assays and traction force microscopic analysis of the basal versus 
the luminal isolated populations revealed that the basal cells are significantly more contractile 
(Fig. 2.1F). The relevance of the altered ratio of highly contractile basal cells to luminal cells was 
explored by co-culturing aggregates of luminal and basal cells and assaying for branching 
morphogenesis. First, we crossed K14-GFP mice with the DDR1 knockout mouse line. We then 
isolated K14- luminal cells and K14+ basal/myoepithelial cells from K14+/DDR1+/+ mouse 
mammary glands by flow cytometry (Fig. A1.1C), aggregated the K14- luminal cells with and 
without K14+ highly contractile basal cells overnight, collected the cell aggregates, and cultured 
them in Matrigel for 3D organoid branching assays. Aggregating K14- luminal cells with K14+ 
contractile basal/myoepithelial cells promoted mammary branching (Supplemental Fig. S1D). We 
then isolated K14- luminal cells and K14+ basal/myoepithelial cells from K14/DDR1+/+ mice and 
K14/DDR1-/- mice by flow cytometry and aggregated K14-/DDR1+/+ and K14-/DDR1-/- luminal cells 
with K14+/DDR1+/+ and K14+/DDR1-/- basal cells (Fig. 2.1G). K14+/DDR1-/- contractile 
basal/myoepithelial cells promoted mammary branching (Fig. 2.1H). Since DDR1 is not 
expressed on myoepithelial cells and incubation of K14-/DDR1-/- luminal cells with K14+/DDR1+/+ 
basal/myoepithelial cells did not promote mammary branching (Fig. 2.1H), this result indicates 
that DDR1 on luminal cells and interaction with K14+ contractile basal/myoepithelial cells is 
required  
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Figure 2.1: DDR1 is expressed in luminal epithelial cells and regulates basal/myoepithelial 
cells. (A) Immunofluorescence of DDR1 (green) and α-SMA (red) in mammy glands from wildtype 
and DDR1-/- mice. (B) Representative images of carmine red wholemount staining from wildtype 
and DDR1-/- mice. Dashed line indicates extent of ductal outgrowth at 5 weeks of age. (C) 
Quantification of primary ductal length and frequency of mammary branching from carmine red 
wholemounts. Data are shown as mean ± SD. n = 3-4 mice per group. Statistical analysis was 
performed using unpaired Student’s t test, *p < 0.05. (D) Representative flow cytometry analysis 
of mammary epithelial and developmental cell populations: basal/myoepithelial cells (Basal/Myo), 
luminal cells (Lu), and stromal cells (Strm). (E) Quantification of cell population abundance from 
flow cytometry. Statistical analysis was performed using one-way ANOVA and unpaired Student’s 
t test, *p < 0.05. (F) Quantification of maximum traction stresses generated by individual sorted 
luminal and basal/myoepithelial cells isolated from wildtype murine mammary glands. Statistical 
analysis was performed using unpaired Student’s t test, **p < 0.01. (G) Populations of K14+ 
(basal/myoepithelial) and K14- (luminal) cells in the mammary glands of wildtype and DDR1-/- 
mice. (H) Phase contrast images of a three-dimensional branching assay from mixed luminal and 
basal/myoepithelial cells from wildtype and DDR1-/- mice. 
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for mammary branching, likely mediated through a combination of tension-mediated interactions 
and paracrine signaling. 
These data suggest stage-specific roles for DDR1 during mammary development. Thus, 
reduction of mammary branching at 5 weeks of age in DDR-/- mice may owe to the loss of DDR1 
functions as a collagen receptor and collective cell migration in luminal cells, whereas the 
accelerated branching in DDR-/- mice at 8 weeks of age may be the result of the expansion of the 
basal/myoepithelial compartment. 
DDR1-/- mammary tumors grow faster and are more basal and necrotic  
To determine how DDR1 alters in breast tumor prognosis we determined whether deletion 
of DDR1 leads to more aggressive breast tumors. We crossed DDR1-/- mice with MMTV-PyMT 
mice, a transgenic luminal B breast cancer model70 (Fig. A1.2A). We validated DDR1 expression 
levels in primary tumors of PyMT/DDR1+/+, PyMT/DDR1+/- and PyMT/DDR1-/- mice by qPCR. As 
expected, PyMT/DDR1-/- mice did not express DDR1, whereas DDR1 expression in 
PyMT/DDR1+/- was intermediate as compared to PyMT/DDR1+/+ (Fig. A1.2B). In support of this 
model, we found that DDR1 expression was higher in luminal-type than basal-type human cancer 
cells71 (Fig. A1.2C).  
Tumors from both PyMT/DDR1+/- and PyMT/DDR1+/+ mice had similar growth rates (Fig. 
2.2A). In contrast, primary tumors of PyMT/DDR1-/- mice grew faster although there were no 
differences in the tumor onset (Fig. 2.2A and Fig. A1.3A), and they often showed necrotic areas 
with hemorrhage (Fig. A1.3B). In H&E stained tissue sections, the tumor tissues had large 
necrotic regions with more differentiated epithelial clusters surrounding the necrotic regions. The 
DDR1+/+ and DDR1+/- mammary tumors were largely made up of large epithelial glandular 
clusters, while the DDR1-/- mammary tumors had small areas of differentiated  
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Figure 2.2: DDR1-/- mammary tumors grow faster and are more basal and necrotic. (A) 
Primary tumor burden of PyMT/DDR1-/- mice compared to PyMT/DDR1+/+ and PyMT/DDR1+/- 
mice. PyMT/DDR1-/- mammary tumors grow faster than control tumors. Data are shown as mean 
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± SD, n=4-7, *p <0.02 (one-way ANOVA and unpaired Student’s t test). (B) DDR1+/+ and DDR1+/- 
mammary tumors showed large epithelial clusters and DDR1-/- tumor showed multiple small 
clusters and central necrosis (orange dots) by H&E staining. Representative photographs are 
shown (13 weeks). n=3. (C) Length of epithelial tumor clusters was measured. DDR1-/- primary 
tumors show small size clusters by H&E staining. Data are shown as mean ± SD, n=3, *p <0.05, 
**p <0.02 (one-way ANOVA and unpaired Student’s t test). (D) Percent of necrotic clusters out of 
small clusters (200-300 µm length) was measured. Necrotic small clusters increased in DDR1-/- 
tumors. Data are shown as mean ± SD, n=3, *p <0.01, **p <0.02 (one-way ANOVA and unpaired 
Student’s t test). (E,F) Immunofluorescence of DDR1+/+ and DDR1-/- mammary tumor tissues used 
anti-keratin 8 (green) and anti-phospho-histone H3 (phH3) (red) antibodies. DAPI (blue) stained 
nuclei. Representative photographs are shown (E). PhH3+ cells were present mainly at the edge 
of the epithelial clusters. The percent of phH3+ cells per epithelial cell (keratin 8+ and phospho-
histone H3+) show that DDR1-/- mammary tumor cells are more proliferative (Data are shown as 
mean ± SD, n=3, *p <0.02, unpaired Student’s t test) (F). (G) Immunofluorescence of DDR1+/+ 
and DDR1-/- mammary tumor tissues using anti-vimentin (red) antibody and DAPI (blue) stained 
nuclei. Representative photographs are shown. (H) Expression levels of vimentin were quantified 
by using ImageJ software. Vimentin levels increased in DDR1-/- epithelial clusters. Data are shown 
as mean ± SD, n=4, *p <0.05 (unpaired Student’s t test). (I,J) Immunofluorescence of DDR1+/+, 
DDR1+/- and DDR1-/- mammary tumor tissues using anti-E-cadherin (green), anti-keratin 14 (red) 
antibodies, and DAPI (blue) stained nuclei. K14+ basal cells were mainly at the edge of the 
epithelial clusters. Representative photographs are shown (I). The ratio of K14+ basal cells per 
epithelial (E-cadherin+ and K14+) cell increased (*p <0.02, **p <0.05, one-way ANOVA and 
unpaired Student’s t test) (J, left panel) and expression of E-cadherin decreased in DDR1-/- 
epithelial clusters (**p <0.05, one-way ANOVA and unpaired Student’s t test) (J, right panel). Data 
are shown as mean ± SD, n=3. (K,L) Immunofluorescence of the primary tumors was performed 
by using anti-keratin 8 (green) and anti-DDR2 (red) antibodies. DAPI (blue) stained nuclei. 
Representative photos of tumor epithelial clusters are shown (K). The ratio of DDR2+ cells per 
epithelial cell increased significantly in DDR1-/- epithelial clusters (L). Data are shown as mean ± 
SD, n=3, *p <0.01 (one-way ANOVA and unpaired Student’s t test). (M,N) Immunofluorescence 
of DDR1+/+, DDR1+/- and DDR1-/- mammary tumor tissues was conducted by using anti-keratin 8 
(green) and anti-keratin 14 (red) antibodies. DAPI (blue) stained nuclei. Representative photos of 
tumor necrotic areas are shown (M). K14+ basal cells including K8+K14+ basal-like cells (yellow) 
significantly increased near necrotic fields of DDR1-/- mammary tumor tissues (N). Data are shown 
as mean ± SD, n=3, *p <0.05 (one-way ANOVA and unpaired Student’s t test). (O) 
Immunofluorescence of DDR1-/- mammary tumor tissues using anti-E-cadherin (green) and anti-
HIF1α (red) antibodies and DAPI (blue) stained nuclei. The white dots represent a border between 
an epithelial and necrotic field (right panel). HIF1α is expressed and localized near necrosis. 
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epithelial clusters with increased areas of necrosis (Fig. 2.2B-D). Even small clusters had 
necrotic areas in the DDR1-/- mammary tumors (Fig. A1.3C). 
We next determined if the proliferative status of these tumors was related to their growth 
rates by staining tissues for phospho-histone H3 (phH3). PhH3+ cells were localized in the tumors 
mainly around the edge of the epithelial clusters. PyMT/DDR1-/- mammary tumors had 
significantly more phH3+ cells than control tumors that expressed DDR1 (Fig. 2.2E and 2.2F). 
This suggests that DDR1-/- mammary tumors are more proliferative than DDR1+/+.  
We also examined expression of luminal markers (E-cadherin and keratin 8) and basal 
markers (keratin 14, vimentin and DDR2) in primary tumors by immunofluorescence. Vimentin 
expression levels increased in DDR1-/- epithelial clusters (Fig. 2.2G and 2.2H). K14+ basal cells 
mainly encircled the edge of the epithelial clusters in all three genotypes (Fig. 2.2I).  However, 
K14+ basal cells in DDR1-/- tumor epithelial clusters increased in numbers, while the expression 
levels of E-cadherin in DDR1-/- epithelial clusters decreased (Fig. 2.2I and 2.2J).  
Since DDR2 also affects tumor progression, we asked if its expression was changed in 
the absence of DDR172,73. We observed that the number of DDR2+ cells increased in DDR1-/- 
epithelial clusters and near necrotic areas (Fig. 2.2K and 2.2L; Fig. A1.3D and A1.3E).  
We also observed a trend towards increased K8+K14+ basal-like cells in DDR1-/- epithelial 
clusters (Fig. A1.3F and A1.3G). However, more K8+K14+ basal-like cells were seen in the 
epithelial regions at the outer edge of the necrosis (Fig. A1.3H and A1.3I). K14+ basal cells 
(K8+K14+ & K8-K14+ cells) significantly increased in DDR1-/- epithelial regions next to necrosis 
(Fig. 2.2M and 2.2N), while K8+K14+ basal-like cells tended to increase (Fig. A1.3J). 
We then determined which cell compartment proliferated in DDR1-/- mammary tumors by 
staining tissues for K8, K14 and phH3. PhH3+ cells were localized mainly in K8+ luminal cells of 
the epithelial clusters (Fig. A1.4A and A1.4B). Moreover, K8+K14+ basal-like cells proliferated at 
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significantly higher rates, especially near the necrotic regions in DDR1-/- mammary tumors (Fig. 
A1.4C and A1.4D). PhH3 positivity correlated with K14+ basal cell numbers (Correlation 
coefficient r=0.75) rather than K8+K14+ basal-like cell numbers (r=0.07) in epithelial clusters. 
Finally, to examine whether DDR1 deletion alters the phenotype of K8+K14+ basal-like 
cells, we stained tumor tissues for K8, K14 and DDR2. K8+K14+ basal-like cells, which 
upregulated DDR2 expression, increased significantly in DDR1-/- mammary tumors (Fig. A1.5A 
and A1.5B). Moreover, DDR1 deletion decreased branching in tumor organoids in vitro (Fig. 
A1.5C and A1.5D). 
These data suggest that tumor growth correlates with K14+ basal cell numbers and that 
when DDR1 is knocked out, the tumors have a more basal phenotype and are more aggressive. 
Taken together these data suggest that loss of DDR1 may lead to breast cancers of poorer 
prognosis. 
Hypoxic regions show increased hypoxia-inducible factor-1a (HIF1a) expression 
Tumor necrosis is significantly associated with hypoxia and in basal-type breast cancer 
and is an independent predictor for early recurrence and death74,75.  Since reduced expression of 
DDR1 in primary tumors increased the amount of necrosis in tumors (Fig. 2.2D), we hypothesized 
that necrosis and hypoxia might be linked in the DDR1-/- tumors. Using immunofluorescent 
staining for HIF1a in primary tumors, we observed that tumor necrosis was associated with 
hypoxia. HIF1a was highly increased in the PyMT/DDR1-/- mammary tumor tissue and was 
expressed near necrotic regions (Fig. 2.2O).  
PyMT/DDR1-/- tumors have increased fibrosis and exhibit increased mechanochemical 
tension  
Basal-like breast tumors often present as highly fibrotic, which contributes to disease 
aggression through enhanced tumor cell mechanosignaling and impaired vascularization leading 
21 
 
to hypoxia76,77. Consistently, picrosirius red staining showed that the more basal-like DDR1-/- 
tumors contain significantly more fibrillar collagen than the DDR1+/+ tumors (Fig. 2.3A and 2.3B). 
Atomic force microscopy (AFM) further revealed that the DDR1-/- tumors have a higher elastic 
modulus than the DDR1+/+ controls (Fig 2.3C and 2.3D). To determine whether the stiffened, 
collagen-rich ECM of DDR1-/- tumors corresponded to a higher level of mechanosignaling within 
the tumor, we analyzed levels of focal adhesion kinase (FAK) phosphorylation at tyrosine 397 in 
tumor lysates (Fig 2.3E). We observed increased FAK phosphorylation in the DDR1-/- tumors, 
which is indicative of integrin-mediated signaling and focal adhesion formation that has been 
shown to promote tumor progression35. Moreover, the loss of DDR1 resulted in more contractile 
tumors, as shown by increased pMLC2 staining in the DDR1-/- tumors (Fig. 2.3F and 2.3G). Given 
the reduction in cell contractility upon DDR1 knockdown in vitro, we asked whether the increased 
contractility in DDR1-/- tumors could be attributed to the dramatic expansion of the 
basal/myoepithelial compartment in DDR1-/- mammary glands. Indeed, using traction force 
microscopy on flow sorted luminal and basal/myoepithelial cells from the murine mammary glands 
we also showed that the basal/myoepithelial cells generated much higher traction forces (Fig. 
2.1F). These data suggest that the aggressive, basal-like phenotype of the DDR1-/- tumors may 
result from a competitive advantage of the already enriched basal population due to a DDR1-
dependent impairment in luminal cell interactions with the ECM.  
Loss of DDR1 results in increased lung metastases  
Since basal tumors with increased basal markers have a poor outcome in breast cancer 
patients78–81, we next determined whether DDR1 plays a role in lung metastasis. When we scored 
the macroscopic and microscopic metastatic burden, we found increased metastasis both in 
volume and in numbers of metastases in the lungs of PyMT/DDR1-/- mice (Fig. 2.4A-C). When we  
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Figure 2.3: PyMT/DDR1-/- tumors have increased fibrosis and exhibit increased 
mechanochemical tension. (A,B) Picrosirius red staining of primary tumors (A) and 
quantification (B) by the percent area of birefringent signal in each image. Representative 
photographs are shown (A). DDR1-/- tumors contain significantly more fibrillar collagen than 
DDR1+/+ tumors (B). Data are shown as mean ± SD, n=3, *p <0.05 (unpaired Student’s t test). 
(C,D) Quantification of tissue elastic modulus measured by AFM. *p<0.0001 (Mann-Whitney U-
test) (C). The histogram shows the distribution of the top 10% of measurements for each group 
(D). DDR1-/- tumors have a higher elastic modulus than DDR1+/+ tumors. (E) Quantification of 
Western blots for pFAKY397 protein in wildtype and DDR1 knockout tumor tissue lysates 
normalized to total FAK protein levels. FAK phosphorylation increased in DDR1-/- tumors. Data 
are shown as mean ± SD, n=6, *p <0.02 (unpaired Student’s t test). (F,G) Immunofluorescence 
of the primary tumors was performed by using anti-keratin 8 (green) and anti-pMLC2 (red) 
antibodies. DAPI (blue) stained nuclei. Representative photographs are shown. The white dots 
represent a border between an epithelium and a stroma (F). The ratio of pMLC2+ cells per 
epithelial cell increased significantly in DDR1-/- tumors (G). Data are shown as mean ± SD, n=3, 
*p <0.05 (unpaired Student’s t test). 
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Figure 2.4: Loss of DDR1 results in increased lung metastases. (A) PyMT/DDR1-/- mice show 
larger and increased lung metastatic tumors macroscopically. (B) PyMT/DDR1-/- mice have larger 
and increased number of lung metastatic tumors by H&E staining. (C) Left panel indicates lung 
tumor volume. Right panel indicates lung tumor number/lobe. *p <0.05 (one-way ANOVA and 
unpaired Student’s t test), **p <0.05 (unpaired Student’s t test). (D-G) Immunofluorescence of 
lung using anti-keratin 8 (green) and anti-keratin 14 (red) antibodies and DAPI (blue) stained 
nuclei. Metastatic tumor cells are located inside the dashed lines. K8+K14+ basal-like cells (yellow 
arrows) are detected in most of the metastatic tumors regardless of DDR1 genotype (Data shown 
as mean ± SD, n=3, unpaired Student’s t test) (D,E). K8-K14+ basal cells (red arrows) significantly 
increased in DDR1-/- small (length <75m) metastatic tumors (n=8-10, *p <0.01, **p <0.05, one-
way ANOVA and unpaired Student’s t test) (F,G).   
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examined the epithelial differentiation state of metastatic tumors in the lungs, we found K8+K14+ 
basal-like cells in most of the metastatic tumors even with any small size regardless of DDR1 
genotype (Fig. 2.4D and 2.4E). Next, to examine whether DDR1 deletion is associated with the 
epithelial differentiation, we focused on the proportion of K8-K14+ basal cells in the small 
metastatic tumors and found that K8-K14+ basal cells significantly increased in DDR1-/- 
metastases (Fig. 2.4F and 2.4G). These results suggest that DDR1 deletion might induce basal 
differentiation. 
CD90+CD24+ cells from PyMT/DDR1-/- tumors transplanted into wild-type mice yield high-
grade tumors resembling the PyMT/DDR1-/- primary tumors 
CD90+CD24+ cells are enriched for metastasis-initiating cells82. Based on the increased 
metastasis, we asked whether PyMT/DDR1-/- tumors are enriched in CD90+CD24+ cells and found 
that the DDR1-/- mammary tumor cell populations contained more CD90+CD24+ cells (Fig. 2.5A 
and 2.5B). To understand the influence on epithelial differentiation by DDR1 deletion, we collected 
CD90+CD24+ cells from both PyMT/DDR1+/+ and PyMT/DDR1-/- primary tumors by flow cytometry. 
We then transplanted 2000 CD90+CD24+ cells into the mammary glands of wild-type recipient 
mice. We observed sections of one grafted tumor from PyMT/DDR1+/+ CD90+CD24+ cells and two 
grafted tumors from PyMT/DDR1-/- CD90+CD24+ cells. The grafted tumors from PyMT/DDR1+/+ 
mice had a more luminal morphology with large epithelial clusters (Fig. 2.5C). In contrast, one 
grafted mammary tumor from PyMT/DDR1-/- cells was less differentiated and its size was larger 
(Fig. 2.5C). The other grafted tumor from PyMT/DDR1-/- cells grew huge once but shrank later, 
had areas of hemorrhagic necrosis (Fig. 2.5C). These PyMT/DDR1-/- CD90+CD24+ cell-derived 
tumors displayed decreased expression of E-cadherin, increased vimentin+ cells, and had 
increased numbers of K14+ basal cells and K8+K14+ basal-like cells near the necrotic areas (Fig. 
2.5D-F). Tumor size correlated with increased K14+ basal cells in DDR1-/- epithelial areas. These 
results indicate that, after transplantation with CD90+CD24+ cells from primary  
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Figure 2.5: CD90+CD24+ cells from PyMT/DDR1-/- tumors transplanted into wild-type mice 
yield high-grade tumors resembling the PyMT/DDR1-/- primary tumors. (A,B) FACS analysis 
from DDR1+/- and DDR1-/- mammary tumor cells using anti-CD90 and anti-CD24 antibodies. 
DDR1-/- mammary tumor cells have more CD90+CD24+ cancer cells than control tumors. Data 
shown as mean ± SD, n=5-6, *p <0.02 (unpaired Student’s t test). (C) 2000 CD90+CD24+ cancer 
cells from PyMT/DDR1+/+ and PyMT/DDR1-/- tumors were transplanted into mammary glands. We 
observed sections of one grafted tumor from PyMT/DDR1+/+ cells and two grafted tumors from 
PyMT/DDR1-/- cells. Mammary tumors from PyMT/DDR1+/+ cells showed large epithelial clusters 
by H&E staining whereas the mammary tumors from PyMT/DDR1-/- cells showed non-cluster 
structures and hemorrhagic necrosis. The blue dots represent a border between an epithelium 
and a necrotic field. Tumor size (µm3) is indicated in each tumor when the tumors were obtained 
at 8 weeks after transplantation. The largest tumor size is also indicated before the necrotic tumor 
from PyMT/DDR1-/- cells shrank. (D) Immunofluorescence of CD90+CD24+ cell-derived mammary 
tumor tissues was conducted by using anti-E-cadherin (green) and anti-vimentin (red) antibodies 
in the upper panel and anti-keratin 8 (green) and anti-keratin 14 (red) antibodies in the lower 
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panel. DAPI (blue) stained nuclei. The dots represent a border between an epithelium and a 
necrotic field. The mammary tumor from PyMT/DDR1-/- CD90+CD24+ cells shows decreased 
expression of E-cadherin, increased vimentin+ cells (D, upper panel) and increased K14+ basal 
cells (D, lower panel). (E,F) The ratio of K14+ basal cells (K8-K14+ and K8+K14+ cells) increased 
in DDR1-/- epithelial areas (E). Increased K14+ (E) and K8+K14+ (F) cells were seen near the 
necrotic field. 
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Figure 2.6: DDR1 expression predicts prognosis in breast cancer. (A) Immunofluorescence 
of MMTV-PyMT luminal-type tumor cells in 2D culture was conducted by using anti-DDR1 (red) 
and anti-E-cadherin (green) antibodies. DAPI (blue) stained nuclei. DDR1 and E-cadherin were 
expressed on the cells. (B) Clinical data of breast cancer patients. DDR1 expression was lower 
in basal type than luminal type. *p <0.05, **p <0.01, ***p <0.001 (Dunn’s multiple comparison 
test). (C) Kaplan-Meier analysis of relapse-free survival for breast cancer patients. Low DDR1 
expression was associated with worse relapse-free survival (Logrank Test). (D, E) 
Immunofluorescence of luminal-type (MCF7, T47D, SKBR3 and BT474) and basal-type (MDA-
MB231 and HS578T) breast cancer cell lines was conducted by using anti-DDR1 (red) and anti-
E-cadherin (green) antibodies. DAPI (blue) stained nuclei. DDR1 and E-cadherin were detected 
on luminal-type cells (except BT474) (D), but not on basal-type cells (E). 
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tumors, the phenotype of the transplanted tumors resembled that of the primary tumor from 
which they were derived and suggest that DDR1 deletion in CD90+CD24+ cells induces basal 
differentiation and that the resulting increase in K14+ basal cells in DDR1-/- epithelium promotes 
tumor growth. 
DDR1 expression predicts prognosis in breast cancer 
DDR1 is overexpressed in some breast, lung, ovarian, brain, and esophageal cancers and 
leukemia37,52–57, implicating DDR1 as a candidate oncogene. In breast cancer cell lines DDR1 
expression was higher in luminal-type than basal-type human cell lines by microarray analysis71 
(Supplemental Fig. S2C). When we stained the luminal-type (MCF7, T47D, SKBR3, BT474) and 
basal-type (MDA-MB231, HS578T) cell lines for DDR1 and E-cadherin by immunofluorescence, 
we observed staining on luminal-type cells (except in BT474), but not on basal-type cells (Fig. 
2.6A and 2.6B). Cultured MMTV-PyMT mouse luminal B-type tumor cells that expressed E-
cadherin also expressed DDR1 (Fig. 2.6C).  
We then analyzed clinical data from breast cancer patients and found that DDR1 
expression was lower in basal-type than luminal-type tumors83 (Fig. 2.6D). The relapse-free 
survival rate was lower in the patient group of low DDR1 expression by a Kaplan-Meier plot84,85 
(Fig. 2.6E). These data suggest that DDR1 expression is prognostic of survival in breast cancer 
patients. 
Discussion 
In the present study, we discovered that luminal cells, but not basal/myoepithelial cells, 
express DDR1, and that after DDR1 deletion, luminal-type MMTV-PyMT mammary tumors exhibit 
basal-type characteristics, grow faster, and have enhanced lung metastasis. The mechanism 
underlying these results may derive from a reduced ability of luminal cells to interact with collagen 
leading to an enrichment of the basal cell population, basal differentiation of DDR1-/-progenitor 
cells with primary tumor growth promoted by basal cells, and the enhanced tumor 
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necrosis/hypoxia seen in DDR1-/- tumors, which, in turn, increases the number of K8+K14+ cells 
in the CD90+CD24+ population. Our data suggest that K8+K14+ progenitor cells, which increased 
in tumors deleted for DDR1, promote primary and metastatic tumor growth. Since DDR1 deletion 
resulted in increased necrosis in the primary tumors and increased rates of CSCs/MICs, it is likely 
that the absence of DDR1 alters the paracrine signaling and promotes an increase in CSCs/MICs. 
Our data suggest that DDR1 thwarts the development of poor prognosis tumors. Thus, elimination 
of DDR1 may result in a more aggressive basal-type breast cancer. In keeping with these results, 
DDR1 expression is lower in basal-type than luminal-type tumors. Since the basal phenotype 
promotes invasion/migration activity of mammary tumor cells73,86–88, this provides a second 
mechanism by which loss of DDR1 acts. Correlating with the DDR1-deficient mammary tumor 
model, we found that basal/myoepithelial cells increased in adult DDR1-/- mammary glands and 
facilitated mammary branching in vitro. This may be a mechanism underlying the mammary 
hyperbranching in adult mammary gland by DDR1 ablation, and this effect may reflect breast 
tumor progression promoted by DDR1 ablation. On the other hand, DDR1 deletion decreased 
branching in mammary organoids and tumor organoids in vitro and reduced mammary branches 
and ductal lengths in mammary development in vivo and luminal tumor cluster size in PyMT 
tumors (Table 1). These findings can be explained by impaired functions in collective cell 
migration and a collagen receptor by loss of DDR1. 
Why does DDR1 deletion promote necrosis in luminal tumor epithelial cell regions? It is 
generally believed that central necrosis is caused by inadequate blood supply and hypoxia due 
to rapid tumor growth89. Since DDR1-/- mammary tumors grew more rapidly, there was an increase 
in fibrillar collagens, and they were comprised of a stiffer ECM, tumor necrosis can occur more 
frequently. Necrosis accretion, in turn, may increase numbers of tumor initiating cells and promote 
lung metastasis. These observations may explain the relationship between tumor necrosis and 
tumor aggressiveness. 
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The basal markers such as vimentin, K14 and DDR2 promote tumor cell invasion and 
correlate with poor prognosis45,65,93,94,72,73,86–88,90–92. Since DDR1-/- tumors had increased vimentin 
expression, K14+ cells and DDR2+ cells, we suggest that DDR1 ablation from the spontaneous 
luminal-type breast cancer model may lead to more basal-type characteristics and enhance tumor 
cell invasion as a mechanism of the tumor progression. However, DDR1 ablation upregulated 
DDR2 expression mainly on K8+ luminal cells and K8+K14+ progenitor cells rather than on basal 
cells or stromal cells, although previous reports indicated that DDR2 on basal cells or cancer-
associated fibroblasts regulate tumor cell invasion72,73. It has been reported that DDR1 switches 
to DDR2 expression by TGFβ-exposed or SLUG-transfected epithelial-to-mesenchymal transition 
(EMT)72,95. Interestingly, ECM stiffness can also regulate DDR2 to promote tumor cell invasion 
through an EMT and is well known to contribute to tumor hypoxia96,97. Hypoxia dramatically 
increases phosphorylation of DDR2 in breast cancer cell lines and DDR2 is involved in hypoxia-
induced breast cancer cell invasion and EMT98. Moreover, a DDR1Low/DDR2High protein profile is 
associated with triple-negative breast cancer and worse prognosis99. More study is necessary to 
understand the mechanisms of the alteration from DDR1 to DDR2 on luminal cells and basal cells 
and determine whether the tumor cells can acquire invasive ability by upregulation of basal 
markers including DDR2.  
Our data add to the concept that the effects of DDR1 are complex. In mammary 
development, its loss inhibits mammary development early in puberty, but increases epithelial 
branching later. Similarly, while our results find that knockout of DDR1 increased tumor 
progression in MMTV-PyMT tumors, knockdown of DDR1 decreased viability of luminal-type 
breast cancer cell lines64, and interference with DDR1 function in a metastatic luminal-type breast 
cancer cell line decreased its ability to colonize lung tissue63. Those results suggest that DDR1 
may behave as an oncogene in some circumstances and as an anti-oncogene in others.  
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How could such diverse effects arise? Since DDR1 knockdown in luminal cells impairs 
collective cell migration, cell adhesion and contractility, this could reduce tumor growth63. In 
addition, induction of DDR1 expression inhibits migration of a DDR1-deficient basal-type breast 
cancer cell line66, which may be caused by enhanced cell adhesion through DDR1 induction. 
Therefore, the results with cell lines and/or in vitro experiments may be based on DDR1 functions 
in collective cell migration and cell adhesion, which is different from possible effects of enhanced 
necrosis and increased K8+K14+ progenitor cells and more basal-type characteristics by DDR1 
deletion in our DDR1-deleted spontaneous model of luminal B-type breast cancer. In support of 
this hypothesis, our in vitro studies demonstrated that the tumor organoids derived from our 
PyMT/DDR1-/- tumors showed decreased branching. In our study, we did not observe an increase 
in carcinogenesis rates of DDR1-/- mice compared to DDR1+/+ mice, as described in a previous 
report, suggesting that DDR1 is not a tumor suppressor gene46.  
Activation and proliferation of K14+ progenitor cells and their invasive activity are 
important for tumor growth and metastasis. Our DDR1 knockout spontaneous breast cancer 
model enriches a population of tumor initiating cells that form tumors with a more basal phenotype 
that may promote metastasis. Thus, our research provides new insights into the complicated 
DDR1 roles in breast cancer that will contribute importantly to understanding of cancer 
mechanisms in the future.  
Methods 
Mouse models 
All animal protocols were reviewed and approved by the UCSF IACUC. Mice were 
maintained under specific pathogen-free conditions in the UCSF barrier facility. DDR1-/- mice on 
a 129/Sv background were kindly provided by the late Wolfgang F. Vogel, University of Toronto46. 
DDR1-/- mice were then backcrossed to the FVB/n background for at least 6 generations.  
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For development studies mammary glands were harvested from DDR1-/- mice on mixed 
129/Sv and FVB/n backgrounds, and stained with carmine alum (Sigma). These mice were 
crossed with K14/GFP transgenic mice (CD1 background) in which GFP expression was 
controlled by a keratin 14 (K14) promoter-driven transgene cassette100. For cancer studies, the 
DDR1-/- mice on the FVB/n background were crossed with MMTV-PyMT mice on the FVB/n 
background. Tumor volumes (mm3) were calculated using the formula: V = 0.52×W2×L. W=width 
(mm), L=length (mm). 
Flow cytometry analysis and cell sorting 
Mammary glands from DDR1-/-, K14/DDR1-/- and littermate control mice or mammary 
tumors from PyMT/DDR1 mice were digested with collagenase101,102. Organoids were collected 
by brief centrifugation and digested with trypsin to dissociate into single cells. Cultured adherent 
cells were trypsinized for single-cell suspensions. The cells were stained with antibodies against 
CD49f, CD24, CD90.1 and lineage markers (CD45, CD31, Ter119) (eBioscience), as described 
previously82,103. Cell sorting was performed on FACS Aria II (Becton Dickinson), and analyzed 
using FlowJo (TreeStar) or FACSDiva software (BD Biosciences). 
Cell adhesion assay 
Cells (2x105) were seeded onto collagen-coated 12 well plates and subsequently washed 
with PBS at the indicated timepoints. After washing, the adhered cells were fixed with 4% PFA for 
10 minutes. The adhered cells were permeabilized and stained with DAPI. Images were taken at 
4x and the number of nuclei per field of view was quantified.  
Collagen Contraction Assay 
Collagen I solution was prepared by neutralizing acid-solubilized rat tail collagen I 
(Corning #354236) with 1 N NaOH and 10X DMEM buffer. Cells (2x105) were seeded in 2 mg/mL 
collagen gels in 48-well plates. Gels solidified at 37 °C for one hour prior to addition of prewarmed 
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media. After one hour in medium, a pipet tip was used to gently detach the collagen gel from the 
wall and bottom of the well. The collagen gel diameter was measured in ImageJ.  
Western blot 
Homogenized tumor tissue or cells were lysed in 2% SDS containing protease inhibitor 
cocktail (Sigma p8340) and phosphatase inhibitor (GenDEPOT P3200). Equal amounts of protein 
per sample were subjected to SDS-PAGE and transferred to a PVDF membrane. The membranes 
were blocked in 5% skim milk in TBST (TBS containing 0.1% Tween 20) for 30 minutes. Primary 
antibodies were incubated overnight at 4 °C in 3% BSA in TBST. Membranes were incubated with 
horseradish peroxidase (HRP)-conjugated secondary antibodies diluted in 5% milk-TBST for 1 
hour at room temperature. Bands were visualized using Pierce ECL Plus Western Blotting 
Substrate (ThermoFisher 32132). Protein expression was quantified by measuring the pixel 
intensity of each band using ImageJ. pFAK/FAK represents the ratio of the pFAK signal to the 
total FAK signal of each sample. 
Antibodies used are as follows: Cell Signaling #5583 Rabbit anti-DDR1, BD Biosciences 
#610088 Mouse anti-FAK, Cell Signaling #8556 Rabbit anti-pFAKY397, and Sigma #A5441 Mouse 
anti-β-actin.  
3D organoid branching assay  
K14- cells and K14+ cells with or without DDR1 were aggregated overnight on ultralow 
attachment plates (Corning). The aggregated cells or organoids were embedded into growth 
factor-reduced Matrigel (BD Biosciences) and grown in serum-free medium supplemented with 
insulin-transferrin (Invitrogen) and 2.5 nM EGF (Invitrogen) or 2.5 nM FGF2 (Sigma) as previously 
described104.  
Cell culture 
MCF7, T47D, SKBR3, BT474, MDA-MB231 and HS578T cells were obtained from the 
ATCC, Lawrence Berkeley Laboratory or the UCSF Cell Culture Facility, and grown in DME H-21 
medium supplemented with 10% FBS and 1 µg/mL insulin. Organoids from MMTV-PyMT 
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mammary tumors (see flow cytometry analysis and cell sorting) were cultured in ACL4 + 5% FBS 
medium in a 3% O2 incubator105.  
DDR1 Knockdown 
HEK293T cells were transfected using polyethylenimine to generate a lentivirus titer used 
to transduce a PyMT tumor-derived cell line with an IPTG inducible lentivirus (pLKO.1) expressing 
short hairpin RNA (shRNA) against DDR1 (5’-
CCGGGATTCCACTTACGATGGATATCTCGAGATATCCATCGTAAGTGGAATCTTTTT-3’) and 
luciferase as a control. Transduced cells were selected by treating with 400 µg/mL G418.  
Immunostaining and histology 
Tissues were fixed in 4% PFA overnight and paraffin processed. We cut 5 µm sections 
from paraffin-embedded blocks for H&E staining and immunohistochemistry. Adherent cells 
cultured in two-well chamber slides and sorted cells after cytospin at 1000 rpm for 4 min were 
stained by immunocytochemistry.  
The following antibodies were used for immunofluorescence at the indicated 
concentrations: DDR1 (Santa Cruz Biotechnology #sc-532, 1:50), E-cadherin (BD Biosciences 
#610181, 1:100), keratin 8 (Developmental Studies Hybridoma Bank TROMA-I, 1:50), keratin 14 
(Convance #PRB-155P, 1:5000), alpha-smooth muscle actin (-SMA) Cy3 conjugate (Sigma 
#C6198, 1:250), vimentin (Sigma V5255, 1:200), DDR2 (LifeSpan BioSciences LS-C164363, 
1:50), phospho-histone H3 (Cell Signaling #9701, 1:100), HIF1α (Novus Biologicals NB100-479, 
1:50), goat anti-mouse IgM µ chain Cy3 conjugate (Jackson ImmunoResearch #115-166-075, 
1:200), Alexa 488 anti-rat, 488 anti-rabbit, 488 anti-mouse and 568 anti-rabbit secondary 
antibodies (Molecular Probes A11006, A24922, A24920, A21069, 1:500). Nuclei were stained 
with DAPI (Vector Laboratories H-1200). Confocal microscopy was performed on a Nikon C1si 
confocal microscope. 
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Picrosirius Red Quantification 
Images were taken using polarized light such that only the birefringent collagen signal is 
visible. The amount of collagen was quantified as the percent area of the image with a positive 
signal using ImageJ. The threshold pixel value to determine a positive signal was held constant 
for each image analyzed. 
qPCR  
Total RNA was isolated from mouse mammary tumors using a Qiagen minikit. cDNA was 
synthesized using the Superscript III RT First Strand Kit (Invitrogen). qPCR was performed using 
the Sybgreen (Applied Biosystems) in an Eppendorf Mastercycler Realplex machine. Ct values 
were normalized to actin, and relative expression was calculated using the 2∆∆Ct method (Slorach 
2011). The forward and reverse primer sequences for mouse DDR1 were 5'- 
TCCATAGACCAGAGGGATC -3' and 5'- CAGGGCATAGCGGCACTTGG -3'. 
Traction force microscopy 
Primary murine mammary luminal and basal epithelial cells were sorted as previously 
described103 and seeded overnight on collagen I-coated polyacrylamide gels with embedded 500 
nm fluorescent red beads. Images of cells and beads were taken at 20 x magnification before 
adding 2% SDS to lyse the cells. A second picture of the beads was taken after lysis and aligned 
with the first image using the ImageJ (http://rsb.info.nih.gov/ij) registration plug-in Linear Stack 
Alignment with SIFT. To assess bead movement, a particle image velocimetry (PIV) program was 
implemented in ImageJ as described previously7. The iterative scheme included a first pass at 
32/64 (i.e., interrogation and search window size in pixels), followed by a second pass at 20/40, 
all at a correlation threshold of 0.60. For PIV postprocessing, a normalized mean test (NMT) was 
performed as described7 with NMT noise of 0.2 and threshold of 2.0 as starting parameters. The 
traction force was calculated by the Fourier transform traction cytometry (FTTC) method with a 
Poisson ratio of 0.5. The maximum traction stress generated was calculated by averaging the five 
largest traction vectors generated by each cell. The PIV and FTTC microscopy software for 
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ImageJ was kindly made available by Qingzong Tseng 
(https://sites.google.com/site/qingzongtseng/tfm). 
Atomic Force Microscopy 
Tumor samples were frozen in OCT and cut into 30μm sections. Each section was thawed 
in room temperature PBS and maintained in 0.5% BSA with protease inhibitor (Sigma p8340) in 
PBS supplemented with propidium iodide (Sigma P4170, 20 μg/mL) for no more than 90 minutes 
after thawing.  
All AFM indentations were performed using an MFP3D-BIO inverted optical AFM (Asylum 
Research) mounted on a Nikon TE2000-U inverted fluorescent microscope. We used silicon nitride 
cantilever with an approximate spring constant of 0.06 N m-1 with a 5 m spherical borosilicate glass 
tip (Novascan Tech). The exact cantilever spring constant was determined using its thermal oscillation 
prior to each experiment. Samples were indented at a 2 µm/s loading rate until a maximum force of 
1nN was achieved. Five 40 x 40 m indentation maps were typically obtained on each tissue section 
in ECM-rich regions as determined through picrosirius red staining of serial tissue sections. The elastic 
modulus of the tissue was determined through fitting to the Hertz model using a Poisson’s ratio of 0.5, 
which assumes the tissue samples are incompressible.  
Transplantation  
2 x 103 cells (CD90+CD24+ CSCs from PyMT/DDR1+/+ or PyMT/DDR1-/- tumors) were 
injected in a 10-µl volume of 1:1 v/v Matrigel:DMEM/F12 medium into mammary glands of FVB/n 
mice by using a Hamilton syringe. Tumors were harvested 8 weeks after transplantation. 
Lung metastasis analysis 
To determine lung metastatic tumor volume and frequency, lung tissue blocks were 
sectioned into 5 µm sections and stained by hematoxylin and eosin. For each mouse analyzed, 
one section was scored for size and number of metastases per lobe106,107. Tumor volumes (µm3) 
were calculated using the formula: V = 0.52×W2×L. W=width (µm), L=length (µm). 
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Computational analysis 
We compared DDR1 expression levels in 25 luminal and 26 basal (A+B) cell lines and in 
61 luminal-type, 13 HER2-type and 30 basal-type human breast tumors and 14 normal human 
breast tissues using the published microarray datasets71,83. Breast cancer patients (n=3951) were 
separated by high (n=2867) versus low (n=1084) DDR1 expression and analyzed for relapse-free 
survival by a Kaplan-Meier plot84,85. 
Statistical analysis  
Statistical analysis was conducted using Prism 4 software (Graph Pad Software, Inc.). 
Kaplan-Meier survival curves were analyzed by log-rank tests to determine the significance of 
observed differences between the curves. All tests used and P values are specified in the figure 
legends. p <0.05 was considered significant. 
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Chapter 3: Collagen crosslinking and stiffening in breast tumors is 
primarily regulated by macrophage-stimulated fibroblasts and 
promotes tumor aggression 
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Introduction  
Pathological accumulation of extracellular matrix (ECM) accompanies the formation of all 
solid tumors26,109,110. The tumor ECM is composed primarily of interstitial collagen that is 
progressively reorganized and stiffened26,30. The collagenous fibrotic tumor ECM compromises 
treatment and is linked to poor patient prognosis111–114. Tumor biopsy analysis showed that a thick 
fibrous collagenous ECM associates with less differentiated tumors and that this phenotype 
predicts poor patient survival, emphasizing the relevance of collagen architecture30,109,115. Patients 
with pancreatic ductal adenocarcinomas (PDACs) that are surrounded by stiff, thick fibrous 
collagens have a shorter survival, and invasive breast carcinomas with the stiffest ECM stroma 
at their invasive front are the most aggressive26,109. These observations suggest that stromal 
stiffness reflects collagen organization may be an important prognostic variable. Consistently, 
preclinical studies using organotypic cultures and rodent models provide plausible evidence for a 
causal relationship between collagen organization, stromal stiffness, tumor cell invasion in culture, 
and metastasis in vivo33,35,116–118. These findings underscore the clinical relevance of collagen 
architecture and stiffness to malignancy and emphasize the need to clarify the molecular nature 
of the collagenous ECM so that new biomarkers can be identified and anti-cancer therapeutics 
may be developed23,26,109,119.   
Interstitial fibrillar collagens assemble to form long, rod-like bundles are the ECM 
components that contribute most significantly to the tensile strength of tissue120. Fibrillar collagen 
α chains are synthesized in the endoplasmic reticulum as pro-α chains, with long propeptide 
regions on either side of the triple helical domain. Prior to triple helix formation, the α chains can 
undergo extensive posttranslational modifications including proline and lysine hydroxylation, 
lysine and hydroxylysine glycosylation, and tyrosine sulfation121,122. Proline hydroxylation by prolyl 
hydroxylases is particularly critical for the stability of the ensuing triple helix. Associations between 
pro- α chains begin with disulfide bonding among their C-terminal propeptides and initiate the 
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formation of the triple helix near the C-terminus123,124. Triple helix formation then propagates 
toward the N-terminus like a zipper forming a procollagen molecule. Formation of the complete 
triple helix quenches further posttranslational modification of the triple helical region. The 
procollagen molecule is shuttled to the Golgi where it packaged for secretion into the extracellular 
space. 
Following their extracellular secretion, extracellular BMP1/tolloid-like proteinases and 
ADAMTS family proteinases cleave the C- and N- terminal propeptides, respectively yielding a 
mature collagen molecule. Mature collagen molecules undergo entropy-driven self-assembly into 
small microfibrils of about 20 nm diameter and 4-12 µm in length. The collagen molecules pack 
together in a longitudinally staggered pattern that form areas of high and low packing density. 
This causes the characteristic 67 nm periodic banding pattern observed in collagen fibrils. 
Immature microfibrils associate with each other and are organized into very long mature collagen 
fibrils that can be 20 – 500 nm in length 125.  
In the final step of collagen maturation, fibrils undergo varying degrees of enzymatic and 
nonenzymatic covalent crosslinking. The mechanical properties of fibrillar collagens are highly 
dependent on these modifications. The lysyl oxidase (LOX) family enzymes catalyze the oxidative 
deamination of peptidyl lysine and hydroxylysine residues in the telopeptide region adjacent to 
the triple helix in the collagen molecule. The aldehyde produced by this reaction spontaneously 
reacts with another LOX-derived aldehyde or with the amine group in helical lysine or 
hydroxylysine residues to form covalent intra- and intermolecular crosslinks. These initial divalent 
crosslinks can mature further into multivalent crosslinks through incorporation of additional amino 
acids126. The hydroxylation of telopeptide lysines by lysyl hydroxylase 2 (LH2; gene name 
procollagen-lysine, 2-oxoglutarate 5-dioxygenase or PLOD) during collagen synthesis in the 
endoplasmic reticulum gives rise to crosslinking maturation products with distinct mechanical 
properties and are enriched in bone, ligaments, tendons, and pathologically fibrotic tissues126,127. 
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Collagen in softer connective tissues such as skin or cornea contain lower levels of hydroxylated 
telopeptide lysine residues and therefore contain a much different profile of mature collagen 
crosslinks. Tissues finely tune the quantity and quality of LOX-mediated collagen crosslinks to 
meet their structural needs. Although many of the crosslinking maturation products have been 
identified, the precise mechanisms by which they all form and are regulated are not fully 
understood. Recent advances in mass spectrometry methods have allowed quantification of 
specific LOX-mediated crosslinking products in tissues to understand their role in tissue structure 
and in the progression of fibrotic disease128,129. LOX activity has traditionally been difficult to assay 
in situ because the posttranslational modifications and copper cofactor required for catalysis 
decouple extracellular LOX protein levels from its enzymatic activity. 
Fibrotic human tumors express high levels of LOX and LH2 enzymes130,131. Tumor grade 
and overall patient survival associate with total tissue LOX and PLOD2 mRNA130,132–134. 
Pharmacological or antibody-mediated inhibition of LOX in MMTV-Her2/Neu mice or genetic 
reduction of PLOD2 in subcutaneously injected lung tumor epithelial cells reduce tissue fibrosis, 
stromal stiffening and collagen crosslinking and concomitantly decrease tumor incidence and 
aggression35,130. Moreover, elevating LOX or LH2-mediated collagen crosslinking enhances 
fibrosis and stromal stiffness and promotes malignant transformation and tumor aggression in 
lung and mammary xenografted tumors35,130. These observations suggest that the direct targeting 
of specific collagen crosslinking enzymes has clinical merit for the treatment of cancer. However, 
given caveats with recent clinical trials targeting ECM modifiers including suboptimal activity of 
inhibitory treatments and the risk of off-target effects, strategies designed to interfere with the 
induction and activation of these crosslinking enzymes offer an attractive alternative135. Towards 
this goal, the identification and causal implication of additional factors that regulate the levels 
and/or activity of collagen crosslinking enzymes has the potential to identify new predictive 
biomarkers and alternative anti-tumor treatment targets.  
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Pre-neoplastic lesions are inflamed, and pathological fibrosis correlates with 
inflammation136,137. Chronic inflammation and experimental manipulations that promote 
inflammation in rodent models induce fibrosis by secreting factors such as metalloproteinases 
and TGFβ118,136,138–140. Furthermore, fibrotic tumors are frequently inflamed, and this inflammation 
promotes tumor aggression, whereas either inhibiting inflammation or decreasing macrophage 
infiltration reduce tumor metastasis and enhance anti-tumor treatment26,137,141–144. Nevertheless, 
it remains unclear if inflammation promotes tumor progression and aggression by inducing 
stromal stiffening, and if so, whether this is regulated via epithelial and/or stromal fibroblast-
mediated collagen remodeling and crosslinking. 
Results 
xAAA profiling identifies increased levels of collagen crosslinks and stromal stiffness as 
indicators of breast tumor aggression  
To clarify the role of collagen crosslinking in tumor fibrosis we developed a crosslinked 
amino acid analysis (xAAA) method that enabled the characterization and quantification of 
specific collagen crosslinks in tissues across a wide range of collagen levels. We utilized solid 
phase extraction (SPE) enrichment followed by high pH amide hydrophilic chromatography 
(HILIC) coupled to a benchtop orbitrap (QExactive) mass spectrometer for these measurements. 
The validated method detected all known LOX-generated crosslinks including divalent 
(lysinonorleucine, dihydroxy lysinonorleucine), trivalent (pyridinoline and deoxy-pyridinoline) and 
tetravalent (desmosine and isodesmosine) crosslinked amino acids linearly over four orders of 
magnitude, with calculated limits of quantification (LLOQ) in the femtomolar range (Fig. A2.1; 
Table A2.1)145. The technique revealed a positive correlation between collagen crosslinking and 
abundance in excised human clinical specimens with very low to very high collagen 
concentrations and varying mechanical properties (Fig A2.2). The method also identified a subset 
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of hydroxylysine aldehyde (Hylald)-derived collagen crosslinks (HLCCs) crucial for the mechanical 
strength of tissue120,146.  
We next obtained snap-frozen biospecimens of normal human breast tissue (N=10; age 
between 22 and 58) and human tumor biopsies representing early stage (stage 1-2) invasive 
breast cancers (IBC) excised from mastectomy specimens. Molecular subtyping that subdivides 
human breast tumors stratified by estrogen receptor (ER+) and human epidermal growth factor 
receptor two (HER2+) status and ER/PR/HER2-negative (triple negative; TN) is a key determinant 
used to direct the treatment of breast cancer patients. Accordingly, we chose human breast tumor 
biopsies that represented ER+ (N=8; age between 42 and 71); HER2+ (N=6; age between 40 and 
76) and TN (N=6; age between 50 and 71). H&E stained tissue sections confirmed the presence 
of normal glandular structures in the normal controls and invasive breast cancer in the tumor 
specimens (Fig. 3.1a; top panels). Polarized light imaging of Picrosirius-stained (PS) tissue 
revealed that the normal breast tissue stroma had very little fibrillar collagen, whereas stromal 
tissue in all patients with IBCs contained abundant fibrillar collagen (Fig. 3.1a; middle panels) 
that second harmonic generation (SHG) imaging indicated was thicker and more linearized (Fig. 
3.1a; bottom panels). Polarized light microscopy and two-photon imaging further revealed that 
the level of fibrosis in the tissue was higher in HER2+ as compared to the ER+ breast tumors, 
and was further increased in the TN tumors, consistent with our previous report that TN tumors 
contain a high density of aligned collagen fibers (Fig. 3.1a; middle and bottom panels)26. AFM 
microindentation revealed a significant increase in the elastic modulus of the stroma associated 
with the invasive front of all the IBC tissues (Fig. 3.1b)26,30,35. xAAA analysis revealed a significant 
increase in total collagen crosslinking in all the IBCs (Fig. 3.1c, Fig. A2.5). These findings are 
consistent with an association between collagen crosslinks, tissue fibrosis and stromal stiffness, 
as has been previously documented in experimental murine models of mammary cancer35. 
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Figure 3.1: Hydroxylysine collagen crosslink abundance correlates with human breast 
cancer aggression. (a) Representative images of normal breast tissue (normal breast; n = 4) 
and invasive tumors diagnosed as estrogen receptor positive (ER+ tumor; n = 8), epidermal 
growth factor receptor two positive (HER2+ tumor; n = 6) and triple negative (TN tumor; n = 6). 
(Top row) Brightfield images of human breast tissue stained with hematoxylin and eosin (H&E). 
(Middle row) Polarized light images of picrosirius red (PS) stained human breast tissue with an 
inset brightfield image shows relative levels of fibrillar collagen. (Bottom row) Two photon second 
harmonic generation (SHG) images of human breast tissue revealing collagen organization 
(turquoise) and propidium iodide (PI; red) stained nuclei. Scale bar, 100 µm. (b) The distribution 
of the top 10% of elastic modulus values of normal breast tissue (n = 10) and invasive breast 
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carcinoma (IBC; n = 10) measured by AFM microindentation. Statistical analysis was performing 
using Mann-Whitney U test (****p < 0.0001). (c) Quantification of the abundance of all detected 
collagen crosslinks in normal breast tissue (n = 4) and in IBC tissues (n = 19) plotted as a scatter 
plot of individual samples with mean ± SEM. Statistical analysis was performed using Mann-
Whitney U test (**p < 0.01). (d-h) Scatter plots showing individual and mean values ± SEM of the 
levels of each LCC and HLCC crosslink measured in normal breast tissues, and in ER+, HER2+ 
and TN breast tumors. The total abundance of crosslinks (i) was calculated by summing all 
individual crosslinks and the total tissue HLCC abundance (j) was calculated by summing DHLNL, 
Pyr, and d-Pyr and plotted as individual and mean values ± SEM. All crosslink values are 
normalized to total collagen content (i.e. hydroxyproline abundance) and wet tissue weight and 
are plotted as log2 transformed normalized peak areas from LC-MS data. Statistical analysis of 
crosslinks was performed using one-way ANOVA test for overall analysis and unpaired t-test was 
used for individual comparisons (*p < 0.05; **p < 0.01). (k,l) Heat maps of Spearman correlation 
coefficients indicating correlations between levels of total collagen crosslinks and collagen I 
content (k) and between levels of each HLCC and the top 10% of elastic modulus measurements 
(l) stratified by tumor subtype. 
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Interestingly, when we subdivided the IBC collagen crosslinking analysis into breast tumor 
subtype the most significant increase in total collagen crosslinks was calculated to be in the TN 
breast tumors (Fig.  3.1i). Furthermore, biochemical quantification of total tissue collagen 1A1 or 
1A2 did not account for the higher total number of collagen crosslinks in the TN breast tumor 
tissue (Fig. 3.1k). Instead, molecular characterization of the isolated tissue collagen revealed that 
the TN tumors had a distinctive crosslink profile due to a strong preference for a combination of 
DHLNL, Pyr, and d-Pyr crosslinks (Fig. 3.1d-j). Subtype analysis further revealed that the level 
of hydroxylysine aldehyde-derived collagen crosslinks (HLCCs) in the TN subtype correlated 
significantly and positively with the stiffness of the stroma at the invasive front of the tumor tissue 
(Fig. 3.1l). These findings highlight the importance of HLCC collagen crosslinking in breast cancer 
aggression.  
Increased collagen crosslinking correlates with high expression of stromal LOX and 
PLOD2 in aggressive tumor subtypes 
To determine if the observed increase in collagen crosslinking and stromal stiffness in TN 
tumors was related to the expression levels of enzymes implicated in regulating collagen 
crosslinking, we analyzed publicly available human breast cancer gene expression array data (n 
= 1904) for the genes coding these enzymes and examined their correlation to breast cancer 
subtype. Bioinformatics analyses revealed a significant increase in the major collagen crosslinking 
enzyme LOX, but not lysyl oxidase like two (LOXL2), in the more aggressive HER2 and TN tumor 
subtypes and indicated that LOX levels were particularly high in TN tumors (Fig. 3.2a-b). The 
arrays also showed bulk gene expression of PLOD2, the major regulator of HLCC accumulation, 
to be highly upregulated in aggressive human TN breast cancers (Fig. 3.2c).  
To gain insight into the cellular sources of LOX and LH2 in human tumors, we used laser 
capture microdissection to isolate regions of tumor epithelium and stroma to identify the origins 
of LOX and LH2 in invasive human breast cancers147,148. Gene expression analysis of stromal and  
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Figure 3.2: LOX and PLOD2 are enriched in TNBC and predominantly expressed by stromal 
cells. (a-c) Gene expression analysis of LOX (a), LOXL2 (b), and PLOD2 (c) stratified by ER+ (n 
= 1355), HER2+ (n = 127), and triple negative (TN; n = 299) subtypes. Gene expression is plotted 
as a scatter plot of mRNA z scores with the mean ± SEM. Statistical analysis was performed using 
one-way ANOVA for overall analysis and unpaired t-test was used for individual comparisons (*p 
< 0.05, **p < 0.01, ***p < 0.001, ****p<0.0001). (d) Scatter plot of individual and mean values ± 
SEM comparing LOX (n = 47) and PLOD2 (n = 57) gene expression in microdissected epithelial 
and stromal compartments of human invasive breast carcinomas. Statistical analysis was 
performed using Mann-Whitney U test (****p < 0.0001). (e) Quantification of LOX and PLOD2 
gene expression fold change from (d) in stromal cells relative to epithelial cells. (f-g) Restriction 
of the stromal/epithelial gene expression analysis in (d) and (e) to estrogen receptor (ER) negative 
and progesterone receptor (PR) negative samples. (LOX n = 11, PLOD2 n = 15). Statistical 
analysis was performed using Mann-Whitney U test (*p < 0.05, **p < 0.01). 
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epithelial compartments revealed that the stromal cells in the tumor tissue expressed significantly 
more LOX and PLOD2 than the associated tumor epithelium. The data further indicated that this 
relationship was more evident in the breast tissue from women with ER-/PR- breast cancer that 
is frequently the more aggressive tumor subclass (Fig. 3.2d-g). 
The findings implicate, but do not definitively demonstrate a role for LOX and PLOD2 in 
generating the increased level and greater complexity of collagen crosslinking we quantified in 
the more aggressive human breast tumors. Nevertheless, the combination of these gene 
expression data with our findings showing increased collagen crosslink abundance provide 
compelling evidence to suggest that increased expression of LOX and PLOD2, particularly from 
stromal cells, likely contribute to elevated levels of collagen crosslinks and HLCCs in TN tumors. 
Moreover, given that TN tumors are the most aggressive and lethal breast cancer, these data link 
human breast tumor aggression to increased levels of total and complex collagen crosslinks and 
higher stromal stiffness. Accordingly, the findings implicate the collagen crosslinking enzymes 
LOX and LH2, and by extension factors that regulate their expression, in breast cancer 
aggression. 
Stromal — and not epithelial — crosslinking enzymes regulate tissue fibrosis and collagen 
crosslinking in vivo 
Prior studies demonstrated that both cancer cell lines and stromal fibroblasts express LOX 
and LH2 to induce tissue stiffening and fibrosis implying they also drove collagen cross-linking. 
Seminal articles identified hypoxia-induced HIF1a as a key regulator of tumor epithelial LOX and 
LH2 expression and suggested epithelial secretion of these enzymes drives collagen remodeling, 
crosslinking and stiffening that foster tumor cell dissemination and primes the pre-metastatic niche 
to facilitate metastatic colonization133,134. Our analysis of breast cancer clinical specimens showed 
that the stromal cells in the breast tissue express higher levels of LOX and PLOD2 as compared 
to the breast tumor epithelium. Moreover, our prior studies showed LOX is expressed in stromal 
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fibroblasts in a transgenic mouse model of ErbB2-induced mammary tumor malignancy. 
Furthermore, we demonstrated that fibroblasts expressing LOX injected into a cleared mammary 
fat pad not only induced ECM remodeling and stiffening but also potentiated the growth and 
malignant progression of pre-malignant tumor cells injected into the modified glands35. Thus, the 
relative contribution of tumor- and stromal- derived collagen crosslinking enzymes to tumor 
fibrosis, ECM remodeling and collagen crosslinking remains unclear; particularly in the context of 
spontaneous tumors and patient tumors in which the ECM evolves concurrently with tumor 
progression.  
To directly test the extent to which epithelial-derived LOX can crosslink collagen and 
induce tissue fibrosis and stromal stiffening in mammary tissue, we created a genetically 
engineered mouse model (GEMM) in which we targeted and controlled luminal epithelial-specific 
expression of mouse LOX using the MMTV-rtTA promoter (Epithelial LOX overexpression [OX]). 
(Fig. 3.3a, Fig. A2.6a-b). We crossed these mice into the PyMT spontaneous mammary tumor 
model to enhanced LOX expression in the mammary tumor epithelium (PyMT epithelial LOX OX) 
and assayed their stromal phenotype as compared to the mammary glands from age-matched 
PyMT control mice (PyMT). Again, despite confirming ectopic LOX expression and elevated levels 
of cleaved LOX protein in the mammary tumor epithelial compartment (Fig A2.6c), we were not 
able to detect any increase in the levels, nor any altered organization of the mammary gland 
interstitial collagen (Fig 3.3b-c). Moreover, xAAA crosslinking analysis revealed that the level of 
collagen crosslinks between the PyMT control and PyMT epithelial LOX OX mammary gland 
stroma were indistinguishable (Fig. 3.3d-i). Nevertheless and importantly, we could easily and 
consistently detect a significant increase in fibrillar collagens, collagen crosslinks and stromal 
stiffness in the PyMT mammary tumors as compared to age-matched FVB mammary glands 
lacking tumors (Fig. 3.4c,f-k). These studies both validate the sensitivity of our crosslinking assay 
and imply that tumor epithelial LOX is not the primary driver of collagen crosslinking and stiffening 
in endogenous mammary tumors.  
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Figure 3.3: Epithelial-derived collagen crosslinking enzymes fail to induce collagen 
crosslinking. (a) Schematic depicting the experimental strategy used to induce epithelial Lox 
overexpression. (b) Polarized light images with brightfield inset of picrosirius red stained murine 
mammary tissues. (c) Quantification of percent area of picrosirius red staining per field of view, 
plotted as a scatter plot of the mean for each animal ± SEM. Statistical analysis was performed 
using Kruskal-Wallis one-way ANOVA (*p < 0.05 ). (d) Scatter plot showing individual and mean 
values ± SEM of total tissue collagen crosslinks in PyMT controls (Water n = 4, DOX n = 4) and 
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PyMT epithelial Lox overexpression (n = 8). (e-h) Scatter plots showing individual and mean 
values ± SEM for each LCC and HLCC collagen crosslink measured in PyMT control and PyMT 
epithelial Lox overexpression tumor tissue. (i) Scatter plot showing individual and mean values ± 
SEM of total HLCCs calculated as the sum of DHLNL and Pyr crosslinks. Quantity of crosslinks 
per tissue was calculated normalizing crosslinks to total collagen content (i.e., hydroxyproline 
abundance) and wet tissue weight. Values were plotted as log2 transformed normalized peak 
areas as quantified from LC-MS data. Statistical analyses for crosslinking data were performed 
using one-way ANOVA for overall comparison and unpaired t-test for individual comparisons (*p 
< 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). 
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Figure 3.4: Stromal-derived LOX regulates collagen crosslinking and stiffening. (a) 
Schematic depicting the experimental strategy used to induce stromal Lox overexpression. (b) 
Representative images of normal murine mammary gland and PyMT control and stromal Lox 
overexpressing tumor tissues. (Top row) Brightfield images of H&E stained murine mammary 
tissues. (Second row) Polarized light images with brightfield inset of picrosirius red stained 
murine mammary tissues. (Third row) Two photon second harmonic generation (SHG) images 
of murine mammary tissues revealing collagen organization (turquoise) and propidium iodide (PI; 
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red) stained nuclei. (Bottom row) Confocal images of mammary tissue stained with anti-FAK 
pY397 monoclonal antibody (red) and DAPI (blue; nuclei). Scale bars are all 100 µm. (c) 
Quantification of fibrillar collagen by picrosirius red staining by percent area per field of view. The 
mean of 3-5 regions was calculated and plotted for each animal ± SEM. Statistical analysis was 
performed using Kruskall-Wallis one-way ANOVA (*p < 0.05) for overall relationship and unpaired 
t-test for comparing individual groups (*p<0.05, **p<0.005). (d) Scatter plot showing individual 
values and mean of the top 10% of elastic modulus measurements performed by AFM 
microindentation on the mammary stroma from mice with PyMT-induced tumors (PyMT Control; 
n = 3 mice) as compared to the stroma in PyMT-induced tumors in which lysyl oxidase was 
elevated in stromal cells (PyMT Lox OX; n = 4 mice). Values reflect measurements taken from 3-
5 individual force map regions per mammary gland. Statistical analyses were performed using 
Mann-Whitney U test (***p < 0.001). (e) Histogram showing the distribution of the top 10% of 
elastic modulus measurements by AFM microindentation in PyMT control and Lox OX tumors. 
Statistical analysis was performed using Mann-Whitney U test (****p < 0.0001). (f) Scatter plots 
showing individual and mean values ± SEM of total collagen crosslink abundance in the normal 
murine mammary gland (n = 4) as compared to glands with doxycycline-induced PyMT tumors (n 
= 3 mice per control group) and PyMT tumors in which stromal lysyl oxidase was elevated (n = 4 
mice per Lox OX group). (g-j) Scatter plots showing individual and mean values ± SEM of LCC 
and HLCC crosslinks quantified in normal mammary gland, PyMT Control tumors and PyMT Lox 
OX tumors. (k) Scatter plot showing individual and mean values ± SEM of total HLCCs calculated 
as the sum of DHLNL and Pyr crosslinks. Quantity of crosslinks per tissue was calculated 
normalizing crosslinks to total collagen content (i.e., hydroxyproline abundance) and wet tissue 
weight. Values were plotted as log2 transformed normalized peak areas as quantified from LC-
MS data. Statistical analyses for crosslinking data were performed using one-way ANOVA for 
overall comparison and unpaired t-test for individual comparisons (*p < 0.05, **p < 0.01, ***p < 
0.001, ****p < 0.0001). 
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We and others have implicated stromal fibroblast LOX as a key promoter of epithelial 
tumor progression and aggression35,118,149. To directly test the functionality of the ectopically-  
expressed LOX and the relevance of fibroblast-specific expression of LOX, we next created 
mouse cohorts of PyMT GEMMs in which we restricted ectopic LOX expression to the stromal 
population using the Col1a1-tTA promoter (MMTV-PyMT+/-; Col1a1-tTA+/-;TetO_mLox+/-; 
herein denoted PyMT LOX OX) (Fig. 3.4a, Fig. A2.7b). To begin with, induction of LOX in the 
stromal cells markedly enhanced the amount of fibrillar collagen in the MMTV-PyMT LOX OX 
mammary glands, as revealed by quantification of polarized images of Picrosirius Red stained 
tissue (Fig. 3.4b, second row images; quantified in c). We also detected more and thicker 
linearized interstitial collagen when LOX was increased in the stromal cells by two-photon second 
harmonic generation imaging (Fig. 3.4b, third row panels). In addition, immunostaining revealed 
more phosphorylated tyrosine 397 focal adhesion kinase protein (pY397FAK) in the mammary 
epithelium of the glands in which stromal LOX was elevated (Fig. 3.4b, bottom panels), likely 
reflecting the increase in elasticity that we measured in the tissue stroma using atomic force 
microscopy (AFM) indentation (12) (Fig. 3.4d-e & Fig. A2.9b). Consistently, we measured higher 
levels of total collagen crosslinks in the PyMT LOX OX mice as compared to the levels quantified 
in the MMTV-PyMT control glands (Fig. 3.4f). Furthermore, the most significant increases that we 
quantified in the PyMT LOX OX glands were dihydroxy lysinonorleucine (DHLNL) and pyridinoline 
(Pyr) crosslinks (Fig. 3.4g-k), which are the crosslinks generated through the HLCC pathway that 
promote mechanical stability and strength in skeletal tissue146,150. Of note, we did not detect any 
increase in DHLNL or Pyr in the mammary glands in which ectopic LOX expression was elevated 
in the mammary epithelium using the MMTV promoter (Fig. 3.3g-h). These findings imply that 
stromal cells are the primary regulators of interstitial collagen crosslinking and stromal stiffening 
in mammary tumors.  
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Tissue inflammation regulates tissue fibrosis, collagen crosslinking and stromal stiffening  
Cancer progression is accompanied by tissue inflammation and the most aggressive 
human breast tumors with the stiffest invasive stroma harbor the highest number of 
macrophages26,144. Consistently, decreasing the number of tumor macrophages, either through 
genetic ablation of macrophage colony stimulating factor (CSF-1) or via pharmacological and 
inhibitory antibody treatment with anti-CSF1 antibody, reduces lung metastasis in the PyMT 
mouse model of mammary cancer142,143,151,152. Interestingly, macrophage ablation was more 
effective at preventing lung metastasis when the treatment was initiated early, prior to malignant 
transformation and coincident with the onset of tissue fibrosis142. These findings raise the 
possibility that macrophage ablation may regulate tumor aggression, at least in part, by promoting 
collagen remodeling and inducing ECM crosslinking and stromal stiffening (Fig. 3.3 & 3.4).  
To assess the possibility that there is a causal association between macrophage-mediated 
tissue inflammation, tumor fibrosis and ECM stiffening and mammary tumor aggression, PyMT 
mice were treated with anti-CSF-1 antibody or an IgG control antibody commencing at four weeks 
of age, prior to the onset of ductal hyperplasia70. Mouse cohorts (6/treatment group/time point) 
were sacrificed at eight and eleven weeks of age. Immunostaining confirmed reduction of tumor 
macrophages at eight weeks of age, that was also evident in the eleven-week-old treated tissue 
(Fig. 3.5a top panel, Fig. A2.8a). The excised lungs from the eleven week mice confirmed 
reduced frequency of lung metastasis in the anti-CSF-1 antibody-treated group (Fig. 3.5b), 
consistent with prior work documenting a significant inhibition of lung metastasis when anti-CSF-
1 treatment was initiated at four weeks142. The mammary glands from the eight and eleven week 
old mice were excised and analyzed for fibrosis and biomechanical properties (Fig. 3.5a,c-i). 
Despite confirming an equivalent number of fibroblasts in the treated and nontreated groups, 
polarized images of PS stained tissue revealed lower levels of total fibrillar collagen in the stroma 
of the eight-week anti-CSF1 antibody treated  
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Figure 3.5: Tumor infiltrating macrophages secrete TGFb to activate stromal-mediated 
collagen crosslinking. (a) Representative images of PyMT tumor tissue from 8 weeks of age 
mice treated with anti-CSF1 blocking antibody or IgG1 control. (Top row) IgG1 treated (n = 6) 
and anti-CSF1 treated (n = 5) PyMT tumor tissue stained for pan-cytokeratin (green) marking 
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epithelial cells, F4/80 (white) marking tumor infiltrating macrophages, and DAPI marking nuclei 
(blue). (Second row) IgG1 treated (n = 6) and anti-CSF1 treated (n = 5) PyMT tumor tissue 
stained for tyrosine 397 phosphorylated focal adhesion kinase (red) indicative of 
mechanosignaling and DAPI marking nuclei (blue). (Third row) Polarized light images with 
brightfield inset of IgG1 treated (n = 6) and anti-CSF1 treated (n = 6) PyMT tumor tissue stained 
with picrosirius red to visualize fibrillar collagen. (Bottom row) Lox mRNA in situ hybridization in 
IgG1 treated (n = 6) and anti-CSF1 treated (n = 5) PyMT tumor tissue and DAPI marking nuclei 
(blue). Scale bar for all images is 100µm. (b) Quantification of the number of metastatic colonies 
in the lung tissues from IgG1 treated (n = 5) and anti-CSF1 treated (n = 6) mice at 11 weeks of 
age via PyMT IHC assessing 5 layers (5 micron section; 5 sections per layer; 50-100 microns 
steps). Statistical analysis was performed using unpaired t-test (*p < 0.05). (c) Quantification of 
fibrillar collagen by picrosirius red staining by percent area per field of view in 8-week-old mice 
treated with anti-CSF1 blocking antibody or IgG1 control. The mean of 3-4 regions was calculated 
and plotted for each animal ± SEM. Statistical analysis was performed using unpaired t-test (p = 
0.08). (d) Histogram showing the distribution of the top 10% of elastic modulus measurements by 
AFM microindentation in PyMT IgG1 treated (n =6) and anti-CSF1 treated (n = 4) tumors. 
Statistical analysis was performed using Mann-Whitney U test (****p < 0.0001). (e) Quantification 
of Lox mRNA signal by percent area of signal per field of view in 8-week-old mice treated with 
anti-CSF1 blocking antibody (n = 5) or IgG1 control (n = 6). The mean of 5-6 regions was 
calculated and plotted for each animal ± SEM. Statistical analysis was performed using an 
unpaired t-test (*p < 0.05). (f-i) Scatter plots showing individual and mean values ± SEM of the 
levels of total hydroxyproline (collagen content) (f), total collagen crosslinks (g), HLCCs (h), and 
HLNL crosslinks (i) in 8-week-old IgG1 treated and anti-CSF1 treated PyMT tumors. Quantity of 
crosslinks per tissue was calculated normalizing crosslinks to wet tissue weight. Values were 
plotted as log2 transformed normalized peak areas as quantified from LC-MS data. Statistical 
analysis was performed using unpaired t-test (*p < 0.05). (j) Quantification of Tgfb1 gene 
expression by RT-qPCR in tumor cells, cancer-associated fibroblasts, and macrophages sorted 
out from PyMT tumors (n = 4). Gene expression was normalized to 18S. Statistical analysis was 
performed using Kruskal-Wallis one-way ANOVA for overall comparison and Mann-Whitney U 
test for individual comparisons (*p < 0.05, ***p < 0.001). (k) Representative images of PyMT tumor 
tissue from mice treated with IgG1 (n = 6) and anti-CSF1 (n = 5) stained for pan-cytokeratin 
(green) marking epithelial cells, SMAD2 pS465/467 (red), and DAPI marking nuclei (blue). (l) 
Scatter plot showing individual and mean values ± SEM of the mean nuclear intensity of 
pSMADS465/467 in stromal cells of IgG1 treated (n = 6) and anti-CSF1 treated (n = 5) PyMT mice. 
The mean for each animal was calculated from 4-7 regions within the tumor. Statistical analysis 
was performed using unpaired t-test (p = 0.06). (m-o) Scatter plot depicting the Spearman 
correlation of CD163 gene expression with LOX (m), PLOD2 (n), and LOXL2 (o) in human breast 
tumors (n = 1904). (p) Representative IHC images of serial human breast tumor sections stained 
for CD68 (top) and pSMAD2S465/467 (bottom) counterstained with hematoxylin to mark nuclei. (q) 
Scatter plot depicting the linear regression correlation of stromal pSMAD2 IHC staining with 
stromal CD68 IHC staining in human breast tumors (n = 10). (r) Scatter plot depicting the linear 
regression of CD14+ CD11b+ HLA-DR+ tumor associated macrophage infiltrate with tumor elastic 
modulus as measured by AFM microindentation in human breast tumors (n = 15). 
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group (Fig. 3.5a, third row panel, Fig. A2.10b-c). AFM microindentation additionally 
demonstrated that the tissue stroma from both the eight week old (Fig. 3.5d), and the eleven 
week old (not shown) mammary glands was softer, likely accounting for the reduced integrin 
mechanosignaling detected in the CSF1-antibody treated tissue, as revealed by less intense 
staining for pY397FAK (Fig. 5a, second row panel). Consistently, we also observed reduced levels 
of Lox mRNA in eight week, anti-CSF1 treated mice by in situ hybridization (Fig. 3.5a, bottom 
panel, Fig. 3.5e). In agreement with prior studies, nearly all the detected Lox mRNA was 
restricted to stromal cells (Fig 3.5a, bottom panel)118. These findings suggest that reducing the 
level of tumor-associated macrophages (TAMs) not only prevents lung metastasis but also 
concomitantly reduces tissue fibrosis and stiffening, likely by preventing stromal cell activation.   
TAMs secrete abundant TGFβ that stimulates fibroblast differentiation to a myofibroblast 
phenotype and induces expression of collagen crosslinking enzymes including LOX118. PCR 
analysis of flow activated cell sorted (FACS) cells from the transformed mammary glands of PyMT 
mice (11 weeks) confirmed that the TAMs expressed by far the highest levels of TGFβ, as 
compared to neoplastic epithelium and the cancer-associated fibroblasts (Fig. 5j). These findings 
suggest that the tumor infiltrating macrophages could promote fibrosis and stromal stiffening 
through secreted TGFβ; a finding supported by a strong stromal pSMAD2 (SMAD2 pS465/467) 
in the IgG control antibody-treated PyMT mammary glands (Fig. 3.5k-l). To examine whether 
TAM recruitment could regulate collagen crosslinking in human tumors we queried a publicly 
available human breast tumor gene expression data set for TAM markers and collagen modifying 
enzymes. Consistent with a role for TAMs in stimulating expression of collagen modifying 
enzymes, gene expression of the TAM marker CD163 positively correlated with both LOX and 
PLOD2 but not LOXL2 in human breast tumors (n = 1904) (Fig. 3.5m-o). Moreover, co-staining 
of resected human breast tumors with the macrophage/monocyte marker CD68 and the 
downstream TGFβ signaling molecule pSMAD2 Ser465/467 revealed a significant positive 
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correlation between pSMAD2 Ser465/467 and infiltrating tumor macrophages at the invasive front 
of human breast tumors (Fig. 3.5p-q). Furthermore, FACS analysis established a significant 
correlation between the infiltrating tumor associated macrophages, as demonstrated by 
CD14hiCD11b+ HLA-DR+ cell surface markers normalized to total CD45 infiltrating cells, and the 
elastic modulus of the invasive front of human invasive breast cancers (Fig. 3.5r). These findings 
suggest that tumor inflammation and macrophage secreted factors such as TGFβ could promote 
tissue fibrosis by enhancing fibroblast expression of the collagen crosslinking enzymes LOX and 
PLOD2, but not LOXL2, to induce collagen crosslinking and stromal stiffening.                                                
LH2 inhibition reduces lung metastasis and stromal LH2 predicts poor prognosis in breast 
cancer patients 
Using the data set generated from the micro-dissected tumors, we next explored the 
clinical relevance of epithelial vs. stromal LOX and PLOD2 expression by assessing their relative 
contribution to overall survival in breast cancer patients. Surprisingly, neither stromal cell nor 
epithelial LOX predicted overall patient survival in this cohort (Fig. 3.6a-b). However, the findings 
clearly showed that overexpression of stromal PLOD2, but not epithelial PLOD2, significantly 
correlated with poor breast cancer patient prognosis (Fig. 3.6c-d). The data provide further 
evidence that HLCCs, formed primarily through the activities of collagen crosslinking enzymes 
expressed by stromal cells, promote breast tumor aggression that contributes to poorer overall 
survival. The findings also highlight the importance of the collagen crosslinking profile and its 
potential impact on stromal stiffness in tumor aggression. 
LH2 (the protein encoded by PLOD2) is a key enzyme that regulates the level of HLCC 
crosslinking of fibrillar collagen and consequently contributes substantially to the tensile properties 
of the tissue stroma130,153,154. We quantified the highest level of HLCC crosslinking and the stiffest 
invasive front in the breast tissue from women with the most aggressive breast cancers (Fig. 3.1j). 
Consistently, when we analyzed the gene expression data from a published cohort of breast 
cancer patients we observed that ER-/HER2- (TN; n=133) breast cancers express the highest 
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level of the PLOD2 gene transcript as compared to the levels expressed in HER2+ (n=73) and 
ER+/HER2- (luminal, n=314) breast tumors (Fig. A2.11a)155. Further analysis showed that high 
PLOD2 expression in breast cancer patients with HER2+ and TN tumors significantly predicts 
reduced distant metastasis-free survival (DMFS), as well as increased risk of relapse in TN tumors 
(Fig. A2.11b-d)84,155. These findings implicate PLOD2/LH2 as a key regulator of breast tumor 
aggression through its ability to induce the HLCC crosslinking of fibrillar collagens that enhance 
the stiffness of the tumor stroma.  
To evaluate whether LH2 does enhance stromal stiffness to promote breast tumor 
aggression, we systemically treated a cohort of PyMT mice with the LH2 inhibitor minoxidil or 
vehicle (PBS) from five weeks of age until sacrifice at either 11-12 weeks or 13-14 weeks of age 
(Fig. 3.6e). Consistent with its predicted role in enhancing stromal stiffness through modifying the 
nature of collagen crosslinks, AFM microindentation revealed that the phenotypically-similar 
collagen-rich ECM adjacent to tumors from the minoxidil treated mice (see polarized imaging of 
picrosirius red stained tissue) was significantly softer when compared to the vehicle-treated 
age/stage-matched PyMT mice (Fig. 3.6f-h). Furthermore, inhibiting LH2 also significantly 
decreased lung metastasis, causally linking HLCC collagen crosslinking to stiffness-mediated 
breast tumor aggression (Fig. 3.6i). Our gene expression data from the epithelial and stromal 
microdissection cohort indicated that stromal PLOD2, but not epithelial PLOD2, strongly predicted 
poor survival in breast cancer patients. Therefore, we next sought to definitively assess the 
relative contribution of stromal versus neoplastic epithelial LH2 protein expression to human 
breast tumor aggression using a large tissue array of annotated human breast tumor biopsies. To 
accomplish this, we first developed an LH2 immunostaining protocol (IHC) and then we analyzed 
neoplastic epithelial and stromal expression of the LH2 enzyme in tissue biopsies from a large 
cohort of histopathologically classified breast cancer patients (N=505) with accompanying clinical  
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Figure 3.6: Stromal LH2 predicts poor patient outcomes. (a-b) Kaplan-Meier plots showing 
overall survival for patients based on levels of LOX expression in epithelial cells (low n = 28, high 
n = 36) (a) or stromal cells (low n = 23, high n = 24) (b). The median level of expression was 
defined as the cutoff for low and high expression. (c-d) Kaplan-Meier plots showing overall 
survival for patients based on levels PLOD2 expression in epithelial cells (low n = 28, high n = 29) 
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(c) or stromal cells (low n = 23, high n = 24) (d). The median level of expression was defined as 
the cutoff for low and high expression. (e) Schematic depicting the experimental timeline used to 
inhibit lysyl hydroxylase 2 in PyMT mice. (f) Representative polarized light images with brightfield 
insets of picrosirius red stained tumor tissue from PBS vehicle treated control (n = 8) and minoxidil 
treated (n = 7) PyMT mice. Scale bar is 100um. (g) Quantification of fibrillar collagen by picrosirius 
red staining by percent area per field of view. The mean was calculated and plotted for each 
animal ± SEM. (h) Histogram showing the distribution of the top 10% of elastic modulus 
measurements by AFM microindentation in PyMT control and Lox OX tumors. Statistical analysis 
was performed using Mann-Whitney U test (****p < 0.0001). (i) Scatter plot quantifying the area 
of lung sections occupied by metastases from vehicle treated (n = 9) and minoxidil treated (n = 8) 
mice at 13 weeks of age via H&E staining and assessing 4 layers (5 micron section; 5 sections 
per layer; 50-100 microns steps). Statistical analysis was performed using a two-tailed unpaired 
t-test (*p < 0.05). (j) Representative phase contrast images of sections from tissue microarrays 
(TMAs) of human breast cancers representing incident breast cancer cases collected and arrayed 
as 1-mm cores from each tumor. Sections were stained with Hematoxylin and Eosin (H&E; top) 
and lysyl hydroxylase two (LH2; bottom) via immunohistochemistry. (k) Bar graphs showing 
clinical correlation between lysyl hydroxylase two (LH2) score as a function of tumor grade (see 
Table 1 for number of patients). LH2 IHC staining was assessed with the semi-quantitative stromal 
specific H-score from 0 to 300. The lowest tertile of LH2 H-scores was defined as H-scores 
between 0 and less or equal to 120, the intermediate H-score to above 120 and equal or less than 
230, and the highest stromal LH2 score as above 230. For tumor grade and LH2 H score, 
statistical analysis was performed using a linear-by-linear association (***P<0.0001). (l) Kaplan-
Meier curves indicating cumulative breast cancer specific survival (BCSS) based on stromal LH2 
H score assessed in breast cancer patients up to 10 years after diagnosis (LH2 low n = 175, 
intermediate n = 188, high n = 146). (m) BCSS curves by stromal LH2 H score including only 
axillary lymph node negative patients (LH2 low n = 116, intermediate n = 116, high n = 90). (n) 
BCSS curves by stromal LH2 H score including only axillary lymph node positive patients (LH2 
low n = 44, intermediate n =63, high n = 54). For Kaplan-Meier curves, statistical analyses were 
performed by LogRank test. 
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information and follow up data (Table A2.2 and Table A2.3). LH2 IHC staining in the epithelium 
and stromal cells was scored as low, intermediate and high and the relationship between epithelial 
versus stromal expression and breast cancer patient outcome was calculated (Fig. 3.6j; Fig. 
A2.12a). IHC scoring analysis revealed that only a modest number of patients with poorly 
differentiated breast tumors expressed moderate to high levels of epithelial LH2 (Fig. A2.12b); a 
finding that accords with prior links between tumor size, hypoxia and LH2-dependent tumor 
aggression130,133. More strikingly however, we observed that a disproportionately high number of 
breast cancer patients with moderately and poorly differentiated breast tumors had high stromal 
cell LH2 (indicated by an H score of above 230; Fig. 3.6k). These data and our observation that 
even well differentiated breast tumors express intermediate levels of stromal cell LH2 (H score 
above 120 and equal or less than 230) imply that stromal cell LH2, rather than epithelial LH2, may 
be a more robust indicator of breast tumor aggression. Consistently, stratification of breast tumor 
patient analysis into ER+/HER2- (N=296); HER2+ (N=36) and TN (N=32) showed an enrichment 
for intermediate and high stromal LH2 H-score in the more aggressive cancer subtypes (Table 
A2.2 and Table A2.3). Furthermore, we uncovered a significant correlation between high stromal 
cell LH2 H-score and shorter breast cancer patient-specific survival when adjusted for age at 
diagnosis (Fig. 3.6l). We also established a significant association between stromal cell but not 
epithelial LH2 levels and survival in lymph node positive breast cancer patients but not lymph 
node negative breast cancers (Fig. 3.6m-n; Fig. A2.12d-e). These clinical data identify stromal 
cell LH2 as a novel biomarker with potential to predict metastatic disease and poor patient survival 
among breast cancers overall, as well as within the highest risk TN breast cancer subtype.   
Discussion 
We identified infiltrating macrophages as key regulators of stromal cell-mediated collagen 
crosslinking, stromal stiffening and tumor metastasis. Our clinical findings corroborated our 
experimental results, revealing significant associations between macrophages and collagen 
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crosslinking enzymes providing evidence for a critical impact of inflammatory stromal cell-
mediated collagen crosslinking and stromal stiffening in tumor aggression and patient outcome. 
Diverse subsets of myeloid cells account for adverse patient outcomes because they differentially 
promote angiogenesis, tumor cell intravasation, and suppress the anti-tumor immune 
response156. Our results expand this perspective to include a key role for early infiltrating 
macrophages in initiating a collagen crosslinking and stiffening program that ultimately fosters 
tumor aggression and progression. We also determined that TN breast cancers contain much 
higher amounts of LH2- and LOX-derived collagen crosslinks. Specifically, we demonstrated that 
significantly higher levels of HLCC crosslinks could explain their higher stromal stiffness and 
aggressiveness26. Intriguingly, in depth collagen analysis suggested that each breast tumor 
subtype exhibits a distinct collagen organization, stiffness and crosslinking profile, raising the 
possibility that distinct collagen architectures and crosslinking signatures may reflect differences 
in tissue pathobiology. Indeed, TN breast cancers often present with high macrophage infiltration; 
an observation that is consistent with our AFM, two photon and collagen crosslinking analysis 
data26. Given that the immune cell infiltrate significantly influences treatment response it is 
tempting to speculate that distinct collagen architectures, crosslinking signatures and stiffnesses 
similarly regulate therapeutic efficacy.  
We determined that stromal LH2 is a robust predictor of survival in breast cancer patients, 
especially in those that are lymph node positive, supporting a potentially important clinical link to 
stromal collagen crosslinking. Our data also revealed that both the upregulation of crosslinking 
enzymes and in turn, collagen crosslinking, occur at an early stage of malignancy that is 
concurrent with tumor cell invasion and coincident with the accumulation of infiltrating 
macrophages157. In part, this may explain why therapeutics targeting LOX and LOXL2 have thus 
far failed to significantly prolong cancer patient survival. Substantial levels of collagen crosslinking 
are likely to have occurred prior to therapy administration, and while these agents may prevent 
further crosslinking activity, they are not capable of reversing crosslinks or collagen modifications 
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already present in the tissue. The early initiation of collagen crosslinking also suggests that a 
detectable increase in stromal LH2 may provide an early prognostic marker of disease 
progression and aggression that could inform treatment strategies. To that end, our results show 
for the first time that LH2-derived collagen crosslinks are not only a distinct feature of enhanced 
stromal stiffening in TN breast cancer but are able to predict distant metastasis-free survival. 
These results also suggest that the profile of collagen crosslinks, and not simply crosslink 
abundance alone, may play a role in promoting tumor aggression, thus warranting further 
investigations into the contributions of HLCCs to ECM mechanical properties and tumor 
aggression.  
Our findings identify fibroblasts as the dominant cell population that promotes 
reorganization and crosslinking of interstitial collagen to stiffen the tissue stroma. Only stromal-
targeted, and not epithelial-targeted, tissue-specific inducible LOX produced any measurable 
change in collagen architecture, stiffness or crosslink abundance in a spontaneous tumor134,158,159. 
Our conclusion is consistent with earlier work in which we failed to detect any alterations in 
fibrosis, collagen organization or stiffness when LOXL2 was either genetically ablated, or 
ectopically-increased in the mammary epithelium of PyMT mouse tumors, despite documenting 
a significant impact on metastasis149. Nevertheless, it is possible that our bulk assay would not 
detect any small increase in collagen crosslinking induced by invading tumor cells expressing 
high levels of LOX. To this end, immortalized tumor cells engineered to overexpress LOXL2 
injected orthotopically as a bolus of cells were able to induce fibrosis and quantifiable changes in 
collagen remodeling and tissue stiffening; a finding we too confirmed using isolated PyMT tumor 
cells overexpressing the LOXL2 enzyme149. Nevertheless, our data support the notion that in 
spontaneous tumors, the proximity of stromal cells to collagen and their significantly higher 
expression of crosslinking enzymes dictate the profile and extent of collagen crosslinking. Given 
that LH2 modifies collagen intracellularly and stromal cells secrete the vast majority of the 
interstitial fibrillar collagen, it is not surprising that this is the case127,160. Moreover, our results 
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stress the necessity of choosing an appropriate model to study tumor associated ECM remodeling 
and suggest that orthotopic models may fail to accurately recapitulate the natural evolution of 
ECM in tumor progression.  
Our findings not only underscore the importance of stromal stiffness and collagen 
crosslinking in cancer-associated fibrosis and disease aggression, but also define in more detail 
the molecular nature of collagen modifications that accompany pathological fibrosis. Clarifying the 
nature of collagen modifications and specific mechanisms regulating those alterations in fibrosis 
will assist in the strategic design of novel, efficacious strategies to combat progressive fibrosis 
and should prove instrumental in enabling further experimentation to understand pathological 
fibrosis. Indeed, defining the molecular regulators that stimulate collagen cross-linking, and 
mechanisms that distinguish resolvable from non-resolvable fibrosis would identify attractive 
therapeutic targets for several pathological fibrotic diseases with limited treatment options. 
Methods 
Human breast specimen acquisition and processing 
Fresh human breast specimens from breast reduction, prophylaxis, or breast tumor 
mastectomy were either embedded in an optimum cutting temperature (OCT) aqueous 
embedding compound (Tissue-Plus, Scigen, Cat# 4583) within a disposable plastic base mold 
(Fisher, Cat# 22-363-554) and were snap frozen by direct immersion into liquid nitrogen and kept 
at -80°C freezer until cryo-sectioning for analysis, or specimens were formalin fixed and paraffin 
embedded (FFPE). All human breast specimens were collected from prospective patients 
undergoing surgical resection at UCSF or Duke University Medical Center between 2010 and 
2014. The selected specimens were de-identified, stored, and analyzed according to the 
procedures described in Institutional Review Board (IRB) Protocol #10-03832 and #10-05046, 
approved by the UCSF Committee of Human Resources and the Duke’s IRB (Pro00034242)26. 
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Mouse studies 
Macrophages were depleted in MMTV-PyMT mice by i.p. injections of 1 mg of anti-CSF1 
antibody clone 5A1 or an IgG1 control every 7 days starting at 4 weeks of age. Mice were 
sacrificed at 8 and 11 weeks of age for tissue analysis.  
Minoxidil and PBS vehicle was administered by i.p. injections of 3 mg/kg minoxidil in PBS 
three times per week starting at 6 weeks of age. Mice were sacrificed at 11-12 and 13-14 weeks 
of age for tissue analysis.  
Generation of mice 
All mouse studies were maintained under pathogen-free conditions and performed in 
accordance with the Institutional Animal Care and Use Committee and the Laboratory Animal 
Research Center at the University of California, San Francisco. 
TetO-mLOX-eGFP construct and transgenic mouse generation   
Full length mouse Lox (mLox) cDNA was purchased from OriGene. The full length ORF 
was amplified by PCR using forward and reverse primers respectively: 
GCAGGGATCCGCCACCATGCGTTTCGCCTGGGCTG  and 
GGCGTCTAGAGCACCATGCGTTTCGCCTGGGCTGTGC. Following digestion with BamHI and 
XbaI, the PCR product was inserted into pSK TetO IRES 3xnlsEGFP161 downstream of the Tet 
regulated minimal CMV promoter and a 5’ UTR containing a chimeric intron of human β-globin 
and immunoglobulin heavy chain genes, which was expressed as a bicistronic mRNA via an 
internal ribosome entry site (IRES2) with eGFP targeted to the nucleus by a N terminal in frame 
fusion of 3 tandem repeats of the SV40 nuclear localization sequence (nls). The fragment 
containing the expression cassette from Tet regulated promoter to SV40 polyadenylation signal 
(SV40pA) was agarose gel purified from XhoI– EagI digested donor plasmid and was used to 
generate TetO-mLox-eGFP transgenic mice by pronuclear injection into FVB/n oocyte (Mouse 
Biology Program at UC Davis; project number MBP-834; colony number PN663).     
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Generation of MMTV-PyMT/Col1a1(2.3)-tTA/TetO-mLox-eGFP mice 
The MMTV-PyMT/Col1a1(2.3)-tTA/TetO-Rs1 triple transgenic mice were generated by 
heterozygote or homozygote crosses of mice carrying the TetO-mLox-eGFP transgene with mice 
carrying heterozygote of the Col1a1(2.3)-tTA transgene (line 139)162 or MMTV-rtTA  and MMTV-
PyMT transgene163 to generate the experimental triple-transgenic genotype. In all breeding 
thereafter, MMTV-PyMT/Col11a1-tTA or MMTV-rtTA/TetO-mLox-eGFP male mice were crossed 
with TetO-mLox-eGFP female mice. Two mg/mL doxycycline hyclate (Alfa Aesar; Cat# J60579) 
was added to 5% sucrose water to modulate TetO-mLox-eGFP transgene expression.  
Preparation of human breast specimens for hydrolysis 
OCT was removed from tissue blocks by first transferring biospecimens to a conical tube 
and then performing 5X washes with 70% ethanol followed by 5X washes with 18 MΩ H2O. Each 
wash consisted of vortexing the sample for 15 minutes at 4°C and then centrifuging at 18,000 x g 
for 15 minutes at 4°C. Between 1 and 3 milligrams of tissue was washed with 1X PBS buffer by 
vortexing for 15 minutes at 4°C and then sonicated on ice for 20 seconds using a Sonic 
Dismembrator M100 (ThermoFisher, San Jose, CA, USA). The homogenate was then centrifuged 
at 18,000 x g for 20 minutes at 4°C. The supernatant was removed and the pellet was re-
suspended in 1mg/mL NaBH4 (prepared in 0.1N NaOH) in 1X PBS for 1 hour at 4°C with vortexing. 
The reaction was neutralized by adding glacial acetic acid to a final concentration of 0.1% (pH ~ 
3 -4)164. The sample was then centrifuged at 18,000 x g for 20 minutes at 4°C. The supernatant 
was removed, and the pellet was washed three times with 18 MΩ H2O to remove residual salt 
that could interfere with downstream LC-MS/MS analysis. The remaining pellet was dried under 
vacuum for further analysis. 
Protein hydrolysis 
The dried sample was placed in a glass hydrolysis vessel and hydrolyzed in 6N HCl, 0.1% 
phenol. The hydrolysis vessel is flushed with N2 gas, sealed and placed in a 110°C oven for 24 
hours. After hydrolysis, the sample was cooled to room temperature and then placed at -80°C for 
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30 minutes prior to lyophilization. The dried sample was re-hydrated in 100μL of 18 MΩ H2O for 
5 minutes, then 100 μL of glacial acetic acid for 5 minutes and finally 400 μL of butan-1-ol for 5 
minutes. Importantly, 10 μL of sample is removed after re-hydration in water and saved for 
determination of hydroxyproline content.   
Preparation of crosslink enrichment column 
CF-11 cellulose powder is loaded in a slurry of butan-1-ol: glacial acetic acid, water (4:1:1) 
solution onto a Nanosep MF GHP 0.45μm spin columns until a settled resin bed volume of 
approximately 5mm is achieved. The resin is washed with 1.5 mL 4:1:1 organic mixture using an 
in-house vacuum manifold set up. Re-hydrated samples are then loaded onto individual columns, 
the vacuum is turned on and the sample is pulled through the resin into glass collection vials. The 
flow through is again passed over the resin to ensure maximal binding of crosslinked amino acids 
and set aside. The column is then washed with 1.5 mL of fresh 4:1:1 organic mixture. A fresh 
collection vessel is placed under the column and 750 μL of 18 MΩ H2O is used to elute crosslinked 
amino acids off of the CF-11 resin. The eluent is then placed in a speed vac and run until complete 
dryness. Dried eluent is then reconstituted in a buffer appropriate for downstream MS analysis on 
amide HILIC UHPLC columns.  
UHPLC analysis 
Up to 20 µL of tissue hydrolysates were analyzed on a Vanquish UPHLC system 
(ThermoFisher, San Jose, CA, USA) using an Acquity UHPLC BEH Amide column (2.1 x 100mm, 
1.7 μm particle size – Waters, Milford, MA, USA). Samples were separated using a 5 minute 
gradient elution (55% - 40% Mobile phase B) at 250 μL/min (mobile phase: (A) 10 mM ammonium 
acetate adjusted to pH 10.2 with NH4OH (B) 95% acetonitrile, 5% Mobile Phase A, pH 10.2, 
column temperature: 35°C.  
MS data acquisition 
The Vanquish UPHLC system (ThermoFisher, San Jose, CA, USA) was coupled online 
with a QExactive mass spectrometer (Thermo, San Jose, CA, USA), and operated in two different 
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modes – 1. Full MS mode (2 μscans) at 70,000 resolution from 75 to 600 m/z operated in positive 
ion mode and 2. PRM mode at 17,500 resolution with an inclusion list of in-tact crosslinked amino 
acid masses (Supplementary Table 2), and an isolation window of 4 m/z. Both modes were 
operated with 4 kV spray voltage, 15 sheath gas and 5 auxiliary gas. Calibration was performed 
before each analysis using a positive calibration mix (Piercenet – Thermo Fisher, Rockford, IL, 
USA). Limits of detection (LOD) were characterized by determining the smallest injected 
crosslinked amino acids (LNL, DHLNL, d-Pyr,) amount required to provide a signal to noise (S/N) 
ratio greater than three using < 5 ppm error on the accurate intact mass. Based on a conservative 
definition for Limit of Quantification (LOQ), these values were calculated to be threefold higher 
than determined LODs.  
MS data analysis 
MS Data acquired from the QExactive were converted from a raw file format to .mzXML 
format using MassMatrix (Cleveland, OH, USA). Assignment of crosslinked amino acids was 
performed using MAVEN (Princeton, NJ, USA)165. The MAVEN software platform provides the 
means to evaluate data acquired in Full MS and PRM modes and the import of in-house curated 
peak lists for rapid validation of features. Normalization of crosslinked amino acid peak areas was 
performed using two parameters, 1. Hydroxy proline content and 2. Tissue dry weight pre-
hydrolysis (in milligrams)164. Hydroxy proline content is determined by running a 1:10 dilution of 
the pre-enrichment sample through the Full MS mode (only) described above and exporting peak 
areas for each run.  
Quantification of crosslinked amino acids 
Relative quantification of crosslinked amino acids was performed by exporting peak areas 
from MAVEN into GraphPad (La Jolla, CA, USA) and normalizing based on the two parameters 
described above. Statistical analysis, including T test and ANOVA (significance threshold for P 
values <0.05) were performed on normalized peak areas. Total crosslink plots were generated by 
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summing normalized peak areas for all crosslinks in a given sample. Total HLCC plots were 
generated by summing normalized peak areas for all HLCC (DHLNL, Pyr, dPyr) for each sample.  
Picrosirius red staining and quantification 
FFPE tissue sections were stained using 0.1% Picrosirius red (Direct Red 80, Sigma-
Aldrich, Cat# 365548 and picric acid solution, Sigma-Aldrich, Cat# P6744) and counterstained 
with Weigert’s hematoxylin (Cancer Diagnostics, Cat# CM3951), as previously described26. 
Polarized light images were acquired using an Olympus IX81 microscope fitted with an analyzer 
(U-ANT) and a polarizer (U-POT, Olympus) oriented parallel and orthogonal to each other. 
Images were quantified using an ImageJ macro to determine percentage area coverage per field 
of view. The ImageJ macro is available at https://github.com/northcottj/picrosirius-red.  
Second harmonic generation image acquisition 
Second harmonic generation (SHG) imaging was performed using a custom-built two-
photon microscope setup equipped resonant-scanning instruments based on published designs 
containing a five-PMT array (Hamamatsu, C7950), as previously published26. The setup was used 
with two channel simultaneous video rate acquisition via two PMT detectors and an excitation 
laser (2W MaiTai Ti-Sapphire laser, 710–920 nm excitation range). SHG imaging was performed 
on a Prairie Technology Ultima System attached to an Olympus BX-51 fixed stage microscope 
equipped with a 25X (NA 1.05) water immersion objective. Paraformaldehyde-fixed or FFPE 
tissue sections were exposed to polarized laser light at a wavelength of 830 nm and emitted light 
was separated using a filter set (short pass filter, 720 nm; dichroic mirror, 495 nm; band pass 
filter, 475/40 nm). Images of x–y planes at a resolution of 0.656 mm per pixel were captured using 
at open-source Micro-Magellan software suite. 
Immunofluorescence/Immunohistochemistry 
Immunofluorescence staining was performed as previously described26. Briefly, mouse 
tissues were harvested and fixed with 10% buffered formalin phosphate (Fisher, Cat# 100-20) for 
16-24 hours at room temperature and then further processed and paraffin-embedded. Five-µm 
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sections dried for 30 minutes in 60ºC, follow by deparaffinization and rehydration. Antigen retrieval 
was perform using DAKO Target Retrieval Solution (DAKO, Cat# S1699) for five minutes in a 
pressure cooker set to high pressure. Tissue sections were incubated with anti-FAK pY397 
antibody (Abcam, Cat# Ab39967, dilution 1:25) overnight at 4°C and with anti-rabbit IgG Alex 
Fluor 633 (ThermoFisher, Cat# A-21070, dilution 1:2000) for one hour at room temperature.  
Antigen retrieval for immunofluorescent staining of SMAD2 pS465/467, cytokeratin 8+18, 
cytokeratin 5, F4/80, vimentin, and PDGFRα was performed using Diva Decloaker (BioCare, Cat# 
DV2004MX) for five minutes in a pressure cooker set to high pressure. Tissue sections were 
incubated with anti-SMAD2 pS465/467 antibody (Millipore, Cat# AB3849-I, dilution 1:100), anti-
F4/80 antibody (AbD Serotec, clone CI:A3-1, Cat# MCA497GA, dilution 1:400), anti-cytokeratin 
8+18 antibody (Fitzgerald, Cat# 20R-CP004, dilution 1:400), anti-cytokeratin 5 antibody 
(Fitzgerald, Cat# 20R-CP003, dilution 1:400), anti-vimentin antibody (Cell Signaling, Cat# 5741, 
dilution 1:100), and anti-PDGFRα (CD140a) antibody (Biolegend, Cat# 135901, dilution 1:100) 
overnight at 4°C and with anti-rat IgG Alex Fluor 488 (ThermoFisher, Cat# A-11006, dilution 
1:1000), anti-guinea pig IgG Alex Fluor 568 (ThermoFisher, Cat# A-11075, dilution 1:1000), anti-
rabbit IgG Alex Fluor 633 (ThermoFisher, Cat# A-21070, dilution 1:2000), anti-rabbit IgG Alex 
Fluor 633 (ThermoFisher, Cat# A-21070, dilution 1:1000) for one hour at room temperature. 
Quantification of stromal nuclear SMAD2 pS465/467 was performed using Imaris 9. 
Surfaces were created around each nucleus and epithelial nuclei were manually excluded based 
on cytokeratin signal and cell morphology. The means of the mean nuclear signal intensity for all 
stromal nuclei were calculated for each field of view and averaged for every animal.  
Lungs from 11-week-old IgG1 control and anti-CSF1 treated PyMT mice were cut into 5 
micron sections from 5 layers with 100 microns between the first three layers and 50 microns 
between the last two layers. Sections were analyzed for metastases by PyMT staining. Antigen 
retrieval was performed in Tris-EDTA buffer at pH 9 for four minutes in a pressure cooker set to 
low pressure. Tissue sections were incubated with anti-PyMT antibody (Novus Biologicals, Cat# 
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NB-100-2749, dilution 1:250) overnight at 4°C and with a biotinylated anti-rat antibody for 1 hour 
at room temperature. Vectastain Elite ABC (Vector, Cat# PK6100) and ImmPACT DAB 
Peroxidase (Vector, Cat# SK-4105) were used for signal detection and nuclei were counterstained 
with methyl green.  
mRNA In Situ Hybridization 
Fresh, RNase-free FFPE sections were stained with RNAscope multiplex fluorescent 
reagent kit V2 according to standard manufacturer protocol. Target retrieval was performed using 
8 minute incubation in a pressure cooker set to low pressure. Opal 520 and Opal 570 
(PerkinElmer) were used at 1:1500 for target visualization.  
Gene expression by RT-qPCR 
 Total RNA was reverse-transcribed using random primers (Amersham Bioscienes) and 
results were normalized to 18S RNA to control for varying cDNA concentration between samples. 
The primer sequences used are 18s forward 5’-GGATGCGTGCATTTATCAGA-3’ and reverse 5’- 
GGCGACTACCATCGAAAGTT-3’, Lox forward 5’-CGGGAGACCGTACTGGAAGT-3’ and 
reverse 5’-CCCAGCCACATAGATCGCAT-3’, Loxl2 forward 5’-CACAGGCACTACCACAGCAT-
3’ and reverse 5’-CCAAAGTTGGCACACTCGTA-3’, and Tgfb1 forward 5’- 
TCATGTCATGGATGGTGCCC-3’ and reverse 5’-GTCACTGGAGTTGTACGGCA-3’. 
Atomic force microscopy data acquisition 
Atomic force microscopy (AFM) measurements were performed as previously described 
(2). Briefly, 20µm OCT-embedded frozen human breast tissue or 30µm mouse mammary gland 
sections were fast thawed by immersion in PBS at room temperature. Next, these sections were 
immersed in PBS containing phosphatase inhibitors (Roche, Cat# 04906845001), protease 
inhibitor (Roche, Cat# 04693124001), and propidium iodide (ACROS, Cat# 440300250) and 
placed on the stage for AFM measurements. AFM indentations were performed using an MFP3D-
BIO inverted optical AFM (Asylum Research) mounted on a Nikon TE2000-U inverted fluorescent 
microscope. Silicon nitride cantilevers were used with a spring constant of 0.06 N m-1 and a 
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borosilicate glass spherical tip with 5 µm diameter (Novascan Tech). The cantilever was calibrated 
using the thermal oscillation method prior to each experiment. The indentation rate was held 
constant within each study but varied between 2-20 μms-1 with a maximum force of 2 nN between 
studies. Force maps were obtained as a raster series of indentations utilizing the FMAP function 
of the IGOR PRO build supplied by Asylum Research. Elastic properties of ECM were reckoned 
using the Hertz model. A Poisson’s ratio of 0.5 was used in the calculation of the Young’s elastic 
modulus. 
Western blotting 
Snap frozen tissues were ground while frozen and lysed in 2% SDS containing protease 
and phosphatase inhibitor. Samples were boiled for 5 minutes (95°C) and loaded onto the SDS-
polyacrylamide gel, and protein was separated at 110 constant volts.  
The protein was transferred onto a pre-wet polyvinylidene difluoride (PVDF) membrane 
(100% methanol, 1 minute) at 250 mA for 2 hours. The PVDF membrane was rinsed with TBST 
and non-specific binding was blocked with 5% nonfat dry milk dissolved in TBST. The membrane 
was then incubated with the primary antibody overnight at 4°C, washed with TBST, incubated 
with horseradish-peroxidase conjugated secondary antibody (1 hour, room temperature; dilution 
1:5000), washed with TBST, and detected with the chemiluminescence system Quantum HRP 
substrate (Advansta #K-12042). Quantification was performed using gel densitometry in ImageJ. 
Primary antibodies used are anti-LOX (1:1000, Abcam Cat# ab174316) and anti-E-cadherin 
(1:1000, Cell Signlaing Cat#3195).  
Flow cytometry 
Mouse tissue was harvested and chopped with a razor blade. Chopped tissue was 
digested in 100 U/mL Collagenase Type 1 (Worthington Biochemical Corporation, Cat# 
LS004196), 500 U/mL Collagenase Type 4 (Worthington Biochemical Corporation, Cat# 
LS004188), and 200 µg/mL DNase I (Roche, Cat# 10104159001) while shaking at 37°C. Digested 
75 
 
tissue was filtered using a 100 µm filter to remove remaining pieces. Red blood cells were lysed 
in ammonium-chloride-potassium buffer and remaining cells were counted. Cells were stained 
with fluorophore-conjugated primary antibodies for 30 minutes on ice and subsequently stained 
with a viability marker. Antibodies used for staining were anti-mouse CD24-PE (BD Pharmingen, 
Cat# 553262), anti-mouse TER-119-APC (BioLegend, Cat# 116212), anti-mouse CD45-APC 
(BioLegend, Cat# 103112), anti-mouse CD29-AF700 (BioLegend, Cat# 102218), anti-mouse 
Ly6G-BV421 (BioLegend, Cat# 127628), anti-mouse F4/80-BV510 (BioLegend, Cat# 123135), 
anti-mouse CD29-AF488 (BioLegend, Cat# 102212), anti-mouse CD140a-PE (BioLegend, Cat# 
135906), anti-mouse CD31-APC (BioLegend, Cat# 102410), anti-mouse CD11c-BV605 (BD 
Pharmingen, Cat# 563057), anti-mouse CD24-BV650 (BD Pharmingen, Cat# 563545), anti-
mouse CD11b-PerCP-Cy5.5 (eBiosciences, Cat# 45-0112-82), anti-mouse CD45-AF700 
(BioLegend, Cat# 103128), anti-mouse Ly6C-BV711 (BioLegend, Cat# 128037), anti-mouse 
MHCII-PE-Cy7 (BioLegend, Cat# 107630), and Zombie NIR Fixable Viability Dye (BioLegend, 
Cat# 423105). Cells were then analyzed on a flow cytometer.  
Patient gene expression analysis  
For the stroma and epithelium specific gene expression analysis, the breast cancer 
datasets from Finak et al. 2008 and Gruosso et al. 2019 have been used. Briefly, whole Human 
Genome 44 K arrays (Agilent Technologies, product G4112A) were used for stroma and epithelial 
expression profiles. Details of laser capture microdissection, RNA extraction, labeling, 
hybridization, scanning and quality filters are described in Finak et al., 2006 and 2008. Briefly, the 
dataset was normalized using loess (within-array) and quantile (between-array) normalization. 
Probes were ranked by Inter-quartile range (IQR) values, and the most variable probe per gene 
across expression data were selected for further analysis. Replicate arrays with a concordance 
above 0.944 were averaged before assessing differential expression.  
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An association between PLOD2 and distant metastasis-free survival (DMFS) has been 
determined using an online tool (http://xena.ucsc.edu) to download GEO data (GSE2034, 
GSE5327, and GSE7390) from 683 patients analyzed on Affymetrix U133A platform as described 
in Yau et al. (46). Patients have been excluded from analyses if their molecular subtyping of 
ER/HER2 status and PAM50 did not align: ER+/HER2- must always be luminal, ER+ or-/HER2+ 
must be HER2+, and ER-/HER2- must always be basal-like. PLOD2 expression levels have been 
divided based on the median for each tumor subtype: ER+/HER2- (low n=157; high=157), ER- or 
+/HER2+ (low n=36; high=37), and ER-/HER2- (low n=66; high=67). All statistical analyses were 
done using GraphPad Prism Version 6.01: Kruskal-Wallis one-way ANOVA test was applied to 
assess the relationship in PLOD2 expression levels among tumor subtypes and log rank P value 
(Mantel-Cox) tests for DMFS curves.  
An association between PLOD2 gene expression and relapse-free survival (RFS) has 
been determined using an online tool (http://kmplot.com/analysis/) from 1,809 patients analyzed 
on Affymetrix platform (HGU133A and HGU133+2 microarrays)84. Affymetrix ID 202619 or 
202620 were used for PLOD2 probes (2014 version) in these analyses. All breast cancer patients 
in this database were included regardless to lymph node status, TP53 status, or grade. No 
restrictions were placed in term of patient treatment. PLOD2 expression levels have been divided 
based on the median for each tumor subtype: ER+/PR+/HER2- (low n=170; high=169), ER-/PR-
/HER2+ (low n=58; high=57), and ER-/PR-/HER- (low n=128; high=127). Hazard ratio (and 95% 
confidence intervals) and log rank P values were calculated and displayed once the data were 
plotted using the online tool.   
The cBioPortal for Cancer Genomics was used to determine the levels of LOX, PLOD2, 
and LOXL2 gene expression in breast cancer patients segregated by ER and HER2 status166,167. 
ER, PR, and HER2 status were determined by gene expression levels. Samples positive for both 
ER/PR and HER2 overexpression were excluded from subtype analysis. All data accessed via 
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cBioPortal are from the 1904 patients in the METABRIC dataset analyzed for gene expression by 
Illumina human v3 microarray168. All 1904 samples were included in correlation analyses.  
Statistical analysis 
GraphPad Prism Version 6.01 was used to perform all statistical analyses with the 
exception of LH2 IHC and RFS correlations with PLOD2. Statistical significance was determined 
using the appropriate tests as noted in the figure legends or method section. 
LH2 IHC and prognostic analyses: 
Study population 
The female Malmö Diet and Cancer Study (MDCS) cohort consists of women born 1923–
1950)169. Information on incident breast cancer is annually retrieved from the Swedish Cancer 
Registry and the South Swedish Regional Tumor Registry. Follow-up until December 31, 2010, 
identified a total of 910 women with incident breast cancer, the following conditions excluded 
patients: 1) with in situ only cancers (n=68), 2) who received neo-adjuvant treatments (n=4), 3) 
with distant metastasis at diagnosis (n=14), 4) those who died from breast cancer-related causes 
≤ 0.3 years from diagnosis (n=2), and finally 5) patients with bilateral cancers (n=17). In addition, 
one patient who declined treatment for four years before accepting surgery was excluded. Patient 
characteristics at diagnosis and pathological tumor data were obtained from medical records. 
Information on cause of death and vital status was retrieved from the Swedish Causes of Death 
Registry, with last follow-up December 31st, 2014. Ethical permission was obtained from the 
Ethical Committee at Lund University (Dnr 472/2007). All participants originally signed a written 
informed consent form. 
Tumor evaluation 
Tumor samples from incident breast cancer cases in MDCS were collected, and a tissue 
microarray (TMA) including two 1-mm cores from each tumor was constructed (Beecher, WI, 
USA). Within the study population (N=910), tumor tissue cores were accessible from 718 patients. 
Four-μm sections dried for one hour in 60ºC were automatically pretreated using the Autostainer 
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plus, DAKO staining equipment with Dako kit K8010 (Dako, DK). A primary mouse monoclonal 
Lysyl Hydroxylase 2 (LH2) antibody (Origene; Cat# TA803224, dilution 1:150) was used for the 
immunohistochemical staining. 
TMA cores were analyzed by a cohort of 4 anatomic pathologists (ACN, AC, JG, AN) using 
the PathXL digital pathology system (http://www.pathxl.com, PathXL Ltd., UK) blinded to all other 
clinical and pathologic variables. Immunohistochemistry for LH2 was assessed separately for 
stromal and neoplastic epithelial components of the tumors. Stromal LH2 staining was assessed 
with the semi-quantitative H-score which combines intensity and proportion positive assessments 
into a continuous variable from 0-300170. Cellular stromal components were assessed (including 
fibroblasts, macrophages, endothelial cells, adipocytes, and other stromal cell types) while areas 
of significant lymphocytic infiltrate were specifically excluded from the percent positive estimation. 
Neoplastic epithelial LH2 staining intensity was scored 0-3+ based on the predominant intensity 
pattern in the tumor — invasive tumor cells did not display significant intra-tumoral heterogeneity 
of LH2 staining within each core.  Verification of inter-observer reproducibility for the H-score was 
established in a training series of 16 cases evaluated by all study pathologists to harmonize 
scoring. Inter-observer agreement in the training set was very high, evaluating the IHC scores 
both as continuous variables (Pearson correlation coefficients ranging from 0.912-0.9566, all p 
values < 0.0001), and after transformation into categorical data (negative, low, and 
moderate/high; weighted kappa coefficients ranging from 0.673-0.786). In addition, 50 cases of 
the study cohort were evaluated blindly by two pathologists to confirm data fidelity; the Pearson 
correlation coefficient = 0.7507 (p = 5.7 E-05), considered a strong level of agreement.  
After exclusion of cases for which LH2 was not evaluable on the TMA, H-scores for 505 
patients were included for statistical associations with clinicopathologic features and patient 
outcome. Each patient was represented by two cores, and TMA core 1 and core 2 were merged 
into a joint variable favoring the highest stromal LH2 H-score or epithelial LH2 intensity because 
we predict that higher H-score would drive patient outcome in accordance with our gene 
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expression data demonstrating high LH2 expression correlated with poor outcome. The Pearson 
correlation coefficient between cores = 0.647, demonstrating moderate agreement among the 
stromal LH2 H-scores for the two cores. In cases with only one TMA core providing a LH2 score, 
the expression of this core was used. Further, the joint stromal LH2 variable was categorized into 
tertiles based on the study population with valid LH2 annotation (N=505). The lowest tertile of LH2 
H-scores were defined as scores between 0 and less or equal to 120 (N=171), the intermediate 
H-score as above 120 and equal or less than 230 (N=188), and the highest stromal LH2 score as 
above 230 (N=146). 
Statistical analyses for LH2 IHC analyses  
Patient and tumor characteristics at diagnosis in relation to stromal LH2 expression were 
categorized and presented as percentages. Continuous variables are presented as the mean and 
min/max. The associations between LH2 expression and grade or tumor size, respectively, were 
analyzed through linear-by-linear association. The association between LH2 expression and 
prognosis was examined using breast cancer-specific mortality as endpoint, which was defined 
as the incidence of breast cancer-related death. Follow-up was calculated from the date of breast 
cancer diagnosis to the date of breast cancer-related death, date of death from another cause, 
date of emigration or the end of follow-up as of December 31st, 2014. Main analyses included the 
overall population; additional analyses were performed in subgroup analyses stratified by 
estrogen receptor (ER) or axillary lymph node involvement (ALNI) status. The prognostic impact 
of stromal LH2 expression was analyzed through Cox proportional hazards analyses, which 
yielded hazard ratios (HR) and 95% confidence intervals (CI) for crude models, and multivariate 
models adjusted for age at diagnosis (model 1) and tumor characteristics ER (dichotomized, cut-
off 10% stained nuclei), ALNI (none or any positive lymph node involvement), histological grade 
(Nottingham grade I-III), and tumor size (dichotomized using cut-off 20 mm). Kaplan-Meier curves 
including the LogRank test indicated LH2 status to particularly impact the first 10 years after 
diagnosis and survival variables constructed to capture these effects were used in Cox regression 
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models investigating the effects during the first post-diagnostic decade.  All statistical analyses 
were performed in SPSS version 22.0 (IBM). 
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Introduction 
Neoadjuvant chemotherapy (NAC) is increasingly used in the treatment of invasive breast 
cancer providing the opportunity to understand the relative sensitivity or resistance of tumors while 
still in situ 171.  Many studies have demonstrated the more aggressive nature of hormone receptor 
negative, HER-2 negative breast cancer (TNBC) compared to other phenotypes, and TNBCs 
have been repeatedly correlated with increased local recurrence, distant recurrence and worse 
overall survival 172. Despite significant advances in targeted therapies for hormone receptor 
positive and HER2 positive disease, cytotoxic chemotherapy remains the standard of care for 
most TNBC, followed by radiation in selected cases.  
TNBC tumors that are completely eradicated in the breast with NAC, known as a 
pathologic complete response (pCR), are associated with an excellent patient prognosis, 
significantly better than for patients whose tumors lack such a response 172. However, this 
response is heterogeneous, and TNBC patients continue to have worse overall outcomes 
compared to breast tumors of other subtypes. Currently, there are no reliable methods to identify 
patients that are likely to respond well and those that are likely to be chemotherapy resistant. The 
ability to improve predicted response would improve personalization of treatment and patient 
outcomes. There is also an urgent need for a deeper understanding of the biological basis for 
chemotherapy response in TNBC that will inform treatment decisions and the development of 
effective strategies to overcome therapy resistance. 
In addition to their highly aggressive phenotype, TNBC have a characteristically high 
degree of extracellular matrix (ECM) remodeling and stiffening. ECM stiffness is well known to 
heavily influence cell behavior and has been shown to extrinsically modulate drug responses via 
blood vessel occlusion that limits transport. ECM stiffness can also regulate cell intrinsic behaviors 
that affect therapy response including proliferation, survival, and growth factor signaling23. Despite 
the important role the ECM plays in regulating cell behavior, it is unclear whether the stiffer ECM 
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measured in TNBC contributes to the underlying mechanisms whereby the evolving ECM may 
impact the development of therapy resistance.  
NF-κB signaling is critically important to ECM-mediated cell survival. The apoptosis 
resistance phenotype of 3D mammary epithelial tissue-like structures in a reconstituted basement 
membrane depended upon the activation of NF-κB, but NF-κB activity per se failed to protect 
mammary epithelial cells from apoptosis when cells were plated as 2D monolayers173,174. 
Importantly, NF-κB activity can drive resistance to chemo- and radiation therapy in many tumor 
types by modifying the expression and stability of apoptosis regulators including the stress-
activated protein kinase, JNK175–179. JNK permits apoptosis induction in a variety of cell types in 
response to assorted cell stress stimuli, including paclitaxel, TRAIL, UV and ionizing radiation 
exposure180–182. Recently, an in vivo screen also implicated JNK as a key mediator of 
chemotherapeutic efficacy 183. Importantly, JNK signaling is responsive to mechanical stimuli such 
as substrate strain and mediates mechanical stretch-induced apoptosis of renal epithelial cells 
17,184. Moreover, Rho GTPases that are elevated in mammary epithelial cells cultured on stiff 
matrices also activate JNK 27,185. Thus, substrate stiffness could enhance JNK activation to 
sensitize mammary epithelial cells to anti-tumor treatment.  
Here we show that residual disease from NAC treated tumors localizes within a soft, 
remodeled ECM niche. We then demonstrate that mammary epithelial cells and tumor cells 
assembled into organoid-like structures in soft ECMs can efficiently engage NF-κB signaling to 
resist apoptosis induction. Conversely, cells interacting with a stiff substrate show reduced NF-
κB signaling and increased JNK activity that sensitize them to several apoptosis inducing agents. 
Consistent with this mechanism, we show human breast tumors that failed to achieve pCR in 
response to NAC were enriched for an NF-κB gene expression signature, and NF-κB levels were 
highly elevated in residual disease of NAC treated TNBC tumors. This study implicates ECM 
stiffness as an important mediator of response to chemotherapy and radiation in TNBC. It has 
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important clinical implications for understanding the heterogenous response to therapy in TNBC 
and for making rational, informed decisions in selecting effective therapies.  
Results 
Residual triple negative breast tumors are surrounded by a soft interstitial stroma  
 We first assessed the organization and biophysical properties of the ECM associated with 
primary human TNBCs and compared these stromal features with the ECM of residual tumor 
tissue of neoadjuvant chemotherapy-treated tumors. Histological analysis of a cohort of primary 
untreated TNBC biopsies demonstrated the presence of an interstitial stroma comprised of 
abundant ECM proteins that was infiltrated by numerous tumor epithelial cells (Figure 4.1 A). 
Picrosirius red staining (PS) and polarized light imaging revealed that the ECM in the primary, 
stage-matched, human TNBCs (N=9) contained abundant quantities of fibrillar type collagens 
(Figure 4.1 B-C), that atomic force microscopy (AFM) indentation showed was significantly stiffer 
than that measured previously in the normal human breast (Figure 4.1 D-E) 26. By contrast, 
hematoxylin and eosin staining indicated that the residual tumor epithelium in the neoadjuvant 
chemotherapy treated TNBCs (N=7) was dramatically reorganized into epithelial aggregates, 
many of which were reminiscent of tubular carcinoma (compare Figure 4.1 A). Polarized light 
imaging of picrosirius red stained tissue further revealed that the residual TNBC tumors were 
surrounded by large quantities of a remodeled collagenous-rich stroma (compare Figure 4.1 B-
C). Nevertheless, AFM analysis revealed that the collagen-rich fibrillar stroma surrounding the 
residual tumor was significantly softer than that measured in the primary TNBCs (Figure 4.1 D-
E). The findings indicate that chemotherapy treatment not only significantly reduces the density 
of the tumor epithelium but also induces substantial remodeling and reorganization of the ECM 
stroma that substantially decreases its stiffness. The data raise also the intriguing possibility that 
the softened, remodeled ECM might be causally linked to the pathogenesis of the treatment 
resistant residual tumor tissue. 
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Figure 4.1: Treatment resistant residual disease localizes within a soft ECM niche. (A) 
Representative hematoxylin and eosin stained tissue sections of untreated human primary tumor 
or residual disease from neoadjuvant chemotherapy treated tumors. (B) Representative images 
of brightfield and polarized light picrosirius red stained primary tumor or residual disease tissue 
sections. (C) Bar graph showing mean and SEM of polarized light picrosirius red signal for primary 
tumor (n = 9) and residual disease (n = 7) from 3-5 fields of view per sample. (D) Scatter plot 
showing mean and SD of atomic force microscopy elasticity measurements of tumor cell adjacent 
extracellular matrix from primary tumor (n = 9) and residual disease (n = 7). Values reflect 
measurements from 3-5 elasticity maps per sample. (E) Histogram showing distribution of the top 
10% of AFM elasticity measurements in each group. Statistical analyses were performed using 
two-tailed Mann-Whitney U test (*p < 0.05, **p < 0.01, ***p < 0.001). All scale bars are 200 µm. 
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ECM stiffness regulates chemotherapy responsiveness of human mammary tumors  
 To determine if a remodeled, compliant ECM could compromise chemotherapy 
responsiveness of mammary tumors and whether any changes in response vary with tumor stage, 
we tested the impact of ECM stiffness on the apoptosis response of premalignant and malignant 
mammary epithelial organoids to a standard chemotherapy agent. We generated proliferating 
organoid structures of estrogen receptor (ER) and human epidermal growth factor receptor 2 
(HER2) negative, premalignant human mammary epithelial (MEC) MCF10A and malignant HMT-
3522 T4-2 cells to model early and late stage TNBCs. MCF10A and T4-2 mammary cells were 
plated on basement membrane (BM)-conjugated polyacrylamide (PA) substrates calibrated to 
recapitulate the low and high end of the elasticity we measured in the normal (E = 150 Pascals; 
Pa) and tumor stroma (E = 5,000 Pa)27,186. The mammary tumor cells were overlaid with growth 
media containing two percent reconstituted basement membrane (rBM; Matrigel) to create a 
three-dimensional (3D) ECM microenvironment. The tumor cells were then grown for 5 days until 
they formed small uniformly proliferating tissue-like colonies (16-24 cells/colony)27,186. The 
organoids were then treated with increasing dose of the chemotherapeutic drug paclitaxel. 
Intriguingly, the treated premalignant colonies cultured on the stiff PA substrate displayed a 
significant, dose-dependent loss of metabolic activity, as measured by the MTT assay, and a 
concomitant increase in apoptosis, as measured by positive staining for cleaved caspase 3 
(Figure 2 A-C). By contrast, the premalignant structures cultured on the soft substrate showed 
only a modest reduction in metabolic activity and apoptosis levels were significantly lower than 
that quantified in the same proliferating structures plated on a stiff ECM substrate, despite 
exposure to the same dosages of paclitaxel (Figure 4.2 A-C). The malignant colonies plated on 
the compliant ECM substrates similarly displayed a striking apoptosis resistance in response to 
the paclitaxel chemotherapy, as indicated by significantly lower levels of cleaved caspase 3 
following paclitaxel treatment, than those malignant colonies grown on the stiffer ECM substrate 
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(Figure 4.2 D-E). Importantly, malignant tumor colonies of T4-2 embedded within stiff ribose 
cross-linked collagen gels and injected into the fat pads of immunocompromised mice were also 
significantly more sensitive to chemotherapy treatment. Indeed, the xenografted tumor colonies 
shrunk significantly more (Figure 4.3 A) and displayed higher levels of apoptosis in response to 
paclitaxel treatment as compared to the orthotopically implanted tumors injected within the soft 
collagen ECM gels (Figure 4.3 B). The findings argue that a stiff ECM sensitizes breast tumors 
to chemotherapy both in culture and in vivo. 
ECM stiffness modulates the radiation responsiveness of mammary tumors 
To investigate whether ECM stiffness influences tumor treatment efficacy by modifying 
drug uptake or tumor cell accessibility we next examined the impact of ECM stiffness on ionizing 
radiation (IR) responsiveness, a standard therapeutic modality used to treat TNBCs that is not 
influenced by multidrug resistance pumps or drug diffusion through ECM. Interestingly, once 
again experiments showed that premalignant mammary organoids cultured on a stiff substrate 
exhibited a significant reduction in metabolic activity and displayed greater numbers of cells that 
stained positively for cleaved caspase 3, 48 hours following exposure to increasing dose of IR 
(Figure 4.4 A-B, Figure A3.1). Furthermore, a clonogenic survival assay revealed that a 
significantly higher proportion of the three-dimensional premalignant mammary cell colonies 
irradiated on a soft substrate not only survived better but were also able to regrow into viable 
colonies when plated on a soft ECM, as compared to parallel cultures of premalignant cell colonies 
irradiated and re-plated on stiff substrates (Figure 4.4 C). A stiff ECM similarly sensitized colonies 
of malignant T4-2 cells to increasing doses of IRs, whereas the same tumor colonies interacting 
with a soft ECM were protected, even when the malignant colonies were exposed to doses up to 
12 Gy of IR (Figure 4.4 D-E). Thus, while a soft ECM apparently protects premalignant and 
malignant mammary tumor tissue from traditional anti-cancer treatments, this effect is not likely 
mediated through reducing drug accessibility or by elevating the activity of a drug efflux pump. 
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Figure 4.2: Stiff ECM enhances chemotherapeutic efficacy. (A) Bar graph with mean and SEM 
of loss of metabolic activity by MTT assay after paclitaxel treatment in MCF10A cells cultured on 
soft or stiff substrates. (B) Representative images of MCF10A cells cultured on soft and stiff 
substrates treated with 10 nM paclitaxel or DMSO vehicle stained for cleaved caspase 3 (green) 
and with DAPI (gray). (C) Bar graph with mean and SEM of the percentage of cleaved caspase 3 
positive cells from MCF10A cultures on soft and stiff substrates with paclitaxel treatment. At least 
300 cells on soft and 900 cells on stiff were counted in each experiment. (D) Representative 
images of T4-2 cells cultured on soft and stiff substrates and treated with 10 nM paclitaxel or 
DMSO vehicle stained for cleaved caspase 3 (green) and with DAPI (gray). (E) Bar graph showing 
mean and SEM of the percentage of cleaved caspase 3 positive cells from T4-2 cultures on soft 
and stiff substrates with paclitaxel treatment. At least 900 cells on soft and stiff were counted in 
each experiment.  Statistical analyses were performed using two-tailed t test (*p < 0.05, **p < 
0.01, ***p < 0.001). Unless otherwise noted, n = 3 for all experiments. All scale bars are 100 µm. 
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Figure 4.3: ECM stiffness sensitizes tumors to chemotherapy in mice. (A) Bar graph showing 
mean and SEM of the change in tumor volume after 14 days of paclitaxel treatment of animals 
with orthotopically injected T4-2 cells in soft (n = 7) or stiff (n = 8) collagen gels. (B) Representative 
images of FFPE tumor tissue sections stained for cleaved caspase 3 from orthotopically injected 
T4-2 tumors in soft or stiff collagen after 14 days of paclitaxel treatment. Statistical analyses were 
performed using two-tailed t test (*p < 0.05, **p < 0.01, ***p < 0.001). Unless otherwise noted, n 
= 3 for all experiments. All scale bars are 100 µm. 
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Apoptosis sensitivity cannot be explained by differences in cell proliferation 
Chemotherapy and radiation efficacy are due in part to exploitation of the rapid division of 
cancer cells to induce apoptosis. A stiff ECM can enhance growth factor-dependent signaling and 
elevate cell growth 23,27,187. This enhanced growth phenotype raises the possibility that the 
differential tumor sensitivity incurred by interaction with a stiff ECM substrate to both the 
chemotherapy and the radiation treatment reflected an increased rate of cell proliferation. 
However, all culture and in vivo experiments were initiated when the tumor colonies were actively 
proliferating. Thus, all treatments were started at days 4-5 of culturing when the premalignant and 
malignant organoids were proliferating at similar levels on both the soft and stiff ECM substrates. 
Indeed, quantification of phosphorylated histone H3 (Ser10) staining confirmed that the level of 
proliferation was equally high in both the premalignant and malignant tumor three dimensional 
colonies plated on the soft and stiff substrates between days 4 and 5, when the anti-tumor 
treatments were initiated (Figure 4.4 A-B). Flow activated cell sorting (FACs) analysis of 
propidium iodide (PI) labeled cells further revealed that neither the doubling time nor the 
proportion of cells in G1, S and G2 of the cell cycle were significantly different on either soft or 
stiff ECM substrates at the time of treatment (Figure 4.5 C-D). Accordingly, the findings rule out 
the possibility that significant differences in cell proliferation or cell cycle status explain the 
differential apoptosis sensitivity exhibited by the premalignant and malignant tumor colonies on 
the soft versus the stiff ECM substrates.  
Nonetheless, to provide further evidence to rule out the possibility that the stiffness-
mediated sensitization of premalignant and malignant colonies to apoptosis inducing agents could 
simply be explained by differences in cell proliferation, we treated the two types of tumor colonies 
with TNF-related apoptosis-inducing ligand (TRAIL), a cytokine that binds to the death receptors 
DR4 and DR5. Importantly, TRAIL is induced in tumors in response to chemo and radiation  
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Figure 4.4: Stiff ECM enhances efficacy of radiation therapy. (A) Representative images of 
irradiated or nonirradiated MCF10A cells cultured on soft and stiff substrates stained for cleaved 
caspase 3 (green) and with DAPI (gray). (B) Bar graph showing mean and SEM of the percentage 
of cleaved caspase 3 positive cells from MCF10A cultures on soft and stiff substrates with 
increasing dose of γ-irradiation. At least 300 cells on soft and 500 cells on stiff were counted in 
each experiment (n = 4-5). (C) Bar graph showing mean and SEM of the percentage of MCF10A 
cells cultured on a soft or stiff substrate that are capable of reforming colonies after γ-irradiation 
(n = 3). (D) Representative images of irradiated or nonirradiated T4-2 cells cultured on soft and 
stiff substrates stained for cleaved caspase 3 (green) and with DAPI (gray). (E) Bar graph showing 
mean and SEM of the percentage of cleaved caspase 3 positive cells from T4-2 cultures on soft 
and stiff substrates with increasing dose of γ-irradiation. At least 800 T4-2 cells on soft and 1000 
T4-2 cells on stiff were counted in each experiment (n = 4). All statistical analyses were performed 
using two-tailed t test (*p < 0.05, **p < 0.01, ***p < 0.001). All scale bars are 100 µm. 
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Figure 4.5: Proliferation cannot explain ECM stiffness-mediated sensitivity to apoptosis-
inducing therapies. (A) Representative images of MCF10A and T4-2 cells at day 5 of culture on 
soft or stiff substrates stained for phosphorylated histone H3 (Ser10). (B) Bar graph showing 
mean and SEM of the percentage of phosphorylated histone H3 (Ser10) positive MCF10A and 
T4-2 cells on day 5 of culture on soft or stiff substrates. (C) Bar graph showing mean and SEM of 
the doubling time of MCF10A cells cultured on soft or stiff substrates each day over five days of 
culture. (D) Bar graph showing mean and SEM of the percentage of MCF10A cells in each cell 
cycle phase at day 5 of culture on soft or stiff substrates. At least 1000 T4-2 cells on soft and stiff 
were counted in each experiment. Statistical analyses were performed using two-tailed t test (*p 
< 0.05, **p < 0.01, ***p < 0.001). Unless otherwise noted, n = 3 for all experiments. All scale bars 
are 100 µm. 
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treatment, and the cytokine induces tumor cell apoptosis through a pathway that is independent 
of cell growth 188,189. Consistent with our conclusion that the differential sensitivity of mammary 
tumors to anti-tumor treatment is independent of cell growth, we noted that the proliferating 
premalignant MCF10A and the malignant T4-2 colonies interacting with soft ECM substrate both 
were protected from TRAIL-induced apoptosis. Thus, we observed a dose-dependent increase in 
apoptosis, as indicated by cleaved caspase 3, in the TRAIL treated tumor colonies cultured on 
stiff as compared to soft ECM substrates (Figure 4.4 E-H). Accordingly, these data demonstrate 
that the sensitivity of the tumors to these anti-cancer treatments is likely not due to differences in 
cell proliferation. Instead the findings suggest that differences in tumor treatment sensitivity likely 
reflect a cell intrinsic phenotype conferred on the tumors by the compliance of the ECM substrate. 
A stiff ECM sensitizes tumor colonies to anti-tumor treatment by enhancing JNK activation  
Cell survival in response to an anti-tumor treatment is regulated by stress response 
pathways whose activity is controlled by a comparatively small number of key molecular 
regulators or signaling nodes 159,190. Jun N-terminal kinases (JNKs) comprise one major signaling 
node that can dictate whether a cell survives or undergoes apoptosis in response to an exogenous 
stress 191,192. JNKs phosphorylate c-Jun, which is a component of the Fos/Jun AP-1 transcriptional 
complex that regulates the expression of key cell growth and survival genes 191. AP-1 levels and 
transcriptional activity can be induced by a stiff ECM, possibly because a stiff ECM increases 
RhoA-ROCK signaling 185. Elevated JNK activity has also been implicated in both the intrinsic 
apoptosis pathway triggered in response to stress-inducing stimuli such as UV radiation or 
chemotherapeutic agents, as well as via the extrinsic apoptosis pathway stimulated in response 
to death receptor signaling 191. Accordingly, we reasoned that a stiff ECM substrate could sensitize 
mammary tumors to anti-tumor treatment by enhancing JNK activity. Consistently, we observed 
a significant and sustained increase in JNK activity following paclitaxel treatment in both the 
premalignant and malignant tumor colonies when they were cultured on the stiff as  
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Figure 4.6: ECM stiffness broadly sensitizes cells to apoptosis through proliferation-
independent pathways. (A) Representative images of vehicle and TRAIL treated MCF10A 
cells cultured on soft and stiff substrates stained for cleaved caspase 3 (green) and with DAPI 
(gray). (B) Bar graph showing mean and SEM of the percentage of cleaved caspase 3 positive 
cells from MCF10A cultures on soft and stiff substrates with increasing dose of TRAIL. At least 
300 cells on soft and 700 cells on stiff were counted in each experiment (n = 3-4).  (C) 
Representative images of vehicle and TRAIL treated T4-2 cells cultured on soft and stiff 
substrates stained for cleaved caspase 3 (green) and with DAPI (gray). (D) Bar graph showing 
mean and SEM of the percentage of cleaved caspase 3 positive cells from T4-2 cultures on soft 
and stiff substrates with increasing dose of TRAIL (n = 4). At least 1000 T4-2 cells on soft and 
stiff were counted in each experiment. Statistical analyses were performed using two-tailed t 
test (*p < 0.05, **p < 0.01, ***p < 0.001). Unless otherwise noted, n = 3 for all experiments. All 
scale bars are 100 µm. 
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compared to the soft ECM substrate (Figure 4.5 A, Figure A3.3). Furthermore, and importantly, 
treating tumor cells with a pharmacological inhibitor of JNK activity, SP600125, significantly 
protected the premalignant tumor colonies plated on the stiff ECM substrate from apoptosis 
induction. Indeed, inhibiting JNK reduced apoptosis as indicated by the percentage of activated 
caspase 3 positive cells, induced in the tumor colonies in response to paclitaxel treatment when 
they were cultured on the stiff ECM substrates, as compared to those cultured on a soft ECM 
substrate that were treated with the same doses (Figure 4.5 B). Furthermore, to more directly 
implicate JNK in the stiffness-mediated sensitization of tumor tissue to anti-cancer treatment, we 
engineered the MCF10A MECs to express either a dominant negative JNK1 or JNK2 construct 
that were designed to prevent kinase activation 193. Consistent with our hyper JNK activation 
hypothesis, both dominant negative JNK constructs rendered the MCF10A MECs interacting with 
the stiff ECM substrates resistant to apoptosis induction following treatment with either paclitaxel 
or TRAIL (Figure 5.5 C). Moreover, to further implicate stiffness-mediated modulation of JNK 
activity in tumor treatment responsiveness, we next tested whether a gain of JNK activity could 
sensitize the tumor tissue interacting with a soft ECM substrate to anti-tumor treatment. The 
MCF10A MECs were engineered to constitutively activate JNK by expressing a MKK7-JNK1 
fusion protein that renders the JNK1 protein constitutively active 194,195. Importantly, increasing 
JNK activity sensitized the tumor tissue to paclitaxel treatment and enhanced the level of 
apoptosis induced, as indicated by greater numbers of activated caspase 3 positive cells, even 
when the cells were cultured on a soft ECM substrate (Figure 5 D). Notably, the level of apoptosis 
induced in the MKK7-JNK1 expressing premalignant tumor cells cultured on the soft ECM 
substrate was virtually identical to that observed in the vector expressing tumor tissue cultured on 
the stiff ECM substrate. The data functionally implicate JNK activity as one key mechanism 
whereby a stiff ECM substrate can sensitize mammary tumors to anti-cancer apoptosis inducing 
agents.  
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Figure 4.7: Enhanced JNK activity in cells on stiff ECM sensitizes cells to chemotherapy. 
(A) Representative Western blot bands for phosphorylated c-Jun (Ser63) in MCF10A cultured on 
soft or stiff substrates after 10nM paclitaxel treatment or paclitaxel with 5 µM JNK inhibitor 
SP600125. (B) Bar graph showing mean and SEM of the percentage of cleaved caspase 3 
positive cells from MCF10A cultured on soft and stiff substrates treated with 10nM paclitaxel or 
paclitaxel plus 5 µM JNK inhibitor SP600125 (n = 2-3). (C) Bar graph showing mean and SEM of 
the percentage of cleaved caspase 3 positive cells from MCF10A cultured on soft and stiff 
substrates and stably transduced with dominant negative JNK1 or JNK2 or the vector control and 
treated with 10nM paclitaxel. (D) Bar graph showing mean and SEM of the percentage of cleaved 
caspase 3 positive cells from MCF10A cultured on soft and stiff substrates and transduced with 
a constitutively active MKK7-JNK1 fusion protein and treated with 10nM paclitaxel. Unless 
otherwise noted, n = 3 for all experiments. Statistical analyses were performed using two-tailed t 
test (*p < 0.05, **p < 0.01, ***p < 0.001). 
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Figure 4.8: A soft ECM increases NF-κB signaling to regulate JNK activity and apoptosis. 
(A) Western blot showing bands for phosphorylated c-Jun (Ser63) in MCF10A cells stably 
transduced with a dominant negative IκBαM mutant (dnIκB) or the vector backbone and cultured 
on soft or stiff substrates at indicated timepoints after 10nM paclitaxel treatment. (B) Bar graph 
showing mean and SEM of Western blot quantifications of phosphorylated c-Jun (Ser63) by pixel 
density normalized to E-cadherin loading control (n = 4). (C) Bar graph showing mean and SEM 
of the percentage of cleaved caspase 3 positive cells from MCF10A or T4-2 cells expressing a 
dominant negative IκBαM mutant cultured on soft or stiff substrates and treated with 10nM 
paclitaxel. At least 400 MCF10A cells or 600 T4-2 cells were counted in each experiment. (D) Bar 
graph showing mean and SEM of the percentage of cleaved caspase 3 positive cells from 
MCF10A or T4-2 cells expressing a dominant negative IκBαM mutant cultured on soft or stiff 
substrates and treated with 200 ng/mL TRAIL. Unless otherwise noted, n = 3 for all experiments. 
Statistical analyses were performed using two-tailed t test (*p < 0.05, **p < 0.01, ***p < 0.001). 
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NF-κB represses JNK activity to promote tumor treatment resistance  
We next assessed whether ECM stiffness could modulate the levels and/or activity of JNK 
regulators previously implicated in tumor treatment resistance. Elevated tumor levels of nuclear 
NF-κB have been implicated in cancer aggression and poor patient outcome 196,197. Experimental 
models have also shown that NF-κB activity enhances tumor cell survival and resistance to anti-
tumor treatment both in culture and in vivo 173,174,198–200. We therefore tested whether ablating NF-
κB activity could sensitize mammary tumor organoids to anti-tumor treatment and if this was linked 
to enhanced JNK activation. We engineered premalignant MCF10A mammary tumor cells with a 
dominant negative IκBαM mutant that sequesters NF-κB in the cytosol. Consistent with prior 
studies, we noted that ablating NF-κB activity significantly increased JNK activity, even in tumor 
organoids cultured on the soft ECM substrate (Figure 4.6 A-B). Furthermore, and importantly, 
inhibiting NF-κB significantly sensitized both the MCF10A and T4-2 colonies to both paclitaxel 
and TRAIL treatment, even when they were grown on a soft ECM substrate (Figure 4.6 C-D). 
These findings not only implicate NF-κB activity as a key regulator of JNK-dependent apoptosis 
signaling, but they also revealed an unappreciated potential link between ECM stiffness, NF-κB 
and JNK activity in the pathogenesis of treatment resistant breast tumors.  
NF-κB activity predicts pathological response to neoadjuvant chemotherapy, modulates 
anti-tumor treatment response, and is elevated in residual TNBCs  
We next explored the relevance of NF-κB activity in breast cancer patient response to 
therapy. Analysis of I-SPY patient data sets from neoadjuvant chemotherapy treated patients 
showed that patients who failed to achieve a pCR had primary tumors that were significantly 
enriched for an NF-κB dependent gene signature with a normalized enrichment score (NES) of 
1.799 (Figure 4.7 A) 201. The findings are consistent with prior studies suggesting NF-κB target 
genes modulate tumor response to chemotherapy.  
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Figure 4.9: NF-κB activity antagonizes tumor therapy. (A) Gene set enrichment analysis for 
NF-κB target genes in human breast cancer samples prior to treatment that failed to achieve a 
pathological complete response (n = 138 total patients). Normalized enrichment score (NES) is 
1.799. (B) Bar graph showing mean and SEM of tumor volume of subcutaneously injected T4-2 
tumors treated with radiation or radiation in combination with NF-κB inhibitor JSH-23 (n = 7-8 
animals per group). Cartoon shows experimental design. (C) Representative images of p65 IHC 
in untreated primary human triple negative breast tumors or in residual disease of chemotherapy 
treated human triple negative breast tumors (n = 6 primary, n = 8 residual disease). (D) Bar graph 
showing mean and SEM of the percent of p65 positive cells in primary human triple negative 
breast tumors or in residual disease of chemotherapy treated human triple negative breast tumors 
(n = 6 primary, n = 8 residual disease). Statistical analyses were performed using two-tailed t test 
(B) or two-tailed Mann-Whitney U test (D) (*p < 0.05, **p < 0.01, ***p < 0.001). Scale bars are 100 
µm. 
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Nonetheless, to directly test whether NF-κB activity could antagonize anti-tumor treatment 
responsiveness, we injected malignant T4-2 cells subcutaneously into the rear flanks of 
immunocompromised nude mice. After two weeks the mice were injected either with vehicle or 
the NF-κB inhibitor JSH-23 and thereafter the tumors were subjected to ionizing radiation (4 Gy) 
treatment. Tumor response rates were assessed by monitoring changes in tumor growth. We 
observed that NF-κB inhibition potentiated therapy response, and those tumors whose NF-κB 
activity had been inhibited with JSH-23, grew significantly slower following radiation treatment as 
compared to the vehicle treated tumors (Figure 4.7 B). These findings further implicate elevated 
NF-κB activity in the treatment resistance phenotype of mammary tumors.  
 To explore the clinical relevance of links between ECM substrate stiffness, elevated NF-
κB activity and treatment resistance, we next examined NF-κB levels in the neoadjuvant treated, 
residual TNBCs surrounded by the highly compliant, remodeled ECM stroma. Consistent with a 
compliant ECM enhancing NF-κB activity to potentially impair the response of TNBCs to anti-
cancer treatment, we quantified a significant increase in NF-κB (p65) in the residual epithelium in 
the chemotherapy treated TNBC patients that were surrounded by the remodeled, soft stroma. In 
contrast, the level of NF-κB was markedly lower in the tumor epithelium in a cohort of untreated 
TNBC patients in which the associated and surrounding ECM was significantly stiffer (Figures 
4.1 D-E, 4.7 C-D). These studies imply that a remodeled, compliant ECM could contribute to the 
treatment resistance of TNBCs to preclude a pathological complete response. The data also 
implicate anti-apoptotic NF-κB activity in the pathogenesis of this residual tumor phenotype.  
Discussion 
In this study, we identified ECM stiffness as a critical modulator of anti-tumor treatment 
response. Using cultured 3D organoids of premalignant and malignant tumors and xenografted 
malignant tumors, we determined that a stiff ECM substrate broadly sensitizes tumor cells to the 
chemotherapeutic agent paclitaxel and to ionizing radiation and did so irrespective of cell cycle 
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status or level of cell proliferation. Surprisingly, we found that the tumor tissue interacting with a 
soft ECM was able to efficiently activate NF-κB to resist even high doses of chemotherapy, 
ionizing radiation and even death receptor signaling. By contrast, we observed that a stiff ECM 
substrate sensitized tumor organoids to anti-tumor therapies by promoting therapy-induced stress 
signaling through JNK to abrogate pro-survival NF-κB signaling. Critically, we determined that 
breast cancer patients whose primary tumors had high NF-κB activity also had a higher rate of 
treatment resistance and post-treatment were enriched for NF-κB activity. Consistently, residual 
chemotherapy resistant TNBC tissue that was surrounded by a highly remodeled, soft ECM also 
showed high levels of nuclear NF-κB. These findings are consistent with prior studies implicating 
NF-κB activity in the treatment resistance of tumors and highlight the importance of tissue context 
in regulating anti-tumor treatment response. These data also suggest therapies designed to inhibit 
NF-κB could be used to improve the treatment response of TNBCs to enhance the long-term 
survival of these patients.  
Consistent with an association between a soft ECM and treatment resistance, we 
observed a profoundly remodeled ECM in post-treatment human TNBCs and showed that this 
modified ECM was softer than that measured in primary TNBCs. Manipulations using 3D organoid 
models in which the substrate biomechanical properties could be precisely manipulated provided 
direct evidence to show that a soft ECM protects whereas a stiff ECM sensitizes tumor cells to 
anti-tumor treatment. The findings are consistent with prior studies which showed that 3D 
mammary organoids grown within soft reconstituted basement membrane gels (Matrigel) exhibit 
improved survival following chemotherapy and radiation by activating NF-κB 174,198,199. Critically 
these and other reports established a link between the 3D culture format and multicellularity in 
generating the treatment resistance phenotype of tumors 173,174,202,203. Our experiments, which 
rigorously controlled for confounding variables including hypoxia, proliferation and drug 
accessibility not only confirmed those results, but also extended those earlier observations to 
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unequivocally demonstrate a role for ECM stiffness and multicellular architecture in modulating 
the treatment response of tumors  204. Our studies also imply that the organoid models used to 
study treatment resistance in culture and to screen for novel anti-tumor agents need to consider 
the biophysical properties of the matrix when interpreting data and designing assays. 
A stiff ECM promotes epidermal growth factor receptor (EGFR) signaling to increase the 
activity of PI3K and ERK that in turn enhance tumor cell growth and survival 23,187. Not surprisingly, 
a stiff tissue microenvironment was shown to promote the resistance of melanomas to targeted 
kinase inhibitors both in culture and in vivo, presumably by potentiating receptor tyrosine kinase 
activity to increase net pro survival signaling 205. Those prior studies addressed the impact of 
therapies that target a specific defined receptor tyrosine kinase signaling pathway whose activity 
is significantly potentiated by ECM stiffness. However, our studies addressed the impact of ECM 
stiffness on agents and treatments that trigger apoptosis by inducing a general cellular stress 
response. To this end we found that a stiff ECM permits an unencumbered chronic elevation in 
JNK activity in response to an exogenous stress such as chemotherapy, and we provided 
evidence that this effect compromised tumor cell survival. Consistent with a reduced stress 
response in cells interacting with a soft ECM, we showed that premalignant MECs treated with 6-
12 Gy ionizing radiation not only failed to die but showed a significantly enhanced clonogenic 
survival only when re-plated on a soft ECM; an observation also observed with chemotherapy 
treated hepatic cancer cells 204. Intriguingly, a set of studies conducted in monolayer 2D cultures 
implicated higher stress signaling through JNK as a protective mechanism whereby cultured 
breast and hepatic cancer cells plated on a stiffer ECM substrate acquired greater resistance to 
the multikinase inhibitor sorafenib 206.  In marked contrast to these monolayer culture studies, our 
work was conducted in cancer organoids in which we recapitulated the 3D tissue-like structures 
of in vivo tumor tissue. Moreover, unlike many 2D studies our culture studies were faithfully 
reproduced in mouse models and patient samples 207,208.  Indeed, while cells grown as 2D 
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monolayers show an absolute requirement for PI3 kinase for survival and for ERK activation to 
progress through G1, cells grown as 3D organoids depend less upon PI3 kinase and ERK and 
instead require Rac GTPase for both their growth and survival 174,209.  
We and others have identified NF-κB as a key regulator of treatment resistance 
173,174,199,210. NF-κB directly mediates the transcription of several anti-apoptotic genes and alters 
angiogenesis, metabolism, immune cell interactions, and metastasis 210,211. We noted an increase 
in NF-κB in the residual tumor of chemotherapy treated patients and mechanistically, we 
determined that the failure of tumor organoids in a stiff 3D ECM to robustly activate NF-κB in 
response to therapy permitted a high degree of JNK activation, which induced apoptosis in these 
cells. These findings are consistent with work from others showing JNK stress signaling reduces 
tumor viability and compromises survival in response to therapy 182. Conversely, JNK activation 
in some contexts, such as cells plated on a stiff 2D substrate, prevents apoptosis to promote drug 
resistance, consistent with its pleiotropic role in apoptosis and stress response 191,206. 
Nevertheless, compelling in vivo evidence identified JNK as a key mediator of chemotherapy 
sensitivity, and furthermore, human TNBC data sets linked a high JNK activity gene expression 
signature with improved chemotherapy response implicating JNK in chemosensitivity 183. Our 
findings further support the physiological relevance of JNK in chemotherapy response and 
demonstrate that the soft, remodeled ECM niche contributes to the ability of residual tumor cells 
to resist apoptosis via NF-κB-JNK signaling. These data suggest that the targeting of additional 
pathways, such as the NF-κB-JNK axis, may sensitize or potentially re-sensitize chemotherapy 
resistant tumor cells to enhance treatment efficacy and eradicate residual tumor cells.   
Resistance to chemotherapy and radiation continue to be significant barriers to overcome, 
particularly in TNBC. Many TNBC patients respond only partially to neoadjuvant chemotherapy 
with as much as 60-70% of these cancers showing some level of residual disease 172. Importantly, 
an incomplete pathological response to therapy associates with worse overall patient survival 172. 
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Indeed, primary TNBCs that fail to respond well to chemotherapy frequently recur with metastatic 
disease that is refractory to nearly all therapies with fewer than 30% of patients surviving beyond 
five years. Targeting the pro-survival molecular effectors activated in cells within a soft ECM niche 
will very likely be a more tractable and efficacious strategy to improve chemotherapy response 
than modulating ECM mechanics directly. Unfortunately, despite promise in many tumor types, 
systemic NF-κB inhibitors have proven immensely toxic due to lack of tumor cell selectivity and 
immune suppression 212. Targeting NF-κB regulated anti-apoptotic proteins has shown more 
promise. A recent clinical trial using LCL161, an antagonist of inhibitor of apoptosis proteins 
(IAPs), in combination with paclitaxel found the rate of pCR more than doubled in this group when 
patients had a high TNFα gene expression signature 213. However, this combination treatment 
was also associated with higher incidence of serious adverse events. Recently, a small molecule 
selectively targeting NF-κB-JNK signaling by disruption of an inactivating interaction between NF-
κB-regulated GADD45β and MKK7 in multiple myeloma enabled MKK7 to phosphorylate JNK and 
sensitized these cells to apoptosis 214. While this mechanism has not been demonstrated in breast 
cancer, it serves as a proof of principle that selective targeting of the NF-κB-JNK pathway may 
be of considerable benefit to patients. Other approaches to indirectly modulate NF-κB activity may 
also mitigate therapy resistance. For example, chemotherapy administered at the maximum 
tolerated dose can activate NF-κB in stromal fibroblasts, triggering the secretion of potent 
cytokines that induce the formation of highly drug resistant tumor initiating cells. Low dose 
metronomic chemotherapy abrogated stromal NF-κB activation, thus potentiating tumor response 
to systemic chemotherapy 215. Clearly more work is needed to clarify the nature of the 
mechanisms that mediate treatment resistance, and develop effective, selective, and safe 
therapeutics. 
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Methods 
Human breast tissue acquisition and processing 
Human breast tumor specimens were either embedded in an optimum cutting temperature 
(OCT) aqueous embedding compound (Tissue-Plus, Scigen, Cat# 4583) within a disposable 
plastic base mold (Fisher, Cat# 22-363-554) and were snap frozen by direct immersion into liquid 
nitrogen and kept at -80°C freezer until cryo-sectioning for analysis, or specimens were formalin 
fixed and paraffin-embedded (FFPE). All human breast specimens were collected from 
prospective patients undergoing surgical resection at UCSF or Duke University Medical Center 
between 2010 and 2014. The selected specimens were de-identified, stored, and analyzed 
according to the procedures described in Institutional Review Board (IRB) Protocol #10-03832 
and #10-05046, approved by the UCSF Committee of Human Resources and the Duke’s IRB 
(Pro00034242) 26. 
Cell culture 
Human mammary epithelial cell lines MCF10A and HMT-3522 T4-2 were grown and 
maintained as previously described 27. Growth medium was supplemented with 2% rBM at the 
time of plating. Growth medium was changed one day after plating and every two days thereafter. 
All assays were performed between days 4 and 5 after seeding.  
Lentiviral infection and vectors 
 MCF10A cells were transduced with the dominant negative forms of JNK: HA-JNK1-APF 
and HA-JNK2-APF and used as previously described (L. Heasley, University of Colorado, Denver) 
193. MCF10A cells were transduced with the constitutively active JNK1, the MKK7-JNK1α fusion 
protein as previously described 194,195.  
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MCF10A and T4-2 cells were electroporated to introduce a transposon (PiggyBac) expressing a 
doxycycline inducible IκBαM and PiggyBac transposase 216. Cells were selected in G418 (500 
μg/mL) for purity. Cells containing IκBαM are denoted as dnIκB. 
Polyacrylamide gel preparation 
Basement-membrane conjugated polyacrylamide gels were prepared as described 217. 
Soft gels with measured elastic moduli of 140 Pascal were prepared with 3% (w/v) acrylamide 
and 0.04% (w/v) bis-acrylamide, and stiff gels with elastic moduli of 5000 Pascal were prepared 
with 5.5% (w/v) acrylamide and 0.15% (w/v) bis-acrylamide.  
Apoptosis assays 
 MECs grown on soft or stiff polyacrylamide gels for 96 hours were treated with either 
paclitaxel (5 or 10 nM), TRAIL (100 or 200 ng/ml), or gamma irradiation (4 – 12 Gy). Apoptosis 
was directly assayed at 24 hours post-treatment via immunofluorescent staining of cleaved 
caspase 3. Percent apoptosis was calculated as the number of cells positive for activated 
caspase 3 expressed as a percentage of the total number of cells.  A minimum of 300 cells per 
condition were counted from several fields of view. Maximum intensity projections of z-stacks 
were used for analysis of cleaved caspase 3 positive cells.  
Immunofluorescence and immunohistochemistry 
Cells were briefly rinsed in PBS and directly fixed using 2-4% paraformaldehyde for 20 
minutes at room temperature. Cells were washed with IF buffer (32.5 mM NaCl, 3.3 mM Na2HPO4, 
76 µM KH2PO4, 1.92 mM NaN3, 0.1% (w/v) BSA, 0.2% (v/v) Triton-X 100, 0.05% (v/v) Tween 20) 
and then incubated with the blocking solution (10% goat serum in IF buffer; 1 hour, room 
temperature). Cells were incubated with primary antibodies in a humidified chamber overnight at 
4°C. Samples were washed with IF buffer (3 X 10 minutes while rocking) and incubated with 
Alexa-488- or Alexa 555-conjugated secondary antibodies (1 hour, room temperature). Samples 
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were washed again with IF buffer (3 X 15 minutes while rocking) and nuclei were counterstained 
with DAPI (1 µg/ml in PBS; 5 minutes, room temperature). Cells on gels were inverted onto a 
number 1 coverglass immediately prior to imaging. 
Fluorescent images were acquired on a spinning disk confocal Nikon Eclipse Ti 
microscope at 20x magnification with a 0.75 NA objective. Cells on polyacrylamide gels were 
inverted directly onto a No. 1 coverslip and imaged immediately at room temperature. The 
images were acquired using an Andor Zyla sCMOS camera and MetaMorph acquisition 
software. Images were processed in ImageJ.  
FFPE slides were deparaffinized in xylene and rehydrated in graded ethanol solutions. 
Heat-mediated antigen retrieval was performed in 10mM citrate buffer pH = 6.0 and endogenous 
peroxidase activity blocked by incubation with 3% hydrogen peroxide. Tissues were incubated 
with primary antibody overnight at 4°C and biotin-conjugated secondary antibody 1 hour at room 
temperature. Vectastain Elite ABC (Vector Laboratories PK-6100) and DAB Peroxidase substrate 
kit (Vector Laboratories SK-4100) were used for signal detection according to manufacturer 
instructions. 
IHC images were acquired on a Nikon Eclipse TE2000-U inverted microscope at 20x 
magnification with a 0.75 NA objective. Images were acquired with a Hamamatsu ORCA-Flash4.0 
LT camera using NIS-Elements software.  
Protein lysates 
Protein lysates were prepared using RIPA (50 mM Tris-HCl, 150 mM NaCl, 0.25% Na-
deoxycholate, 0.1% SDS, and 1.0 % IGPAL CA-630 (NP-40); pH 7.4 at room temperature) or 
Laemmli lysis buffer (50 mM Tris-HCl, 2% SDS, and 5mM EDTA; pH 7.4 at room temperature). 
Immediately prior to cell lysis, a cocktail of protease inhibitors was added to the buffer (1.2 µg 
Leupeptin, 1.2 µg Pepstatin, 2.4 µg Aprotinin, 12 µg E-64, 0.5 mM Benzamidine, 50 mM NaF, and 
1.2 µg Pefabloc), and the phosphatase inhibitor Na Orthovanadate (1mM activated with 1.5% 
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H2O2). RIPA lysates were done on ice, while Laemmli lysates were performed at room 
temperature due to SDS precipitation at cold temperatures. After rinsing the dishes with PBS, 
lysis buffer was added and cells were scraped off the dish with a cell scraper. RIPA lysates were 
sonicated 3 times, each for 10 seconds, while Laemmli lysates were passed through a fine pipet 
tip (p200) several times. Both were centrifuged for 10 minutes at 20,817 rcf to pellet any internal 
organelles and cellular debris. Supernatant was collected and fast frozen on dry ice. Protein 
concentration was determined using the BCA assay kit (Promega), following the manufacturer’s 
protocol.  
Cytoplasmic and nuclear protein extracts were obtained with a kit using manufacturer 
instructions (ThermoFisher #78833). 
Western blotting 
Cells were lysed as described above and equal amounts of protein were separated on 
reducing SDS-polyacrylamide gels, immunoblotted and detected with an ECL-Plus system. 
Samples were boiled for 5 minutes (95°C) and loaded onto the SDS-polyacrylamide gel, and 
protein was separated at 120 constant volts.  
The protein was transferred onto a pre-wet polyvinylidene difluoride (PVDF) membrane 
(100% methanol, 1 minute), either at 300 mA for 2 hours or at 25 constant volts overnight (4°C). 
The PVDF membrane was rinsed with TBST and non-specific binding was blocked with 5% nonfat 
dry milk dissolved in TBST. The membrane was then incubated with the primary antibody 
overnight at 4°C, washed with TBST, incubated with horseradish-peroxidase conjugated 
secondary antibody (1 hour, room temperature; dilution 1:5000), washed with TBST, and detected 
with the chemiluminescence system Quantum HRP substrate (Advansta #K-12042). 
Quantification was performed using ImageJ. 
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Metabolic activity assay 
MECs were washed with 1X PBS and incubated with MTT working solution (a 5 mg/ml  
(w/v) MTT stock solution in PBS, diluted tenfold in DMEM/F12 for a final MTT concentration of 
500 µg/ml) for 2 hours at 37°C.  MTT was solubilized with DMSO for 10 minutes at 37°C. The 
plate was tapped vigorously to extract all of the MTT from the cells and once the solution was an 
even purple color and 100 µl was transferred to a 96-well plate. The absorbance was measured 
directly using a plate reader set at 550 nm and background subtraction set at 630 nm. Absorbance 
values were normalized to the untreated controls to determine relative metabolic activity.   
Irradiation 
All cell culture and mouse experiments used a J L Shepherd Mark I model-20 137Cesium 
source irradiator.  
Proliferation assay 
To measure the proliferation rate of MECs in log phase of growth on soft (E=140 Pa) and 
stiff (E=5000 Pa) polyacrylamide gels, cells were trypsinized and counted at 24 hour intervals. 
The growth rate constant, k, was derived using the equation: N/No = ekt, where No is the initial 
absorbance or cell number, and N is the absorbance or cell number at time t. The doubling time, 
td, was calculated using the derived k and setting N/No = 2 in the following equation: td  =  (ln 2)/k. 
To assess the proliferation rate of MECs in 3D rBM, cultures was fixed and stained at 
different time points with anti-phosphorylated histone H3. Proliferating cells or colonies (positive 
phH3 staining) were scored using a fluorescence microscope. A minimum of 250 cells per 
condition were scored from several fields of view. 
Colony size was determined by measuring the diameter of MEC colonies after 10-14 days 
in 3D rBM or 3D collagen/rBM. The colony diameters were measured using a pre-calibrated 
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eyepiece on a light microscope. At least 50 colonies per sample were scored from different fields 
of view in the center of each gel.  
Cell cycle analysis 
The percentage of cells in each stage of the cell cycle was determined by propidium iodide 
(PI) staining and FACS analysis for DNA content (FACS Calibur, Becton Dickinson, San Jose, 
CA). MECs were grown on soft and stiff polyacrylamide gels and processed on days 4 and 5 in 
order to determine cell cycle status. Briefly, MECs were trypsinized, counted, and washed with 
ice-cold 1% BSA/DPBS. MECs were fixed with a 1:4 dilution of 1% BSA/DPBS in 96% ethanol. 
Fixed MECs were centrifuged at 259 rcf, washed with ice-cold PBS, and incubated in PI staining 
solution (50 µg/ml PI in PBS supplemented with 3.8 mM sodium citrate and 500 µg/ml RNase A; 
500 µl per 2x106 cells; 3 hours on ice). DNA content was determined using the FACS Calibur set 
to low flow and data was acquired for 20,000 cells within the gated region of cells in G0/G1, S 
and G2/M phases of the cell cycle. 
Clonogenic survival assay 
MECs were grown for 4 days on soft and stiff polyacrylamide gels and treated with 
apoptosis inducers on day 4 as described. Cells were trypsinized and replated on soft or stiff 
polyacrylamide gels at low density on day 4 (500 cells in a 60 mm gel; triplicates), grown for 7-10 
days, and assayed for colony formation. Briefly, cells were rinsed with 1X PBS, fixed (ice-cold 
100% methanol, 10 minutes, -20°C), rinsed with 1X PBS, stained with crystal violet (0.5% (w/v) 
solution, 10 minutes, room temperature), rinsed with 1X PBS, rinsed with ddH2O, and air dried by 
inverting onto a paper towel (overnight).  
Plates were scanned with a conventional flatbed scanner (grayscale, 150 dpi, tif). Colonies 
were counted using a MATLAB script (K. Tsai, Weaver Lab). First a representative positive colony 
was chosen for calibration, where a positive colony contained 50-100 cells (about 10 square 
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pixels). The program output was the number of colonies greater than or equal to the size indicated 
for a positive colony. Any fused colonies in the program output were accounted for by adding one 
to the final colony number for each fusion. 
Mouse experiments 
Five-week-old nude mice were orthotopically injected with 106 T4-2 cells in soft or stiff, 
ribose crosslinked collagen gels. Collagen gels were prepared as previously described 187. Briefly, 
collagen was incubated with 500mM L-ribose for at least 4 weeks at 4 °C prior to neutralization 
and gelation. Intraperitoneal paclitaxel injections (10 mg/kg) were given every two days starting 
seven weeks after tumor cell injection, coinciding with the emergence of measurable tumors. Mice 
were sacrificed, and tissue was harvested 14 days following the start of paclitaxel injections.  
Five-week-old nude mice were injected with 5 million T4-2 cells subcutaneously in 
collagen gels. Mice were given three intraperitoneal injections with NF-κB inhibitor JSH-23 (4.8 
mg/kg) or DMSO vehicle with the final injection coinciding with 4 Gy ionizing irradiation of the 
tumor. Mice were sacrificed and tissue harvested two weeks after irradiation.  
All mouse studies were maintained under specific pathogen-free conditions and performed 
in accordance with the Institutional Animal Care and Use Committee and the Laboratory Animal 
Research Center at the University of California, San Francisco. 
Picrosirius red staining and quantification 
FFPE tissue sections were stained using 0.1% Picrosirius red (Direct Red 80, Sigma-
Aldrich, Cat# 365548 and picric acid solution, Sigma-Aldrich, Cat# P6744) and counterstained 
with Weigert’s hematoxylin (Cancer Diagnostics, Cat# CM3951). Brightfield and polarized light 
images were acquired using an Olympus IX81 microscope fitted with an analyzer (U-ANT) and a 
polarizer (U-POT, Olympus) oriented parallel or orthogonal to each other, respectively. The 
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percentage of picrosirius red signal per field of view was quantified in polarized light images 
using ImageJ. 
Atomic force microscopy data acquisition 
Atomic force microscopy (AFM) measurements were performed using 30 µm thick OCT-
embedded frozen human breast tumor tissue sections were thawed by immersion in room 
temperature PBS. Thawed sections were immersed in PBS containing phosphatase inhibitor 
(GenDEPOT Xpert #P3200-001), protease inhibitor cocktail (GenDEPOT Xpert # P3100-001), 
and propidium iodide (ACROS, Cat# 440300250) and placed on the stage for AFM 
measurements. AFM indentations were performed using an MFP3D-BIO inverted optical AFM 
(Asylum Research) mounted on a Nikon TE2000-U inverted fluorescent microscope. Silicon 
nitride cantilevers were used with an approximate spring constant of 0.06 N m-1 and a 
borosilicate glass spherical tip with 5 µm diameter (Novascan Tech). The cantilever was 
calibrated using the thermal oscillation method prior to each experiment. Specimens were 
indented at 1 μms-1 loading rate. Force maps were obtained in tumor adjacent ECM as a raster 
series of indentations utilizing the FMAP function of the IGOR PRO build supplied by Asylum 
Research. Elastic properties of ECM were determined by fitting data with the Hertz model. A 
Poisson’s ratio of 0.5 was used in the calculation of the Young’s elastic modulus. 
Antibodies and reagents 
 We used commercial extracellular matrix (Matrigel™; Collaborative Research) for the 
reconstituted basement membrane (rBM) assays. Primary antibodies used were: cleaved 
caspase-3 (1:400, Cell Signaling #9661), phospho-c-Jun (serine 63) (1:1000, Cell Signaling 
#3270), JNK1/JNK2 (1:1000, BD PharMingen #554285), E-cadherin (1:1000, Cell Signaling 
#3195), phospho-JNK (G-7) mAb (1:100, Santa Cruz Biotechnology #sc-6254), and HA.11 clone 
16B12 (1:2000, BabCO, Richmond, CA), p65 (1:1000 Western blot, 1:800 IHC, Cell Signaling 
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#8242) . The secondary antibodies used were: horseradish peroxidase-conjugated anti-rabbit and 
mouse (Amersham Biosciences, Piscataway, NJ); and Alexa Fluor 488- and 555-conjugated anti-
mouse and rabbit IgGs (Molecular Probes, Carlsbad, CA). The following reagents were used in 
these studies: propidium iodide, diaminophenylindole (DAPI), 3-(4,5-dimethyl thiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT), Trichrome Masson Stain, and Weigert’s Iron Hematoxylin 
(all from Sigma, St. Louis, MO); N-Tetra-methyl-ethylenediamine (TEMED), 30% acrylamide/bis 
solution (37.5:1, 2.6% C), 40% acrylamide solution and 2% bis solution (Bio-Rad Laboratories, 
Hercules, CA); TRAIL (100-200 ng/ml), paxlitaxel (5-10 nM), and the JNK inhibitor SP600125 
(5µM, ApexBio #A4604), recombinant human TNFα (20 ng/ml, Invitrogen #68-8786-63), and NF-
κB inhibitor JSH-23 (Millipore #481408).  
Gene set enrichment analysis 
GSEA was performed to assess differential expression of NF-κB target genes in patients 
that achieved or failed to achieve a pathological complete response to neoadjuvant chemotherapy 
using publicly available software maintained by the Broad Institute218. Publicly available gene 
expression and treatment response data from the ISPY-1 trial were used (GSE32603)201. The NF-
κB gene signature gene set was taken from publicly available CHIP-Seq data from the Cistrome 
data browser. The gene set consisted of the top 100 targets from a p65 (RELA) CHIP-Seq 
experiment in the MCF-7 mammary epithelial cell line treated with TNFα compared with vehicle 
treated cells 219.  
Statistics  
Unless otherwise noted, all tests for statistical significance were done using an unpaired 
student’s t-test, assuming unequal variances and a two-tailed distribution, with a significance 
level of 0.05. Data were analyzed using GraphPad Prism. All data reported herein displays one 
star denoting a p-value ≤ 0.05, two stars denoting p ≤ 0.01, and three stars denoting p ≤ 0.001. 
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For all data presented, the number of biological replicate experiments conducted is denoted as 
n. 
Study approval 
All human breast specimens were collected from prospective patients undergoing surgical 
resection at UCSF or Duke University Medical Center between 2010 and 2014. Informed consent 
was received from patients prior to tissue collection. The selected specimens were de-identified, 
stored, and analyzed according to the procedures described in Institutional Review Board (IRB) 
Protocol #10-03832 and #10-05046, approved by the UCSF Committee of Human Resources and 
the Duke’s IRB (Pro00034242)26. All mouse studies were maintained under specific pathogen-
free conditions and performed in accordance with the Institutional Animal Care and Use 
Committee and the Laboratory Animal Research Center at the University of California, San 
Francisco. 
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Introduction 
 As breast tumors grow, they recruit several types of innate immune cells to the tumor 
microenvironment that promote continued growth, immune evasion, and metastasis. The Weaver 
lab has shown that the most fibrotic subtypes of human breast tumors also contain the highest 
level of immune cell infiltration, particularly macrophages26. We have also shown that infiltrating 
immune cells recruited early in tumor development are key activators of tumor fibrosis through 
secretion of TGFβ (Chapter 3). However, it is unclear whether ECM stiffness can in turn alter the 
recruitment of phenotype of tumor associated-immune cells. Many myeloid cells including 
macrophages and neutrophils react to substrate stiffness in vitro, but how ECM stiffness may 
regulate their behavior in the tumor microenvironment has not been investigated220–224. 
One of the most abundant immune cell types in breast tumor stroma is the tumor-
associated macrophage (TAM)225. Macrophages are a diverse population of myeloid cells that, 
depending on tissue context, can phagocytose infectious bacteria and cell debris, orchestrate 
stromal behavior in wound healing, and present antigens to T cells. TAMs consist of distinct 
populations of tissue resident macrophages and bone marrow derived macrophages, which are 
recruited to the tumor as circulating monocytes and differentiate into macrophages after 
extravasation. Macrophages polarize into different activated phenotypes upon encountering 
specific cytokine signals that instruct their differentiation. Breast tumors contain multiple 
subpopulations of differentially polarized macrophages, but in general, early in tumor initiation 
these cells may be phagocytic and immune activating, but inevitably become immunosuppressive 
and support tumor cell invasion as tumors progress144,226,227. Much attention and effort has been 
given to understand the mechanisms by which TAMs promote metastasis and to therapeutically 
target these cells228.  
 Until recently, neutrophils have been ignored as insignificant relative to macrophages, but 
mounting evidence over the last ten years argues that neutrophils also play a key role in shaping 
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the tumor microenvironment and promoting metastasis. Neutrophils are exceptionally unique 
cells. Like the other granulocytes/polymorphonuclear leukocytes basophils and eosinophils, they 
have a characteristic lobed nucleus that becomes hyper-segmented upon activation229. 
Neutrophils are produced in massive quantities in the bone marrow in response to G-CSF. Unless 
neutrophils are stimulated, they circulate for a short time and return to bone marrow to die. In 
humans, 60-70% of circulating leukocytes are neutrophils, and they have an average half life of 
13-19 hours230,231. To maintain their place as the most abundant leukocytes, humans produce an 
average of 1011 neutrophils per day. Canonically, neutrophils perform critical functions as the first 
responders to sites of injury or infection. Within minutes neutrophils are recruited to sites of acute 
injury through adhesion to activated endothelium and chemotaxis toward damage associated 
molecular patterns (DAMPs), pathogen associated molecular patterns (PAMPs) such as 
formylated peptides, and chemokines such as CXCL8229,232. The first wave of recruited neutrophils 
release potent secondary chemoattractants like leukotriene B4 (LTB4) that initiate the recruitment 
of large number of neutrophils from long distances233,234. The perform three main effector functions 
in response to infection and tissue injury: phagocytosis, degranulation to release antimicrobial 
molecules and proteases, and forming neutrophil extracellular traps (NETs). Because neutrophils 
are required to respond immediately upon stimulation, they likely do not rely on de novo 
transcription to synthesize materials needed to carry out their effector functions235. Instead, they 
presynthesize the necessary proteins and store them within different types of cytoplasmic 
granules that are released upon a variety of stimuli. 
 Multiple lines of evidence exist suggesting that neutrophils play a prometastatic role in 
breast cancer. Neutrophil production is upregulated in many breast tumor models including the 
highly metastatic 4T1 and PyMT models236,237. This is primarily due to elevated G-CSF that 
stimulates granulopoiesis in the bone marrow. Neutrophils in mouse tumors have been shown to 
be potently immunosuppressive and often make up a large portion of the ambiguous population 
118 
 
of immunosuppressive myeloid cells called myeloid-derived suppressor cells (MDSCs). 
Neutrophils suppress T cell function through high arginase activity, which depletes arginine 
required for cytotoxic T cell proliferation, and ROS production, which also dampens T cell effector 
function238,239. Neutrophils also secrete protumor cytokines such as TGFβ, PDGF, and VEGF240. 
Depletion of neutrophils in orthotopic and spontaneous murine tumor models significantly reduces 
metastatic burden in the lung241–243. Furthermore, interfering with neutrophil recruitment using 
CXCR2 inhibitors or blocking antibodies also inhibits tumor metastasis239,244,245.  
 In addition to the prometastatic role of neutrophils found within the primary tumor, 
neutrophils that populate future sites of tumor metastasis modify this environment to become 
hospitable to tumor cells upon their arrival. Neutrophils arrive to organ sites prior to tumor cells 
and condition the premetastatic niche through the release of ECM proteases such as MMPs, 
cathepsins, and neutrophil elastase as well as immunosuppressive signaling246,247. Neutrophils 
have also been implicated in arousing dormant tumor cells via NET-mediated ECM protease 
release that exposes laminin binding sites to tumor cells248.  
 Despite the wealth of evidence implicating neutrophils in prometastatic functions, some 
reports demonstrate neutrophils may also restrict tumor growth and metastasis. Neutrophils have 
been shown to release cytotoxic factors like nitric oxide in mice and humans that mediate tumor 
cell killing249,250. Another study harvested neutrophils from the lungs of 4T1 tumor-bearing mice 
and when injected into the tail vein following 4T1 cells, inhibited the formation of metastatic foci251. 
Antibody depletion of neutrophils had no effect on tumor growth in this model but potently reduced 
metastasis. Interestingly, G-CSF conditioned neutrophils failed to inhibit metastasis when injected 
following tumor cells suggesting that similar to macrophages, neutrophils can adopt different 
phenotypic states, an idea that only recently has become broadly accepted. In support of this 
view, studies in mice receiving a systemic TGFβ inhibitor revealed distinct populations of 
neutrophils with those receiving the inhibitor exhibiting more tumor cytotoxicity242. 
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 Much of our knowledge of neutrophil biology, including their role in cancer, has been 
gained through mouse models; however, key differences in mouse and human neutrophil biology 
present important caveats to keep in mind when interpreting these studies. Neutrophils make up 
only 10-20% of circulating neutrophils in mice, compared to 60-70% in humans. Moreover, mice 
lack orthologs to many important neutrophil chemokines, including CXCL8, as well as FcαRI, an 
Fc receptor that triggers neutrophil effector functions252. Human neutrophils are also identified 
using different markers and contain different material within their granules, which complicates 
comparisons of these cells between mouse and human.  
 In these preliminary studies, we manipulated stromal LOX activity and ECM stiffness in in 
vivo breast tumor models to understand how tumor-associated ECM remodeling affected the 
tumor immune landscape. We observed that neutrophil abundance in the primary tumor and in 
premetastatic lung was regulated by ECM stiffness but varied between tumor contexts. These 
preliminary studies pave the way forward for more focused mechanistic studies regarding how 
the ECM influences neutrophil recruitment and phenotype to alter metastasis.  
Results 
 In order to understand how ECM stiffness may regulate tumor immunity, we used the 
stromal LOX overexpressing mouse model, MMTV-PyMT; Col1a1-tTA; TetO-mLox, introduced in 
Chapter 3, which stiffens the tumor ECM by increasing LOX-mediated collagen crosslinking. We 
used flow cytometry to analyze the immune cell compartment in control and LOX overexpressing 
tumors, particularly focusing on myeloid cells. We focused on myeloid cells because of their 
abundance in the tumor stroma, the critical contribution of myeloid cells in orchestrating tumor 
immunity, and technical limitations on the number of channels we could successfully resolve253. 
We observed a modest reduction in TAMs and a significant expansion of the neutrophil population 
in the stromal LOX overexpressing tumors to near double that of control mice (Figure 5.1 A). The 
total abundance of CD45+ cells and the relative abundance of dendritic cells (DCs) and monocytes 
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remained about the same. Because the Col1a1 promoter used is expressed in osteoblasts and 
osteocytes, we profiled circulating immune cell populations in PyMT negative mice to confirm that 
LOX overexpression did not cause altered bone marrow hematopoiesis (Peng et al Endocrinology 
2008). Indeed, all major circulating immune cell populations remained nearly identical between 
wildtype FVB, TetO-mLOX, and Col1a1-tTA; TetO-mLOX mice (Figure 5.1 B).  
 Neutrophils have been widely reported to play a prometastatic role in breast tumor 
progression in the PyMT model236,241. Therefore, we focused on characterizing these neutrophils, 
understanding how LOX regulated their abundance, and how they affected tumor metastasis. We 
sought to establish whether the increase in neutrophils occurred exclusively in the primary tumor 
or whether neutrophil numbers were elevated systemically. We profiled neutrophils in lungs and 
in blood of control and stromal LOX overexpressing tumor bearing mice. The number of 
neutrophils remained unchanged in the lungs of control and LOX overexpressing mice, while the 
neutrophil population appeared slightly larger in blood of LOX overexpressing animals (Figure 
5.1 C,D). Given that the population of neutrophils nearly doubled in the tumors of LOX 
overexpressing mice, it is unlikely that this modest increase in circulating neutrophils is the 
primary driver of the increase within the tumor.  
 We next looked to determine how stiffness might regulate the size of the neutrophil 
population in the primary tumor. Neutrophils could accumulate via one or a combination of three 
possible mechanisms: increased production and release from bone marrow, increased 
chemotaxis, or increased survival in the tumor bed. Upon activation and recruitment to peripheral 
tissues, neutrophils are thought to die there and be phagocytosed by macrophages235. However, 
recent evidence suggests that neutrophils recruited to the site of sterile injury may reverse migrate 
back into circulation254. The fate of tumor associated neutrophils is unknown and it could also be 
possible that that the rate of reverse migration from the tumor back into circulation may influence 
neutrophil.  
121 
 
Figure 5.1: Stromal LOX overexpression causes neutrophil accumulation in tumors. (A) 
Scatter plot showing mean and individual values of immune cell abundance by flow cytometry 
from primary tumor. CD45+ population is plotted as percentage of live cells and remaining 
populations are plotted as percentage of CD45+ cells. (B) Scatter plot showing mean and 
individual values of abundance of immune cell populations circulating in peripheral blood of non-
tumor bearing mice plotted as a percentage of live cells. (C) Scatter plot showing mean and 
individual values of neutrophil abundance by flow cytometry from lungs of tumor-bearing mice 
plotted as percentage of CD45+ cells. (D) Scatter plot showing mean and individual values of 
neutrophil abundance by flow cytometry from peripheral blood of tumor-bearing mice plotted as 
percentage of live cells. Statistical analysis was performed using Mann-Whitney U-test *p < 0.05.  
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Both chemotaxis and neutrophil production are regulated by cytokines. We analyzed the 
cytokines produced from PyMT tumor cells on 400 Pa and 60 kPa polyacrylamide gels using a 
cytokine array and found that three cytokines related to neutrophil production or chemotaxis were 
upregulated in cells cultured on a stiffer substrate (Figure 5.2 A). G-CSF is the primary cytokine 
that triggers neutrophil production in the bone marrow.  IL-23 stimulates γδ T cells to produce IL-
17, which leads to increased G-CSF production by bone marrow stromal cells, ultimately 
increasing neutrophil production238. CXCL5 binds the chemokine receptor CXCR2 and can recruit 
neutrophils into tissues. Interestingly, CXCL5 is a YAP target, and high YAP activity in prostate 
cancer has been shown to induce CXCL5 expression to recruit polymorphonuclear MDSCs to the 
tumor244. This would be consistent with CXCL5 being regulated by stiffness. However, when we 
profiled cytokine levels in the PyMT control and stromal LOX overexpressing tumors, we did not 
detect significant changes in any of these three cytokines (Figure 5.2 B,F). Levels of G-CSF 
increased slightly in LOX overexpressing tumors, but the trend did not approach statistical 
significance (Figure 5.2 B). Notably, IL23 was not measured in these tumors, but given the 
modest change in G-CSF and its role in promoting G-CSF expression, it seems unlikely to be 
playing a major role in neutrophil production in the LOX overexpression model. We detected a 
trend toward increased levels of GM-CSF in LOX overexpressing tumors, which can stimulate 
production of both granulocytes and monocytes (Figure 5.2 C). GM-CSF also promotes 
neutrophil recruitment, degranulation, cytotoxicity, and survival255. The three canonical 
chemokines that signal through CXCR2 to recruit neutrophils into tissue in mice, CXCL1, CXCL2, 
and CXCL5, all showed no change or a slight decrease in abundance in LOX overexpressing 
tumors (Figure 5.2 D-F). CCL3, which can recruit neutrophils, was higher in LOX overexpressing 
tumors, but the difference did not achieve statistical significance (Figure 5.2 G). Taken together, 
these data suggest that both enhanced neutrophil production and increased neutrophil 
recruitment may contribute to the increase in neutrophils within the primary tumor. However, given  
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Figure 5.2: Stromal LOX overexpression modulates some cytokines related to neutrophil 
production and chemotaxis. (A) Protein blots from cytokine array of cell culture media from 
PyMT tumor cells cultured on 400 Pa (soft) and 60 kPa (stiff) fibronectin coated polyacrylamide 
gels. (B-J) Scatter plots showing mean ± SEM and individual values of cytokine levels from whole 
tumor lysates (n = 7 Control, n = 9 LOX OX). Statistical analyses were performed using Mann-
Whitney U-test.  
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the modest differences and lack of statistical significance, it is difficult to draw a confident 
conclusion from these data regarding the magnitude of the contributions of each.  
 In addition to understanding what might be regulating neutrophils, cytokine levels also 
provide information about the general status of the immune microenvironment within the tumor. 
Three of the most significantly altered cytokines were IL7, IL15, and IL10 with all three higher in 
the LOX overexpressing mice (Figure 5.2 H-J). IL7 enhances production and proliferation of 
lymphocytes, and IL15 promotes the formation of CD8+ memory T cells. Both have been linked to 
an anti-tumor T cell response and are clinically relevant cytokines with potential to enhance the 
anti-tumor immune response256–259. Interestingly, IL10 is an anti-inflammatory cytokine that 
generally acts to suppress the anti-tumor immune response. However, IL10 can elicit several 
pleiotropic effects and has been shown to stimulate anti-tumor immunity in some tumor 
contexts260–264. Taken together, these cytokines would indicate LOX overexpressing tumors may 
support a more robust anti-tumor T cell response compared to control tumors.  
 We also investigated whether neutrophils were retained longer in LOX overexpressing 
tumors. Mouse bone marrow progenitors proliferate rapidly to generate approximately 107 
neutrophils per day, but once released into circulation, neutrophils cease to proliferate. We 
labelled proliferating stem and progenitors using 3 i.p. BrdU injections 72, 48, and 24 hours prior 
to sacrificing mice265–267. We then used flow cytometry to analyze the fraction of BrdU positive 
neutrophils in the primary tumor, lung, and blood. Neutrophils older than 72 hours will remain 
BrdU negative, while most neutrophils younger than 72 hours should be BrdU positive. We 
observed a slight increase in BrdU positive neutrophils in both lung and blood of LOX 
overexpressing mice (Figure 5.3 B-C). This is consistent with a slight increase in neutrophil 
production in LOX overexpressing mice. However, the primary tumors of LOX overexpressing 
mice showed a considerably lower percentage of BrdU positive neutrophils compared to control 
tumors (Figure 5.3 A). This suggests that the neutrophils found within LOX overexpressing 
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tumors are older and survive longer than neutrophils populating control tumors; although more 
mice should be analyzed to confirm these findings. Also of note, the percentage of BrdU positive 
neutrophils in blood much lower than expected in both conditions266. This could be due to strain-
specific or tumor-specific differences in the kinetics of neutrophil production, incomplete BrdU 
labelling, or poor permeabilization and anti-BrdU accessibility in these samples. Circulating 
neutrophils in tumor bearing mice often display an immature morphology suggesting that they are 
released from bone marrow prior to full maturation, which would alter production and release 
kinetics. Therefore, it is possible that some circulating BrdU negative neutrophils could have been 
released from the bone marrow following the last BrdU pulse.  
Interestingly, aged neutrophils have been reported to highly reactive to inflammatory 
stimuli and more phagocytic than non-aged neutrophils268. It is still unclear whether neutrophils 
from LOX overexpressing tumors are phenotypically distinct from those within control tumors. In 
order to gain some insight into whether these neutrophils were pro- or anti-tumor and into the 
influence of stromal LOX overexpression, we measured the abundance of circulating tumor cells 
and the number of metastatic foci in the lungs. Both the levels of circulating tumor cells and 
metastatic foci were the same between the two groups (Figure 5.3 D-E). This contradicts data 
from the Weaver lab in which tumor-bearing mice treated systemically with LOX inhibitor β-
aminopropionitrile (BAPN) had significantly reduced levels of circulating tumor cells and lung 
metastasis (data not shown). The reasons for this discrepancy are unclear. It is tempting to 
speculate that the effects of a more robust anti-tumor immune response in the LOX 
overexpressing mice competes with prometastatic collagen crosslinking negate each other, but 
there is not enough evidence to draw such a conclusion.  
To overcome some technical limitations with the Col1a1 LOX overexpression mouse 
model, we generated a new stromal LOX overexpressing tumor model: MMTV-PyMT; Pdgfrb- 
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Figure 5.3: Neutrophils in LOX overexpressing tumors are older but do not alter 
metastasis. (A-C) Scatter plots showing mean and individual values of the percentage of BrdU+ 
neutrophils out of total neutrophils in primary tumor (A), lung (B), and peripheral blood (C). (D) 
Scatter plot showing mean ± SEM and individual values of PyMT mRNA expression in circulating 
blood normalized to 18S. (E) Scatter plot showing mean ± SEM and individual values of number 
of metastatic foci counted in H&E stained lung sections per animal.  
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rtTA; TetO-mLox. This is a Tet on model that overexpresses Lox in cells that express Pdgfrb 
including fibroblasts, mural cells, adipocytes, and some neurons of the brain. We expected this 
promoter to be more robustly expressed than the Col1a1 promoter with the caveat of being 
expressed by stromal cells other than fibroblasts in the tumor microenvironment and in the 
metastatic site. After backcrossing to achieve a ≥ 99% FVB background, we profiled the immune 
cell populations within primary tumors and lungs. Unexpectedly, we have not observed an 
increase in neutrophils within the primary tumor, although not enough tumors have yet been 
profiled (Figure 5.4 A). In contrast, lungs of LOX overexpressing mice contain higher abundance 
of neutrophils relative to control mice (Figure 5.4 B). LOX overexpressing mice also have a higher 
prevalence of metastatic foci in the lungs (Figure 5.4 C). Surprisingly, pilot experiments 
performed in mixed background mice while backcrossing from the C57BL6/J to FVB yielded the 
opposite trend in metastasis with LOX overexpressing mice containing fewer metastatic foci than 
control mice (Figure 5.4 D). The two pilot studies displayed are from the first backcross (F1, 50% 
C57BL6/J, gray/blue) and the second backcross (N2, 25% C57BL6/J, black/red). Notably, the F1 
cohort, although small, had an extraordinarily large difference in metastasis. While it is admittedly 
difficult to interpret mixed background studies, these data would suggest that LOX overexpression 
on the C57BL6/J background is anti-metastatic while LOX overexpression on the FVB 
background is pro-metastatic.  
 To better understand the role of stiffness in regulating immunity and conditioning of the 
premetastatic niche, we used two patient derived xenograft (PDX) models with higher and lower 
metastatic capacity: HCI-001 and HCI-002, respectively. We orthotopically implanted these 
tumors in NOD-SCID mice in soft or ribose-crosslinked stiffened collagen. Flow cytometry 
analysis revealed no differences in the size of immune cell populations in the lung in mice bearing 
HCI-001 tumors (Figure 5.5 A). However, in contrast with the LOX overexpressing models, mice  
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Figure 5.4: Stromal LOX overexpression using the Pdgfrb promoter increases lung 
neutrophil abunance and modulates metastasis. (A) Scatter plot showing mean and individual 
values of immune cell abundance by flow cytometry from primary tumor in control and LOX 
overexpressing tumors (Pdgfrb-rtTA promoter). CD45+ population is plotted as percentage of live 
cells and remaining populations are plotted as percentage of CD45+ cells. (B) Scatter plot showing 
mean and individual values of immune cell abundance by flow cytometry from lung in control and 
LOX overexpressing tumors (Pdgfrb-rtTA promoter). CD45+ population is plotted as percentage 
of live cells and remaining populations are plotted as percentage of CD45+ cells. (C) Scatter plot 
showing mean ± SEM and individual values of number of metastatic foci in control and LOX 
overexpressing lungs from the FVB/N strain. (C) Scatter plot showing mean ± SEM and individual 
values of number of metastatic foci in control and LOX overexpressing lungs from mixed 
background C57BL6/J:FVB/N mice. F1 generation (gray/blue) is pure C57BL6/J crossed with 
pure FVB/N and N2 generation (black/red) is F1 crossed with FVB/N. 
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Figure 5.5: PDXs with soft ECM have more lung neutrophils and increased 
proinflammatory signaling. (A) Scatter plot showing mean and individual values of immune cell 
abundance by flow cytometry from lung in soft and stiff HCI-001 tumors. CD45+ population is 
plotted as percentage of live cells and remaining populations are plotted as percentage of CD45+ 
cells. (B) Scatter plot showing mean and individual values of immune cell abundance by flow 
cytometry from lung in soft and stiff HCI-002 tumors. CD45+ population is plotted as percentage 
of live cells and remaining populations are plotted as percentage of CD45+ cells. (C) Volcano plot 
showing differentially regulated genes between soft and stiff HCI-001 tumors. Significantly altered 
genes are colored in red. (D) Differentially regulated gene ontology pathways from primary tumor 
RNA-seq in soft and stiff HCI-001 tumors. Pathways upregulated in stiff are colored in orange and 
those upregulated in soft are colored in blue. (E) Volcano plot showing differentially regulated 
genes between soft and stiff HCI-002 tumors. (D) Differentially regulated gene ontology pathways 
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from primary tumor RNA-seq in soft and stiff HCI-002 tumors. Pathways upregulated in stiff are 
colored in orange and those upregulated in soft are colored in blue. 
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injected with the less metastatic HCI-002 tumors in soft collagen had a significant increase in the 
number of neutrophils in lungs (Figure 5.5 B). It is still unclear whether these neutrophils are 
phenotypically distinct and whether this difference in neutrophils has any influence on metastasis. 
The neutrophils were sorted out of the lungs from each condition in both PDX models and will be 
analyzed by RNA-seq to assess any potential phenotypic differences. Immune cell profiling was 
limited to major myeloid populations because these mice lack lymphocytes and NK cells.  
 Whole tumor mRNA of soft and stiff tumors from HCI-001 and HCI-002 was analyzed 
using RNA-seq to uncover any differential regulation of stiffness on tumor phenotype or immune 
regulation at the primary tumor. Only 29 genes were found to be differentially regulated (FDR < 
0.05) between soft and stiff in HCI-001 tumors, and zero differentially regulated genes met the 
FDR threshold for significance between soft and stiff in HCI-001 (Figure 5.5 C,E). However, gene 
ontology analysis of these RNA-seq data suggest that in both PDXs, cytoskeletal and ECM 
binding pathways are upregulated in the stiff condition (Figure 5.5 D,F, orange). Interestingly, the 
soft conditions in both PDXs upregulate pathways associate with immune and inflammatory 
processes such as antigen processing, toll-like receptor signaling, response to interferon gamma, 
and innate immune response (Figure 5.5 D,F blue). These data would suggest that the soft 
tumors elicit a more proinflammatory immune response and that the increase in lung neutrophils 
in soft HCI-002 tumors may have a cytotoxic, anti-tumor phenotype. Further studies are necessary 
to test these hypotheses.  
Discussion 
 These studies demonstrate a potential role for LOX in regulating tumor immunity via 
neutrophil abundance and phenotypes within primary tumors and metastatic sites. However, 
these studies are highly exploratory and additional experiments are required to understand 
unexpected discrepancies between models and to generate data that coalesce to support a 
mechanistic understanding of LOX-mediated regulation of tumor associated neutrophils.   
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 These studies explored how ECM stiffness may regulate tumor immunity. Profiling of 
immune cell types in LOX overexpressing PyMT tumors revealed a near twofold increase in 
neutrophil abundance. Neutrophil count in blood appeared slightly higher and unchanged in lung. 
Because LOX-mediated crosslinking of collagen stiffens the ECM and promotes metastasis, these 
data fueled the hypothesis that ECM stiffness may promote metastasis through regulating the 
neutrophil population in tumors. Interestingly, studies utilizing a similar but stronger stromal LOX 
overexpressing tumor model show an increase in neutrophils in lung. Many possibilities could 
explain this observation including that this model causes a more robust systemic increase in 
neutrophil levels, higher LOX overexpression in the lung directly recruits or activates neutrophils, 
or increased ECM stiffness modulates levels of tumor secreted factors that promote neutrophil 
recruitment to the premetastatic site. This model also had higher levels of lung metastasis, which 
may be attributable to the increase in neutrophil population.  
Cytokine analysis within the tumors of LOX overexpressing mice suggest chemotaxis may 
play a role in the increased abundance of neutrophils but likely is not the main driver. These 
analyses also did not implicate increased neutrophil production, although we would also need to 
profile serum cytokines to better assess this. Bone marrow progenitor labelling indicate prolonged 
survival or retention may account for neutrophil accumulation. This would be consistent with a 
higher degree of neutrophil activation, which prolongs neutrophil lifespan, or it could be indicative 
of a population of aged neutrophils reported to support tumor growth and metastasis. Interestingly, 
the general cytokine profile of LOX overexpressing tumors reflected a robust T cell response with 
elevated levels of IL7 and IL15. This could indicate that stiffness primes a more robust immune 
response and would be consistent with a report showing constitutively active YAP enhances T 
cell response to tumors269. More in depth characterization of lymphocytes in this model is 
necessary to understand this observation. An enhanced anti-tumor immune response could 
explain why tumor metastasis does not change with LOX overexpression, when in other models 
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LOX inhibition drastically reduces metastasis and injecting tumors orthotopically in stiffened 
collagen increases metastasis.  
 In a different PyMT model using the Pdgfrb promoter to overexpress LOX instead of 
Col1a1, we also observed changes in the neutrophil population. Not enough animals have been 
profiled to draw conclusions about the primary tumor, but the premetastatic lungs had an increase 
in neutrophils with LOX overexpression. Interestingly, this model also had an increase in lung 
metastasis with LOX overexpression, consistent with reports of neutrophils playing a critical role 
in remodeling the lung to permit metastatic colonization. The source of increased neutrophils in 
this model is unclear. This phenotype could depend on altered interactions within the primary 
tumors, or stronger expression of this promoter in the lung could be fueling the rise in neutrophils 
independent of stiffness of the primary tumor. This could be experimentally tested by conditioning 
the lungs by inducing LOX overexpression with doxycycline and injecting tumor cells by tail vein 
to assess metastatic seeding and outgrowth.  
 Surprisingly, pilot experiments performed in mixed background mice while backcrossing 
to a pure FVB background indicate that the metastasis phenotype observed in this model is strain 
specific. The higher the percentage of C57BL6, the more LOX overexpression inhibited 
metastasis. If these observations hold true on a pure C57BL6 background, it could yield 
tremendous insight into how tumors respond to LOX and ECM stiffness and how the same 
perturbation in different contexts can lead to drastically different outcomes. One of the key 
differences between FVB and C57BL6 mice is how their immune systems react to early 
transformation events. C57BL6 mice mount a more active and robust antitumor immune response 
leading to a much longer latency period for MMTV-PyMT tumors. Based on the results from this 
model, it is plausible that LOX overexpression boosts this response even further to inhibit 
metastasis, whereas the more subdued FVB tumor immune response is overcome by known 
prometastatic effects of LOX activity such as increased invasion and intravasation. Alternatively, 
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the increased latency and thus duration of LOX overexpression in C57BL6 could induce such a 
high level of crosslinking that tips the balance toward fibrosis that blocks cell invasion and 
intravasation. Our previous studies demonstrate the importance of using a spontaneous tumor 
model rather than orthoptic models to study LOX and ECM remodeling, but this observation 
suggests appropriate model choice may be more complex. Human tumors grow and develop 
much slower than many commonly used spontaneous tumor models including PyMT, and time 
could be an important factor governing ECM evolution in tumors. Collagen crosslinking is 
catalyzed by LOX but then proceeds in a spontaneous fashion that requires time for crosslinks to 
mature into higher valency products. It will be important for additional studies to clarify whether 
slower growing tumor models more accurately recapitulate the evolution and biological 
consequences of LOX activity and tumor fibrosis in human patients.  
 In contrast, PDX tumors injected orthotopically in soft or stiffened collagen show an 
increase in inflammatory signaling and neutrophil abundance when injected in soft tumors. Mice 
with soft HCI-002 tumors had higher numbers of neutrophils in lung and soft HCI-001 upregulated 
transcripts associated with inflammatory signaling. These data are interesting in that they suggest 
that LOX may play a role in regulating tumor immunity that is independent of ECM stiffness and 
that the role of ECM stiffness is clearly context dependent. Xenograft hosts lack T cells, B cells, 
and NK cells, which may also be essential to the phenotype observed in LOX overexpressing 
PyMT tumors. ECM stiffness also clearly has a stronger influence on some tumors more than 
others as HCI-002 had zero differentially expressed transcripts between the soft and stiff 
conditions, whereas HCI-001 had 29. It is unclear what factors cause some tumors to respond 
more to ECM stiffness than others.  
 Neutrophils play a critical role in cultivating the premetastatic niche to permit metastatic 
colonization. Multiple models used in these studies show ECM stiffness of the primary tumor may 
modulate neutrophil levels in the lung, where the vast majority of breast tumor metastasis occurs 
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in mice. Additional studies are needed to explore the possibility that ECM stiffness affects the 
formation of the premetastatic niche by regulating neutrophils. Neutrophils from the lungs of PDX 
tumor-bearing mice were sorted and will be analyzed by RNAseq to assess any changes in 
phenotype between the soft and stiff conditions. Moreover, frozen lung was harvested from all 
tumor models and could be subjected to proteomic analysis of ECM components as well as 
matrisome associated proteins. Comprehensive proteomic analysis of the ECM and matrisome 
associated proteins has never been reported from a spontaneous murine mammary tumor model 
and will likely yield novel, impactful insights into mechanisms promoting tumor metastasis in 
addition to understand how the stiffness of the primary tumor may influence this process.  
 These preliminary results have inspired the generation of several hypotheses regarding 
ECM regulation of tumor immunity and metastasis that require thoughtful follow up. Further 
analysis of the interplay between tumor immunity and ECM stiffness may benefit from more 
extensive use of syngeneic C57NL6 orthotopic tumor models that are less variable than 
spontaneous models. This approach could incorporate the stromal LOX overexpression to 
condition the stiffness of the mammary gland prior to tumor cell injection as well as other useful 
tools such as OT-I ovalbumin restricted T cells and a multitude of genetic manipulations. 
Understanding how ECM stiffness regulates immune cell populations and phenotypes in tumors 
may shed light on novel strategies to enhance the efficacy of immunotherapy to improve 
outcomes of breast cancer patients.   
Methods 
Mice 
MMTV-PyMT; Col1a1-tTA; TetO-mLox mice were generated as previously described 
(Chapter 4). MMTV-PyMT; Pdgfrb-rtTA; TetO-mLox mice were generated using Pdgfrb-rtTA mice 
purchased from JAX Laboratories (Stock no. 028570). These mice were backcrossed to FVB 
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TetO-mLox mice for 5 generations and then screened for strain purity by SNP analysis. Mice with 
98% FVB background or higher were backcrossed for 2 more generations and then used for tumor 
studies.  
HCI-001 and HCI-002 were revived in NSG mice from Charles River and passaged into 
NOD-SCID mice for experimentation. Equal sized tumor pieces were placed in the inguinal 
mammary gland in 4 mg/mL rat tail collagen I that had previously been incubated with or without 
2.5M L-ribose to glycate and stiffen the matrix. The collagen was supplemented with 20 % 
Matrigel.  
All mouse studies were maintained under pathogen-free conditions and performed in 
accordance with the Institutional Animal Care and Use Committee and the Laboratory Animal 
Research Center at the University of California, San Francisco. 
Flow cytometry 
Mice were perfused with ice cold PBS and tissue was harvested and chopped with a razor 
blade. Chopped tissue was digested in 100 U/mL Collagenase Type 1 (Worthington Biochemical 
Corporation, Cat# LS004196), 500 U/mL Collagenase Type 4 (Worthington Biochemical 
Corporation, Cat# LS004188), and 200 µg/mL DNase I (Roche, Cat# 10104159001) while 
shaking at 37°C. Digested tissue was filtered using a 100 µm filter to remove remaining pieces. 
Red blood cells were lysed in ammonium-chloride-potassium buffer and remaining cells were 
counted. Cells were stained with fluorophore-conjugated primary antibodies for 30 minutes on ice 
and subsequently stained with a viability marker. Antibodies used for staining were anti-mouse 
CD45-APC-R700 (BD, Cat# 565478), anti-mouse Ly6G-BV421 (BioLegend, Cat# 127628), anti-
mouse F4/80-BV510 (BioLegend, Cat# 123135), anti-mouse CD140a-PE (BioLegend, Cat# 
135906), anti-mouse CD140b-APC (BioLegend, Cat# 136006), anti-mouse CD11c-BV605 (BD 
Pharmingen, Cat# 563057), anti-mouse CD24-BV650 (BD Pharmingen, Cat# 563545), anti-
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mouse CD11b-PerCP-Cy5.5 (eBiosciences, Cat# 45-0112-82), anti-mouse CD45-AF700 
(BioLegend, Cat# 103128), anti-mouse Ly6C-BV711 (BioLegend, Cat# 128037), anti-mouse 
MHCII-PE-Cy7 (BioLegend, Cat# 107630), anti-mouse CD3ε-BV605 (BioLegend, Cat# 100351), 
anti-mouse CD4-PE/Cy7  (BioLegend, Cat# 116015), anti-mouse CD8a-BV711 (BioLegend, Cat# 
100747), and Zombie NIR Fixable Viability Dye (BioLegend, Cat# 423105). Cells were then 
analyzed on a flow cytometer.  
BrdU assay 
 Mice were injected i.p. with 100 µL BrdU (10 mg/mL) 72 h, 48 h, and 24 h prior to tissue 
collection. A subset of cells stained for flow cytometry analysis were stained for BrdU using the 
BD FITC BrdU Flow Kit (BD Pharmingen #559619) according to the manufacturer’s instructions.  
Cytokine analysis 
 A PyMT-derived tumor cell line was seeded on 400 Pa or 6 kPa polyacrylamide gels 
coated with 10 µg/mL fibronectin. Equal numbers of cells were seeded on gels and cultured for 
48 hours and conditioned media was analyzed with the Proteome Profiler Mouse XL Cytokine 
Array (R&D Systems #ARY028). Cells cultured on the cells were trypsinized and counted. 
Conditioned media from cells on stiff gels was diluted with PBS by the factor in which cells on the 
stiff gel outnumbered cells on the soft gel at the study endpoint to control for differences in cell 
proliferation.  
 Whole tumor tissues were homogenized in RIPA buffer containing protease inhibitor. 
Homogenates were centrifuged at 10,000 xg for 10 minutes at 4 degrees and the supernatant 
was collected. BCA assay was used to quantify protein and equalize protein concentration in each 
sample. Samples were sent to Eve Technologies for cytokine analysis.  
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Cell culture 
PyMT cells (Flox3) were obtained from the Hal Moses laboratory at Vanderbilt University 
and grown in DMEM/F12 medium supplemented with 10% FBS and antibiotic/antimycotic.  
Circulating tumor cell analysis 
 PyMT mRNA is used as a measurement for circulating tumor cells in blood. Whole blood 
was collected in RNALater and stored at -80C until further processing. Blood was processed using 
Mouse RiboPure Blood RNA Isolation Kit (Invitrogen #AM1951) according to manufacturer’s 
instructions. Genomic DNA was digested with DNase (Invitrogen #AM2238).  RNA quality was 
verified using NanoDrop, reversed transcribed, and analyzed for PyMT transcripts by quantitative 
real-time PCR. PyMT expression was normalized to 18s in each sample.  
Metastasis Analysis 
 Lungs were inflated with 10% formalin and fixed for 24 hours. Tissues were processed, 
paraffin embedded, and sections. Four sections 50 µm apart were stained with hematoxylin and 
eosin to visualize metastatic foci. All foci were summed and plotted as number of metastatic foci 
per mouse.  
RNASeq 
 mRNA from Trizol preps was sent to the UC Berkeley – QB3 Genomics core. The core 
prepared libraries and sequences the samples on a NovaSeq 6000. Data were analyzed in R and 
pathway analysis was performed using the GAGE package.  
Statistical analysis 
GraphPad Prism Version 6.01 was used to perform all statistical analyses with the 
exception of LH2 IHC and RFS correlations with PLOD2. Statistical significance was determined 
using the appropriate tests as noted in the figure legends or method section. 
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Chapter 6: Conclusions and Future Directions 
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 This thesis advances our understanding of ECM signaling in breast tumor progression, 
therapy response, and metastasis. It builds upon the prior work of many groups that implicates 
chemical and mechanical ECM cues in regulating breast tumor biology by enhancing tumor cell 
proliferation, survival, invasion, and escape from dormancy as well as by tuning tumor cell 
metabolism and inflammatory cell phenotypes23,25,76. Thus, tumor-ECM interactions have grown 
to be broadly appreciated as a key factor orchestrating events in the tumor microenvironment. 
While many studies demonstrate integrins are critical mechanosensors of ECM stiffness and their 
interactions with remodeled tumor ECM drive a malignant phenotype, they are by no means the 
only receptors transducing signals from the ECM. Moreover, many of the far-reaching effects of 
ECM signaling remain underexplored and poorly understood. In light of these shortcomings, this 
thesis specifically addressed the following unanswered questions: 
1. How does the loss of DDR1 signaling in luminal epithelial cells affect mammary gland 
homeostasis and the emergent breast tumor phenotype? 
2. What regulates LOX-mediated collagen crosslinking breast tumor initiation and 
progression, and how does it correlate with tumor phenotype and patient outcome?  
3. How does ECM stiffness influence therapy response of triple negative breast cancers 
and can targeting molecular mechanisms associated with prosurvival ECM signaling 
enhance therapeutic efficacy? 
4. Does ECM stiffness regulate breast tumor metastasis through coordinating neutrophil 
phenotypes and abundance in the primary tumor and/or premetastatic niche? 
This thesis addressed each of these questions through four independent research projects 
to test the overarching hypothesis that evolving chemical and mechanical ECM cues control 
breast tumor phenotype and regulate metastasis. The results of these studies yielded novel 
insights into mechanisms of cell-ECM interactions that govern tumor initiation, metastasis, and 
therapy response and expanded our mechanistic understanding of ECM remodeling over the 
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course of breast tumor progression. Each of these projects has also opened exciting avenues of 
future follow up work to uncover further mechanistic details of pro-metastatic ECM remodeling 
and signaling and to validate the efficacy of potential therapeutic strategies and targets designed 
to antagonize pro-tumor ECM signaling. The conclusions and future directions of each project are 
summarized in the following sections.  
Loss of DDR1 biases mammary epithelial homeostasis and fosters a basal-like tumor 
phenotype 
 Previous studies of DDR1 in tumor development have produced seemingly conflicting 
results regarding whether DDR1 serves to promote or restrain tumor progression. DDR1 is 
overexpressed in many tumors and cell lines but low expression is correlated with worse relapse-
free survival45,57,60. We confirmed that DDR1 signaling occurs exclusively in luminal epithelial cells 
and that its loss compromises cell adhesion and disrupts ductal morphogenesis resulting in an 
expansion of basal/myoepithelial cells. Similarly, DDR1-/- tumors also present with a more basal-
like phenotype with a higher abundance of vimentin, K14, and DDR2 expressing cells. These 
tumors also exhibit traits characteristic of basal-like tumors including faster growth, increased 
fibrosis, and more lung metastases. Moreover, DDR1-/- are enriched for K8+ K14+ progenitor cells 
and CD90+ CD24+ cells known to be enriched for tumor initiating cells. When injected into wildtype 
mammary glands, CD90+ CD24+ tumor initiating cells formed tumors that recapitulated the basal-
like phenotype of DDR1-/- tumors and contained higher levels of K14+ basal/myoepithelial cells. 
These data suggest that while DDR1 signaling may independently promote cell proliferation, its 
loss fundamentally alters the mammary epithelial cell population to favor the basal/myoepithelial 
lineage resulting in highly aggressive and metastatic tumors.  
 These results have implications both for understanding the role of DDR1 in mammary 
gland biology. The precise molecular mechanism leading to basal/myoepithelial expansion 
remains unclear. Loss of DDR1 compromises adhesion in luminal cells, so it is possible that the 
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loss of adhesion could impair migration or proliferation thus imparting basal/myoepithelial cells 
with a competitive advantage. In this case basal/myoepithelial cells would grow out to compensate 
for the crippled luminal cells. However, it is also possible that DDR1 plays a direct role in luminal 
cell differentiation and maintenance of the luminal cell phenotype. It would be interesting to 
observe whether basal/myoepithelial cells also expand in an inducible DDR1 knockout model in 
which the knockout doesn’t occur until after puberty when the mammary ductal network has been 
established.  
 These data also have implications for understanding the role of DDR1 in breast cancer. 
Given that basal tumor cell lines have significantly lower levels of DDR1 and the loss of DDR1 in 
mice leads to an aggressive, basal-like tumor phenotype, DDR1 may play a role in thwarting the 
development of aggressive tumors. Further elucidation of this molecular mechanism may yield 
promising targets for the treatment of basal-like breast cancers. It’s unclear whether the altered 
phenotype of DDR1-/- tumors results directly from the increased number of basal/myoepithelial 
cells present at tumor initiation that then shape the behavior of the tumor or whether the cell type 
of origin in DDR1-/- tumors is more often a basal/myoepithelial cell. Furthermore, because loss of 
DDR1 compromises adhesion and migration, it is likely that extrinsic effects of the loss of DDR1 
on cell-cell communication within the tumor microenvironment play a major role in facilitating 
tumor metastasis. DDR1-/- tumors are much more fibrotic than their wildtype counterparts 
indicating that signaling to fibroblasts is likely different in this context. Consistently DDR1-/- tumors 
are more hypoxic and necrotic, which likely serve to enhance metastasis. Understanding these 
cell-cell interactions in more depth may also yield important insights and actionable targets for 
tumor therapeutics.  
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Collagen crosslinking in breast tumors is primarily regulated by macrophage-stimulated 
fibroblasts and predicts poor survival 
 The Weaver lab and others have demonstrated that collagen deposition and stiffening 
accompany malignancy, compromise treatment and promote tumor aggression. This study 
sought to clarify the molecular nature of the tumor-associated collagen matrix and the factors that 
regulate remodeling. Using an optimized, analytical method to profile lysyl oxidase-mediated 
LCCs and HLCCs. We quantified the greatest number of collagen crosslinks in biopsies of the 
more aggressive HER2+ and triple negative human breast cancer subtypes with the stiffest 
stroma. Using publicly available gene expression data, we confirmed that triple negative and 
HER2+ subtypes also have higher expression of LOX and PLOD2, which may explain their 
elevated levels of collagen crosslinks. When gene expression from tumor epithelium and tumor 
stroma are analyzed separately, we found the tumor stroma expressed much higher levels of both 
LOX and PLOD2.  
LOX is produced by both tumor cells and stromal cells, but the relative contribution of each 
to collagen crosslinking is unknown. To address this knowledge gap, we generated two mouse 
models to directly assess the degree of crosslinking occurring with conditional LOX 
overexpression in either the epithelial or stromal compartments. Surprisingly, while we measured 
a significant increase in crosslink abundance with stromal LOX overexpression, we were unable 
to detect changes in crosslink abundance with epithelial LOX overexpression. These data indicate 
that despite synthesizing LOX, tumor cells contribute very little toward collagen crosslinking, 
particularly in the early stages of tumor development. Instead, we identify macrophages as key 
activators of fibroblasts in neoplastic lesions that initiate collagen crosslinking. Consistently, we 
found macrophage depletion was associated with low stromal levels of LOX and PLOD2 
expression. Macrophage depletion also reduced collagen crosslinking, stromal stiffening, and 
tumor metastasis. We found high levels of stromal PLOD2 correlated with poor survival. 
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Immunohistochemical analysis of a large cohort of breast cancer patient biopsies confirmed that 
stromal LH2, the enzyme that enables high valency collagen crosslinks, correlated significantly 
with poor patient outcome and disease specific mortality. The findings provide a compelling link 
between tissue inflammation, stromal cell-mediated collagen crosslinking and stiffening and tumor 
aggression. 
These results clearly and directly demonstrate that epithelial derived LOX does not 
contribute significantly to collagen crosslinking in breast tumors, and understanding the 
mechanism behind the failure of epithelial-derived LOX to crosslink collagen is an essential 
unanswered question. Many potential causes could explain this lack of observed catalytic activity 
by epithelial-derived LOX, and more studies are needed to fully understand the biological basis 
of this finding. One possibility is that epithelial cells fail to produce an enzyme with the necessary 
posttranslational modifications for catalytic activity. LOX enzymatic activity requires a copper 
cofactor, a lysine tyrosylquinone cofactor formed through a self-processing, intramolecular 
reaction, and protease cleavage of the LOX propeptide. However, another group has shown that 
LOXL2 overexpressing mammary tumor cells injected orthotopically into mice do alter ECM 
organization, so it is likely that epithelial cells are competent to produce a catalytically active 
enzyme149. Yet it remains possible that in spontaneous tumor formation, LOX secreted from tumor 
cells does not encounter sufficient levels of BMP1 to efficiently cleave the propeptide. Similarly, it 
is also possible that epithelial LOX is retained within epithelial clusters and relatively little enzyme 
reaches the collagen-rich stroma. This could be particularly true for the PyMT model, which forms 
characteristic epithelial-dense tumor cell clusters. Many human tumors appear much more 
diffuse, and it is possible that LOX secreted from these cells may prove more active than we have 
observed. Future work should carefully characterize the catalytic activity of epithelial-derived 
versus stromal-derived LOX and identify if spatial localization plays a role in the failure of epithelial 
LOX-mediated crosslinking. If so, it will be important to validate this finding tumor models with 
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varying histologies to verify whether this phenomenon is universal among breast tumors or 
morphology-specific.  
These studies also open broader questions relevant to understanding basic LOX biology 
in homeostasis and disease. Breast tumor epithelium produce abundant levels of LOX protein, 
especially in hypoxic environments, but if epithelial-derived LOX does not function efficiently for 
crosslinking, then what does it do? Recent works are discovering that multiple enzymes, 
particularly metabolic enzymes, have unexpected noncanonical activities that are independent of 
their primary functions270,271. LOX has been implicated in regulating transcription mediated by both 
the cleaved propeptide and by enzymatic histone modification272,273. Amazingly, nuclear LOX 
lacks its propeptide suggesting it is released into the extracellular space where it is cleaved by 
BMP, then endocytosed and transported into the nucleus. If this is the case, then administration 
of BAPN, a commonly used irreversible LOX family inhibitor, would be preventing this epigenetic 
function of LOX in addition to suppressing collagen crosslinking. This phenomenon should be 
studied more in depth and may yield insights that enable more accurate reinterpretation of seminal 
experiments in the LOX field. 
We also identified stromal LH2 as a potential biomarker that could be useful to stratify 
patients for therapy. Particularly in lymph node positive patients, which are likely to be more 
metastatic, stromal LH2 levels correlated with significantly worse breast cancer specific survival. 
When speculating around tumor aggression to make treatment decisions, most of the information 
used comes from analysis of the tumor cells themselves. However, our findings and previous 
reports demonstrate that the stroma may also be an important consideration in these decisions 
and could help improve treatment decisions148. This result also suggests a potentially important 
implication for understanding the role of ECM remodeling in breast tumor aggression. Most 
studies of tumor-associated collagen remodeling focus on the LOX family of enzymes that act 
immediately prior to crosslink formation, yet our data indicate stromal LH2 may be a much more 
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powerful predictor of poor outcomes than epithelial or stromal LOX. This implies that the type or 
profile of collagen crosslinks formed may be equally if not more important than the total 
abundance of crosslinks. Future work should further characterize the role of different LOX-
mediated collagen crosslinks on ECM material properties and tumor phenotype.  
Furthermore, these studies have significant implications for the development of ECM 
normalization strategies for breast tumor therapy. Despite much excitement and promise, 
strategies designed to normalize fibrotic tumor-associated ECM have largely failed. The LOXL2 
antibody simtuzumab failed to add clinical benefit in phase II pancreatic cancer trials. It is difficult 
to understand exactly why this drug failed with publicly available data. Our data indicate that 
crosslinking is initiated very early on in tumor progression, and inhibiting further crosslinking does 
not act to reverse the crosslinks already formed. Thus, if LOX or LOXL2 inhibitors are 
administered following extensive crosslinking, they will have little effect on stromal stiffness. Our 
data would suggest inhibition of crosslinking enzymes is not a viable strategy for ECM 
normalization. It would likely be more effective to target profibrotic fibroblasts and disrupt signaling 
that upregulates collagen production and crosslinking enzymes, including lysyl hydroxylases.  
ECM compliance drives treatment resistance in triple negative breast cancer by regulating 
the NF-κB-JNK signaling axis 
 Triple negative breast cancers are highly fibrotic and have much higher rates of 
chemotherapy response than hormone receptor positive tumors. In this study we characterized 
the ECM of chemotherapy treated breast tumors and assessed the role of ECM stiffness in 
regulating tumor cell response to apoptosis-inducing tumor therapeutics. We found that following 
neoadjuvant chemotherapy, treatment resistant triple negative breast cancers have a high degree 
of fibrillar collagen deposition but are surrounded by softer ECM compared to that of untreated 
primary tumors. 3D organoid cultures and xenograft studies further demonstrated that a soft ECM 
protects tumor cells from undergoing apoptosis in response to commonly used therapeutics 
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paclitaxel and radiation. We found this phenotype was not caused by proliferation rate but rather 
cells cultured on soft substrates resisted treatment by elevating pro-survival NF-κB activity that 
silenced pro-apoptotic JNK activity. We observed elevated JNK activity in cells cultured on stiff 
substrates and activating JNK in cells grown on soft substrates was sufficient to induce apoptosis 
upon paclitaxel or radiation treatment. Critically, treatment resistant residual human TNBCs 
residing within soft stroma had elevated NF-κB levels, and disengaging NF-κB activity sensitized 
tumors in a soft matrix to therapy. Accordingly, the biophysical properties of the ECM modify 
treatment response, and ancillary agents that modulate stiffness-dependent NF-κB or JNK activity 
could enhance chemotherapeutic efficacy in patients with TNBC. 
 Future directions of this work will further explore the mechanistic interactions between NF-
κB and JNK and the transcriptional responses that mediate cell survival. RNA sequencing of cells 
cultured on soft or stiff substrates with and without chemotherapy would provide useful insight. 
NF-κB has also been shown to enhance cell survival in a transcriptionally independent manner, 
but the precise molecular mechanism has not been elucidated. Greater clarity into the molecular 
effectors of this phenotype have much higher potential to identify actionable targets to augment 
chemotherapy in breast cancer treatment. This will likely be necessary given the difficulty of 
targeting NF-κB.  
 Future work will also incorporate these findings into ongoing projects within the lab 
exploring how a soft ECM may upregulate nuclear repressor coreceptor 2 (NCoR2) to enable 
chemotherapy resistance and tumor recurrence. NCorR2 is a powerful epigenetic transcriptional 
repressor known to associate with treatment resistance and poor prognosis. NCoR2 has also 
been reported to suppress the JNK pathway and thus may act alongside NF-κB. 
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LOX-mediated ECM stiffening reshapes immune cell populations and regulates tumor 
metastasis 
 Immunotherapy holds immense promise for curing cancers but is currently only effective 
in a minority of tumor types. Consequently, a considerable amount of funding and effort has been 
devoted to understanding how immune function is regulated in tumors and how to translate that 
information to improve immunotherapy. Unravelling the complex interactions influencing tumor 
immunity has proven to be a difficult task. Not only do breast tumor microenvironments contain a 
multitude of immune cell types, but also many can also assume a variety of distinct phenotypes. 
Their interactions with each other and with tumor and stromal cells dictate their response to the 
tumor that evolves as the tumor progresses. The immune response to tumors is commonly 
described as progressing through three phases: elimination, equilibrium, and escape. These 
phases describe the process in which the immune system initially responds by attacking the tumor 
but will be reprogrammed to support tumor growth and metastasis if the tumor persists.  
 In this project, we explored how ECM stiffness altered tumor immunity. We profiled 
immune cell types present in mammary gland tumors of LOX overexpressing mice and found that 
LOX overexpression increased the abundance of neutrophils in the primary tumor nearly twofold. 
In this model, the increase in neutrophils occurred exclusively in the primary tumor. Neutrophil 
count remained unchanged in the premetastatic lungs and may be slightly elevated in peripheral 
blood, but more animals need to be profiled to draw this conclusion. These data fueled the 
hypothesis that ECM stiffness may regulate the neutrophil population in tumors. Further 
characterization of this model revealed an upregulation of cytokines that have been reported to 
induce chemotaxis as well as a general cytokine profile indicative of a productive anti-tumor 
immune response. A progenitor labelling experiment suggested that neutrophils present in the 
primary tumors of LOX overexpressing mice were older than those of control tumors. While a 
wealth of data support an immunosuppressive role of neutrophils in PyMT tumors, it is plausible 
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that neutrophils recruited to LOX overexpressing tumors maintain an anti-tumor phenotype. 
Additional experiments directly profiling these cells are needed to confirm this hypothesis. Given 
the wealth of data indicating that LOX activity and ECM stiffness promote metastasis, it is tempting 
to speculate that metastasis does not increase in the LOX overexpressing tumors due to a 
counteracting anti-tumor immune response. Future work should explore this hypothesis.  
 Additional in vivo models modulating ECM stiffness produced varied results with regards 
to neutrophil infiltration. One of two triple negative PDX models, HCI-002, showed an increase in 
neutrophil abundance in lung in mice injected with tumors in soft collagen. Neutrophil abundance 
was not measured in the primary tumor; however, RNA-seq data from whole tumor mRNA showed 
indications of altered inflammatory signaling. In fact, HCI-001 may have higher inflammatory cell 
recruitment in the soft condition. However, these PDX studies are performed in immune 
compromised mice, which may be an important caveat to consider when drawing conclusions 
about innate immune cell behaviors in these models. In a PyMT model with stromal LOX 
overexpression using a different stromal promoter to drive LOX, the lungs have more neutrophils, 
but it is still unclear whether the primary tumors have more neutrophils. Interestingly, this model 
showed a strain dependent metastasis phenotype in which LOX overexpression on the FVB 
background promoted metastasis but seemed to inhibit metastasis on the C57BL6/J background. 
These two strains have characteristically different immune responses to tumors with FVB more 
type 2-like and C57BL6 more type 1-like. It is interesting to speculate that LOX overexpression 
interacts differently with these drastically different immune responses to promote or inhibit 
metastasis. Because of their more robust anti-tumor immune response, C57BL6 PyMT tumors 
take longer to develop, and it is also possible that increased crosslinking in this time prohibit tumor 
cells from entering or exiting circulation. Future work should characterize potential differences in 
crosslinking and in immune cell phenotypes in these two strains to understand how LOX may 
impart both prometastatic and antimetastatic qualities.  
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 One of the key roles of tumor promoting neutrophils in mice is to condition the 
premetastatic niche to create a receptive environment for incoming tumor cells. Neutrophils 
secrete proteases and ECM proteins to create a hospitable niche for tumor cell survival and 
outgrowth. Future directions of this work should also include characterizing changes in the 
premetastatic niche both to understand how modulating neutrophil levels and phenotype alter the 
niche and to discover potent prometastatic mediators. The matrisome and matrisome associated 
proteins have never been profiled in the context of a spontaneously forming mouse mammary 
gland tumor and these studies could yield important and interesting insights into how metastatic 
sites are remodeled to promote tumor colonization. These studies could be expanded into mouse 
models with other organ-specific metastases such as bone or brain to characterize differences 
occurring in these tissues prior to tumor cell arrival. Studies of this nature have high potential for 
yielding impactful insights into mechanisms of tumor metastasis and organotropism.  
Broad Implications and Final Comments 
 While the work discussed here focused only on breast cancer, these findings have broader 
implications for other tumor types and fibrotic pathologies. Fibrosis correlates with poor outcomes 
in many carcinomas including those of pancreas, lung, liver, prostate, and ovary23,25,76,274. Thus, 
our results with respect to understanding stromal activation early in tumorigenesis, weighing the 
relative contributions of stromal cells and tumor epithelium to matrix remodeling, and 
understanding how ECM stiffness modulates chemotherapy response may be directly applicable 
to other fibrotic tumors. It will be important to keep in mind however, that ECM is highly tissue 
specific and the unique features of each of these local environments should be considered when 
designing experiments and interpreting results. These tissues also have unique stromal cell 
populations and tissue resident immune cells, which may alter how tumors in these tissues 
respond to a fibrotic environment.  
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  This thesis sought to understand tumor associated ECM remodeling and fibrosis in 
greater detail and how signals from the tumor ECM influenced tumor pathology and therapy 
response. This work occurred across length scales from in vitro cell culture manipulations to 
several orthotopic and genetically engineered mouse models to carefully dissect the roles of 
DDR1 signaling and ECM stiffness on specific cell behaviors and demonstrate their relevance in 
the mouse tumor microenvironment. Human tissues and datasets validate that our observations 
translate to human disease and both provide LH2 as a potentially useful biomarker to stratify 
patients for therapy and inform treatment strategies that antagonize ECM-mediated tumor 
promoting signaling pathways. These studies have also launched several exciting new avenues 
of study to more precisely understand the role of stromal LOX in ECM remodeling and how ECM 
regulation of tumor immunity influences metastasis. This ongoing work has tremendous potential 
to further our understanding of how ECM remodeling and stiffening occur in cancer, how these 
activities regulate tumor biology, and how we might improve therapeutics to treat cancer and 
improve patient outcomes.   
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Appendix 1: Supplementary Material for Chapter 2 
 
Supplementary Figure A1.1: (A) Quantification of the number of cells adhered to collagen 
coated tissue culture polystyrene at the indicated time point. Measurements were taken by 
imaging the culture wells and counting the number of cells per field of view. (B) Quantification of 
collagen gel contraction by cells seeded in free-floating collagen gels. Data are shown as the 
change in collagen gel diameter over time. (C, D) K14- and K14+ mammary epithelial cells were 
isolated by flow cytometry from K14-GFP mice (C). K14- luminal cells with or without K14+ 
basal/myoepithelial cells were aggregated overnight in vitro and then used in a 3D branching 
assay in Matrigel. K14+ basal/myoepithelial cells promoted mammary branching (D). 
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Supplementary Figure A1.2: (A) We crossed DDR1-/- mice with MMTV-PyMT to determine the 
effects of DDR1 deletion in mammary tumorigenesis. (B) DDR1 expression levels of primary 
tumors from PyMT/DDR1+/+, PyMT/DDR1+/- and PyMT/DDR1-/- mice by qPCR. PyMT/DDR1-/- 
tumor did not express DDR1 and DDR1 expression level of PyMT/DDR1+/- tumor was ~ 40% of 
PyMT/DDR1+/+ tumors. Data are shown as mean ± SD, n=2-4, *p <0.001, **p <0.01 (one-way 
ANOVA and unpaired Student’s t test). (C) DNA microarray datasets (Neve et al. 2006) were used 
to determine DDR1 expression in breast cancer cell lines. DDR1 expression was higher in 
luminal-type than basal-type (Basal A+B) cell lines. *p <0.001 (unpaired Student’s t test). 
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Supplementary Figure A1.3: (A) Day of primary tumor onset were not statistically significantly 
different in DDR1+/+, DDR1+/- and DDR1-/- mice (Data shown as mean ± SD, n=4-7, unpaired 
Student’s t test). (B) Representative photographs show that hemorrhagic necrosis was 
characteristic of DDR1-/- mammary tumors (13 weeks). n=3-7. (C) Rate of necrotic clusters out of 
small clusters (200-300 µm length) was measured. Necrotic small clusters increased in DDR1-/- 
tumors. Data are shown as mean ± SD, n=3, *p <0.01, **p <0.02 (one-way ANOVA and unpaired 
Student’s t test). (D, E) Immunofluorescence of the primary tumors was performed by using anti-
keratin 8 (green) and anti-DDR2 (red) antibodies. DAPI (blue) stained nuclei. Representative 
photographs of tumor necrosis are shown (D). The ratio of DDR2+ cells per epithelial cells 
increased significantly near necrotic fields of DDR1-/- mammary tumor tissues. Data are shown as 
mean ± SD, n=3, *p <0.01, **p <0.02 (one-way ANOVA and unpaired Student’s t test) (E). (F-J) 
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Immunofluorescence of the primary tumors was performed by using anti-keratin 8 (green) and 
anti-keratin 14 (red) antibodies. DAPI (blue) stained nuclei. K8+K14+ basal-like cells (yellow) 
showed an increased trend in DDR1-/- epithelial clusters (F, G), which was not statistically 
significant (Data shown as mean ± SD, n=3, unpaired Student’s t test). Representative photos of 
tumor epithelial clusters (DDR1+/-, H left panel) and necrosis (DDR1-/-, H right panel) are shown. 
The white dots represent a border between an epithelium and a necrotic field (H right panel). 
The ratios of K8+K14+ basal-like cells per epithelial (K8+ and K14+) cell increased significantly near 
necrotic fields (I). Data are shown as mean ± SD, n=9, *p <0.01 (unpaired Student’s t test). 
K8+K14+ cells showed an increased trend near necrotic fields of DDR1-/- mammary tumor tissues 
(J), which was not statistically significant (Data shown as mean ± SD, n=3, unpaired Student’s t 
test).  
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Supplementary Figure A1.4: (A-D) Immunofluorescence of the primary tumors was performed 
by using anti-keratin 8 (green), anti-keratin 14 (red) and anti-phospho-histone H3 (white) 
antibodies. DAPI (blue) stained nuclei. K8+ luminal cells were mainly proliferating in the epithelial 
clusters of DDR1-/- mammary tumors (A, B). K8+K14+ basal-like cells were proliferating slightly 
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but significantly near the necrotic regions in DDR1-/- tumors (C, D). Data are shown as mean ± 
SD, n=3, *p <0.01, **p <0.05 (one-way ANOVA and unpaired Student’s t test). 
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Supplementary Figure A1.5: (A, B) Immunofluorescence of the primary tumors was performed 
by using anti-keratin 8 (green), anti-keratin 14 (red) and DDR2 (white) antibodies. DAPI (blue) 
stained nuclei. Rate of K8+K14+ basal-like cells in DDR2+ cells increased significantly in DDR1-/- 
tumors. Data are shown as mean ± SD, n=3, *p <0.05 (one-way ANOVA and unpaired Student’s 
t test). (C, D) Primary tumors from 10-week-old PyMT/DDR1+/+ or PyMT/DDR1-/- mice were 
digested with collagenase into organoids. The 3D assay of the organoids was performed in 
Matrigel in duplicate. Representative photographs were shown (C). DDR1-/- tumor organoids 
showed decreased branching structures (Data shown as mean ± SD, n=2, *p <0.05, unpaired 
Student’s t test) (D). 
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Appendix 2: Supplementary Material for Chapter 3 
Supplementary Table A2.1: Serial dilutions of crosslinked amino acid standards were prepared 
in the background of E. coli hydrolysates and the lowest limit of detection (LLOD) and the lowest 
limit of quantification (LLOQ) were determined on a QExactive mass spectrometer. The LLOD is 
defined here as the concentration that is required to produce a signal that is three times the noise 
level. The LLOQ is the analyte concentration that is required to produce a signal that is three 
times that of the LLOD. *Denotes isomers that were not resolved.  
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Supplementary Table A2.2: Characterization of breast cancer patients used to develop 
neoplastic epithelial LH2 H-score. 
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Supplementary Table A2.3: Characterization of breast cancer patients used to develop stromal 
LH2 H-score. 
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Supplementary Figure A2.1: Partial assignment of MS2 fragmentation spectra of crosslinked 
amino acid standards. MS2 fragmentation spectra of commercially available crosslinked amino 
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acid standards with partial assignment of MS2 fragmentation spectra (LNL, top; DHLNL, middle; 
dPyr, bottom). Protonated forms of precursor ions are denoted by MH+ labels. Colored circles 
above fragment ions are matched to their suggested fragment ion structure above the full spectra 
or are listed above the ion if space permits.  
  
190 
 
 
Supplementary Figure A2.2: (a) xAAA workflow schematic. Clinical specimens are hydrolyzed 
and enriched by solid phase extraction (SPE). (b) The enriched hydrolysate is analyzed by LC-
SRM on a hybrid quadrupole orbitrap instrument. MS2 spectra is used to accurately identify xAAs 
such as dihydroxy lysinonorleucine (DHLNL) (c) Bar graphs showing quantification of tissue 
collagen and (d) total crosslinked amino acids (xAA) measured in human breast, lung, skin, bone, 
trachea and tendon (pooled n = 3 each tissue). The calculated amino acid crosslink values are 
normalized to total tissue collagen content (hydroxyproline abundance) which is calculated based 
on wet tissue weight. The final values have been plotted as relative abundance based on peak 
area. Bar graphs depict relative abundance of Lysine derived-collagen crosslink (LCC) and 
hydroxylysine-derived collagen crosslink (HLCC) species. 
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Supplementary Figure A2.3: (a) Schematic of a mature fibrillar collagen fiber. N- and C- terminal 
telopeptides are hydroxylated by lysyl hydroxylase 2 (LH2). N- and C- terminal propeptides are 
cleaved by procollagen endopeptidases to form the mature collagen fiber (300 nm). (b) Lysine 
(Lys) and the hydroxylysine (Hyl) residues in the telopeptide region of mature collagen are 
targeted by the crosslinking enzyme lysyl oxidase (LOX), which forms reactive aldehyde groups 
that spontaneously undergo aldol condensation reactions to form covalent collagen crosslinks.  
  
192 
 
Supplementary Figure A2.4: Lysine aldehyde (Lysald) and hydroxylysine aldehyde (Hylald)  
crosslinking pathway. Lysyl oxidase modifies Lys residues to form allysine (Lysald), which 
spontaneously reacts with Lys and Hyl residues in the helical region to form the Schiff bases 
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dehydro-hydroxylysinonorleucine (deH-HLNL) dehydro-lysinonorleucine (deh-HLNL). These 
crosslinks can be reduced with NaBH4 to form LNL and HLNL. The mature products of these 
crosslinks are currently unknown. Allysine can combine with an additional allysine residue to form 
allysine aldol. Allysine aldol can form the trivalent crosslink hydroxyl merodesmosine, aldol 
histidine, or the tetravalent crosslink histidino-hydroxymerodesmosine (HHMD) (only post-
reduction products shown) through aldol condensation reactions with Hyl or histidine (His), or a 
combination of the two. Red and green shading denotes lysine-derived collagen crosslinks (LCC) 
or hydroxyl lysine-derived collagen crosslinks (HLCC). Telopeptide lysine residues are modified 
by lysyl hydroxylase. Lysyl oxidase modifies Hyl residues to hydroxyl allysine (Hylald), which 
spontaneously reacts with Lys and Hyl residues to form the Schiff bases dehydro-
dihydroxylysinonorleucine (deH-DHLNL) and dehydro-hydroxylysinonorleucine (deh-HLNL). 
They then undergo Amadori rearrangements to form hydroxylysino-keto-norleucine (HLKNL) or 
lysine-keto-norleucine (LKNL), respectively. These crosslinks can be reduced with NaBH4 to form 
LNL and DHLNL. Mature crosslink products (Pyr and dPyr) are formed from the reaction of lysine 
ketonorleucine (LKNL) or hydroxyl lysinoketonorleucine (HKLNL) with hydroxyl allysine. Red and 
green shading denotes lysine-derived collagen crosslinks (LCC) or hydroxyl lysine-derived 
collagen crosslinks (HLCC).  
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Supplementary Figure A2.5: (a) Scatter plot showing the mean and SEM of patient age for 
normal and tumor tissue samples by subtype. (b-f) Scatter plots showing the levels of each LCC 
and HLCC crosslink measured in normal and tumor breast tissues versus patient age. The total 
abundance of crosslinks (g) was calculated by summing all individual crosslinks and the total 
tissue HLCC abundance (h) was calculated by summing DHLNL, Pyr, and d-Pyr. All crosslink 
values are normalized to total collagen content (i.e. hydroxyproline abundance) and wet tissue 
weight and are plotted as log2 transformed normalized peak areas from LC-MS data. The best fit 
line and its slope and r2 value are displayed on each plot.  
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Supplementary Figure A2.6: (a) Representative dot plots (n = 2) of GFP expression in mouse 
mammary epithelial cells analyzed by flow cytometry. GFP and mLOX are encoded on the same 
mRNA transcript with independent translation initiation sites. (Top panel) GFP expression is 
induced in DOX treated MMTV-rtTA+/-; TetO_mLox+/- mice. (Middle and Bottom panels) GFP 
expression is not induced in control mice lacking the MMTV-rtTA promoter (Middle) or control 
mice not treated with DOX (Bottom). To select for mammary epithelial cells were gated out cells 
positive for anti-mouse CD45-APC, anti-mouse CD31-APC, anti-mouse Ter119-APC antibodies. 
(b) Quantification of Lox gene expression in whole mouse mammary gland by RT-qPCR in control 
MMTV-rtTA-/-; TetO_mLox+/- mice (n = 2) and Lox overexpressing MMTV-rtTA+/-; TetO_mLox+/- (n 
= 2) mice. (c) Western blot of whole tumor lysate from control and epithelial LOX overexpressing 
PyMT tumors. Scatter plots with mean ± SEM quantify optical density of each band normalized to 
E-cadherin. Statistical analyses were performed using Mann-Whitney U test (**p < 0.01).  
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Supplementary Figure A2.7: (a) PCR results and sequence of PCR primers of N- and C-terminal 
ends to confirm TetO_mLox transgene incorporation. (b) Diagram of inducible TetOFF system. 
TetO_mLox transgene is reversibly turned off or on in the presence or absence of doxycycline, 
respectively.  
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Supplementary Figure A2.8: (a) Scatter plot showing mean ± SEM of the number of F4/80 
positive cells per field of view in IgG1 treated (n = 6) or anti-CSF1 treated (n = 4) PyMT tumors 
from 8-week-old mice. Statistical analysis was performed using a two-tailed unpaired t-test (*p < 
0.05). (b) Representative images from 8-week-old IgG1 treated and anti-CSF1 treated PyMT mice 
stained for cytokeratin 8/18 (green), PDGFRα (magenta), vimentin (yellow), and DAPI (blue). 
Scale bar is 100 µm. (c) Scatter plot showing mean ± SEM of fibroblasts (vimentin+ and PDGFRα+) 
per field of view in 8-week-old IgG1 treated (n = 6) and anti-CSF1 (n = 5) treated PyMT mice.  
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Supplementary Figure A2.9: (a) Scatter plot showing mean and individual values of atomic force 
microscopy (AFM) microindentation measurements of individual human samples categorized as 
normal breast tissue (black circles) or invasive ductal carcinoma (IDC; red squares). (b) Scatter 
plot showing mean and individual values of AFM microindentation measurements of individual 
mouse mammary tumors from doxycycline treated MMTV-PyMT+/-; Col1a1-tTA+/-; TetO-mLox 
control mice (DOX-ind PyMT Con; black circles) or water treated mice overexpressing stromal 
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Lox (Water PyMT Lox OX; red squares). (c) Scatter plot showing mean and individual values of 
AFM microindentation measurements of individual mouse mammary gland tumors from 8 week 
old IgG1 treated (IgG Control; red squares) and anti-CSF1 treated (aCSF1 Ab; black circles) 
PyMT tumors. (d) Scatter plot showing mean and individual values of AFM microindentation 
measurements of individual mouse mammary gland tumors from PBS vehicle treated (Veh 
Control; red squares) and minoxidil treated (black circles) PyMT tumors. 
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Supplementary Figure A2.10: Gating strategy for sorting tumor cells, cancer-associated 
fibroblasts, and tumor-associated macrophages from PyMT mice via flow cytometry.  
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Supplementary Figure A2.11: (a) Log2 scaled data graphs showing relative PLOD2 gene 
expression levels in patients stratified by estrogen and epidermal growth factor receptor two 
(ER/HER2) status (ER+ HER2- n=314; ER- or + /HER2+ n=73; ER-/HER2- n=133). Statistical 
analysis was performed to compare PLOD2 expression levels among subtypes using Kruskal-
Wallis test (***p < 0.001) and Mann-Whitney U test for individual comparisons (***p < 0.001). (b) 
Line graphs showing distant metastasis-free survival (DMFS) for patients with estrogen receptor 
positive and epidermal growth factor receptor two negative breast tumors (ER+/- HER2-; low 
n=157 & high=157). (c) Line graph of DMFS for patients with estrogen receptor negative or 
negative and epidermal growth factor receptor two positive breast tumors (ER- or +/HER2+; low 
203 
 
n=36 & high=37). (d) Line graph of DMFS for patients with estrogen receptor negative epidermal 
growth factor receptor negative breast tumors (ER- HER2-; low n=66 & high=67). Error bars 
represent minimum and maximum values for each group. Statistical analyses were performed to 
compare PLOD2 and DMFS for each subtype or Log-rank (Mantel-Cox) test (*P<0.02 and 
*P<0.01 for ER+/-HER2+ and TN, respectively). (e-g) Kaplan-Meier curves indicating the 
probability of relapse-free survival assessed in ER+/PR+ (e), HER2+ (f), and triple negative (g) 
breast cancer patients up to 16 years after diagnosis. A correlation between PLOD2 (gene 
encoding LH2) expression and RFS has been determined using an online tool 
(http://kmplot.com/analysis/) as described in the methods. Top and bottom panels represent two 
distinct Affymetrix PLOD2 probes (202619 and 202620) from the same database. For Kaplan-
Meier curves, statistical analyses were performed using LogRank test. 
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Supplementary Figure A2.12: (a) Tumor samples from incident breast cancer cases were 
collected, and a tissue microarray (TMA) including two 1-mm cores from each tumor was 
constructed. Neoplastic epithelial LH2 staining was assessed with semi-quantitative intensity 
score and stratified as negative, low, or moderate/high. (b) Clinical correlation of neoplastic 
epithelial LH2 intensity score with tumor grades. (c) Kaplan-Meier curves indicating cumulative 
breast cancer specific survival (BCSS) based on epithelial LH2 intensity assessed in breast 
cancer patients up to 10 years after diagnosis (LH2 negative n = 271, weak n = 112, 
moderate/high n = 77). (d) BCSS curves by epithelial LH2 intensity including only axillary lymph 
node negative patients (LH2 negative n = 175, weak n = 67, moderate/high n = 50). (e) BCSS 
curves by epithelial LH2 intensity including only axillary lymph node positive patients (LH2 
negative n = 84, weak n = 42, moderate/high n = 26). For tumor grade and LH2 intensity score, 
statistical analysis was performed using a linear-by-linear association (***p < 0.001). For Kaplan-
Meier curves, statistical analyses were using LogRank test. 
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Appendix 3: Supplementary Material for Chapter 4 
 
Supplementary Table A3.1: Human triple negative breast tumor patient data for AFM and 
picrosirius red analysis 
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Supplementary Figure A3.1: Bar graph showing mean and SEM of loss of metabolic activity by 
MTT assay after gamma irradiation treatment in MCF10A cells cultured on soft or stiff substrates 
(n = 3). Statistical analyses were performed using two-tailed t test (*p < 0.05, **p < 0.01, ***p < 
0.001).  
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Supplementary Figure A3.2: (A) Western blot validating dnJNK construct expression in 
MCF10A cells. (B) Western blot of phosphorylated JNK 1/2 in vector and dnJNK transduced 
MCF10A cells treated with 10nM paclitaxel. (C) Western blot for p65 in cytoplasmic and nuclear 
protein extracts from MCF10A containing the dnIκB construct and treated with recombinant 
human TNFα. (D) Western blot for p65 in cytoplasmic and nuclear protein extracts from MCF10A 
containing the dnIκB construct and treated with recombinant human TNFα. 
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Supplementary Figure A3.3: (A) Western blot showing bands for phosphorylated c-Jun (Ser63) 
in T4-2 cells cultured on soft or stiff substrates after 60 min incubations with 10nM paclitaxel 
treatment or 200 ng/mL TRAIL. (B) Bar graph showing mean of Western blot quantification of 
phosphorylated c-Jun (Ser63) in T4-2 cells by pixel density normalized to E-cadherin loading 
control (n = 1). 
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Supplementary Table A3.2: Human breast tumor patient data for gene set enrichment analysis. 
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